Nitrogen-containing heterocyclic compound having MYT1 inhibitory activity
Patent Information
- Application Number
- MYPI2025005000
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-02-28
- Filing Date
- 2024-02-27
- Publication Date
- 2024-08-28
AI Technical Summary
Current therapeutic methods for cancers with abnormalities in genes and proteins involved in the DNA Damage Response pathway, such as MYT1, lack effective drugs, necessitating the development of new compounds with MYT1 inhibitory activity for cancer treatment.
A nitrogen-containing heterocyclic compound with MYT1 inhibitory activity, its salts, or solvates, is developed for use in pharmaceuticals to treat and prevent cancer by targeting the MYT1 enzyme, which regulates CDK1 and plays a role in cell cycle regulation.
The compound effectively inhibits MYT1, potentially leading to synthetic lethality in certain cancers, providing a new therapeutic approach for cancer treatment by targeting the DNA Damage Response pathway abnormalities.
Smart Images

Figure PI2025005000_DRAWING_001 
Figure PI2025005000_DRAWING_002 
Figure PI2025005000_DRAWING_003
Abstract
Description
Nitrogen-containing heterocyclic compounds with MYT1 inhibitory activity
[0001] The present invention relates to a nitrogen-containing heterocyclic compound or a salt thereof, or a solvate thereof, which has MYT1 inhibitory activity, and also to a pharmaceutical composition containing the compound or salt as an active ingredient, which is useful for treating and preventing cancer.
[0002] Cells are exposed to exogenous or endogenous stress factors daily, resulting in DNA damage. Typically, cells with DNA damage repair the DNA damage by activating the DDR (DNA Damage Response) pathway. It is known that many cancers have abnormalities in genes and proteins involved in the DDR pathway, and treatments are being investigated (Non-Patent Documents 1-2). One method for treating cancers with abnormalities in genes and proteins involved in the DDR pathway is the use of PARP inhibitors, which are used to treat cancers with BRCA1 mutations or BRCA2 mutations (Non-Patent Document 3). Currently, genes and proteins involved in the DDR pathway, such as ATM, ATR, CHK1, DNA-PK, and WEE1, are being identified as potential targets, and active research is being conducted on these targets (Non-Patent Document 4).
[0003] MYT1 is an enzyme of the WEE1 family and is known to be a negative regulator of CDK1. MYT1 phosphorylates CDK1, inactivating it and playing an important role in regulating the cell cycle. In recent years, new MYT1 inhibitors have been reported, which have been shown to induce synthetic lethality in certain cancers (Non-Patent Document 5). However, no approved drugs have yet been developed, and new therapeutic agents are desired.
[0004] Cancers (Basel), 2020 Apr 23;12(4):1050. Front Pharmacol., 2021 Feb 8;11:629266. N. Engl. J. Med., 2018 Dec 27;379(26):2495 - 2505. Nat. Rev. Cancer, 2023 23, 78 - 94. Nature, 2022 Apr;604(7907):749 - 756. T. W. Greene, P. G. M. Wuts, Protective Groups in Organic Synthesis (5th ed, John Wiley & Sons 2014) Tetrahedron Lett., 2019 vol.60, 151147 Chem. Rev., 1995, vol.95, no.7, p.2457 - 2483. Acc. Chem. Res., 2008, vol.41, No.11, p.1461 - 1473. Synthesis, 1992, vol.9, p.803 - 815. Org. Process Res. Dev., 2018, vol.22, no.4, p.430 - 445. Tetrahedron, 1992, vol.48, no.44, p.9577 - 9648. Aldrichimica Acta, 2005, vol.38, no.4, p.71 - 88. Chem. Soc. Rev., 2011, vol.40, p.5084 - 5121. Chem. Rev., 2016, vol.116, p.12564 - 12649. Org. Process Res. Dev., 2022, vol.26, no.6, p.1690 - 1750. J. Am. Chem. Soc., 2016, vol.138, no.26, p.8084 - 8087. ACS Med. Chem. Lett., 2020, vol.11, no.4, p.597 - 604. Nature, 2021, 598, p.451 - 456. ACS Cent. Sci.2017, vol.3, issue 6, p.647 - 653. Tetrahedron 2008, vol.64, p.5139 - 5146. Nature. 2019 May;569(7757):503 - 508. PLoS Comput Biol. 2019 May 20;15(5):e1006752.
[0005] An object of the present invention is to provide a novel compound or a salt thereof, or a solvate thereof, which has inhibitory activity against MYT1, and to provide a pharmaceutical agent containing the compound or salt as an active ingredient, which is useful for the treatment and prevention of cancer.
[0006] That is, in one aspect of the present invention, the following invention is provided: [A1] Formula (1): [In the formula, R 4 is an optionally substituted C 6 -C 10 Aryl (R 4A ), optionally substituted 4- to 10-membered heterocyclyl, and optionally substituted 5- to 10-membered heteroaryl (R 4HA ) selected from the group consisting of; R 5 and R 6 are taken together with the atoms to which they are attached to form an optionally substituted D ring; and the D ring is selected from the group consisting of a 3- to 10-membered monocyclic alicyclic ring, a benzene ring, a 3- to 12-membered monocyclic heterocyclic ring, and a 5- to 6-membered monocyclic aromatic heterocyclic ring (D HA any two adjacent substituents on ring D may be taken together with the atoms to which they are attached to form ring E which may be substituted.] or a salt thereof, or a solvate thereof. [A2] A compound represented by the formula (I) or (II), wherein ring D is a benzene ring or a 5- to 6-membered monocyclic aromatic heterocycle (D HA [A3] The compound according to [A1], or a salt thereof, or a solvate thereof, wherein the D ring is a benzene ring. [A4] The compound according to [A1], or a salt thereof, or a solvate thereof, wherein the D ring is a 5- to 6-membered monocyclic aromatic heterocycle (D HA [A5] A compound according to [A1], a salt thereof, or a solvate thereof, wherein the compound is a 5- to 6-membered monocyclic aromatic heterocycle (D HAThe compound according to [A4], or a salt thereof, or a solvate thereof, wherein the 5- to 6-membered monocyclic aromatic heterocycle (D) is selected from the group consisting of a furan ring, a thiophene ring, a pyrrole ring, an imidazole ring, a pyrazole ring, a thiazole ring, an isothiazole ring, an oxazole ring, an isoxazole ring, an oxadiazole ring, a thiadiazole ring, a triazole ring, a tetrazole ring, a pyridine ring, a pyrimidine ring, a pyridazine ring, a pyrazine ring, and a triazine ring. [A6] The compound according to [A4], or a salt thereof, or a solvate thereof, wherein the 5- to 6-membered monocyclic aromatic heterocycle (D) is selected from the group consisting of a furan ring, a thiophene ring, a pyrrole ring, an imidazole ring, a pyrazole ring, a thiazole ring, an isothiazole ring, an oxadiazole ring, a thiadiazole ring, a triazole ring, a tetrazole ring, a pyridine ring, a pyrimidine ring, a pyridazine ring, a pyrazine ring, and a triazine ring. HA [A7] The compound according to [A4], or a salt thereof, or a solvate thereof, wherein D is selected from the group consisting of a pyridine ring, a pyrimidine ring, a pyridazine ring, and a pyrazine ring. HA [A8] The compound according to [A4], or a salt thereof, or a solvate of the compound or the salt, wherein ring D is unsubstituted or substituted with one or more R D and one or more R D are each independently deuterium, halogen, cyano, nitro, hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, oxo, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, wherein the hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 The compound according to any one of [A1] to [A7], or a salt thereof, or a solvate thereof, wherein the aryl and the 5- to 10-membered heteroaryl are optionally further substituted. [A9] The compound according to any one of [A1] to [A7], or a salt thereof, or a solvate thereof, wherein the D ring is unsubstituted or substituted with one or more R D and one or more R D are each independently a halogen, a cyano, a hydroxy, 1 -C 6 Alkylthio, C 1 -C 6 Acylamino, Mono C 1 -C 6 Alkylamino, C 1 -C 6 Alkylsulfonylamino, C 3 -C 8 Cycloalkylsulfonylamino, C 1 -C 6 Alkoxy, HaloC 1 -C 6 Alkoxy, hydroxy C 1 -C 6 Alkoxy, C 1 -C 6 Alkoxy C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkoxy, 4- to 10-membered heterocyclyl C 1 -C 6 Alkoxy, C 3 -C 8 cycloalkoxy, 4- to 10-membered heterocyclyloxy, C 1 -C 6 Acyl, Mono C 3 -C 8 Cycloalkylaminocarbonyl, 4- to 8-membered cyclic aminocarbonyl, diC 1 -C 6 Alkylphosphoryl, C 1 -C 6 Alkyl, haloC 1-C 6 Alkyl, hydroxy C 1 -C 6 Alkyl, diC 1 -C 6 Alkylaminocarbonyl C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, Hydroxy C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, hydroxy C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, 1 -C 6 Alkylthio, C 1 -C 6 Alkoxy, C 1 -C 6 Alkoxy C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkoxy, 4- to 10-membered heterocyclyl C 1 -C 6 Alkoxy, C 3 -C 8 cycloalkoxy, 4- to 10-membered heterocyclyloxy, C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10The aryl and 5- to 10-membered heteroaryl may further independently be selected from halogen, cyano, hydroxy, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, oxo, halo C 1 -C 6 Alkyl, and C 3 -C 8 [A10] The compound according to any one of [A1] to [A7], or a salt thereof, or a solvate of the compound or the salt, wherein the ring D is unsubstituted or substituted with one or more substituents selected from the group consisting of R D and one or more R D are each independently a halogen, C 1 -C 6 Alkoxy, HaloC 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkoxy, C 1 -C 6 Alkyl, haloC 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkyl, and C 3 -C 8 [A11] The compound according to any one of [A1] to [A7], or a salt thereof, or a solvate thereof, wherein ring D is unsubstituted or is selected from the group consisting of R D and one or more R D are each independently C 1 -C 6 Alkoxy, C 1 -C 6 Alkyl, and C 3 -C 8[A12] The compound according to any one of [A1] to [A7], or a salt thereof, or a solvate thereof, wherein ring D is unsubstituted or is selected from the group consisting of R D and one or more R D are each independently selected from the group consisting of methoxy, ethoxy, propoxy, propan-2-yloxy, 3-methylbutoxy, [(2S)-butan-2-yl]oxy, [(2R)-butan-2-yl]oxy, methyl, ethyl, propyl, propan-2-yl, 2-methylpropyl, butan-2-yl, 3-methylbutyl, pentan-3-yl, cyclopropyl, cyclobutyl, cyclopentyl, 1-methylcyclopropyl, 3,3-dimethylcyclobutyl, and spiro[2.3]hexan-5-yl, or a salt thereof, or a solvate thereof. [A13] The compound according to any one of [A1] to [A12], or a salt thereof, or a solvate thereof, wherein any two adjacent substituents on ring D, together with the atoms to which they are attached, form an optionally substituted ring E. [A14] The ring E is a 3- to 10-membered monocyclic alicyclic ring, a benzene ring, a 3- to 12-membered monocyclic heterocycle, or a 5- or 6-membered monocyclic aromatic heterocycle (E HA [A15] The compound according to any one of [A1] to [A13], or a salt thereof, or a solvate thereof, wherein ring E is a benzene ring or a 5- to 6-membered monocyclic aromatic heterocycle (E HA [A16] The compound according to any one of [A1] to [A13], or a salt thereof, or a solvate thereof, wherein ring E is a benzene ring. [A17] The compound according to any one of [A1] to [A13], or a salt thereof, or a solvate thereof, wherein ring E is a 5- to 6-membered monocyclic aromatic heterocycle (E HA [A18] A compound according to any one of [A1] to [A13], a salt thereof, or a solvate thereof, wherein E HAThe compound according to [A17], or a salt thereof, or a solvate thereof, wherein the 5- to 6-membered monocyclic aromatic heterocycle (E HA The compound or salt thereof according to [A17], or a solvate thereof, wherein E ) is selected from the group consisting of a thiophene ring, an imidazole ring, a pyrazole ring, a thiazole ring, an isothiazole ring, a pyridine ring, a pyrimidine ring, a pyridazine ring, and a pyrazine ring. [A20] The compound or salt thereof according to [A17], or a solvate thereof, wherein E ) is selected from the group consisting of a thiophene ring, an imidazole ring, a pyrazole ring, a thiazole ring, an isothiazole ring, a pyridine ring, a pyrimidine ring, a pyridazine ring, and a pyrazine ring. HA The compound or salt thereof, or a solvate thereof, according to [A17], wherein E ) is selected from the group consisting of a pyridine ring, a pyrimidine ring, a pyridazine ring, and a pyrazine ring. [A20.5] A 5- to 6-membered monocyclic aromatic heterocycle (E HA [A21] The compound according to [A17], or a salt thereof, or a solvate of the compound or the salt, wherein E ) is a pyridine ring or a pyrazine ring. HA [A22] The compound according to [A17], or a salt thereof, or a solvate of the compound or the salt, wherein the D ring and the E ring are represented by the following formulae: (where * represents R in formula (1) 5 is the carbon to which R is bonded, and ** is the carbon to which R is bonded in formula (1). 6 and represent carbon atoms to which they are bonded. In the formula, the D ring is represented as "D ring" and the E ring is represented as "E ring". [A23] The compound according to [A17], or a salt thereof, or a solvate of the same, wherein the D ring and the E ring are represented as (where * represents R in formula (1) 5 is the carbon to which R is bonded, and ** is the carbon to which R is bonded in formula (1). 6and each represent a carbon atom to which R is bonded. In the formula, the D ring is represented as "D ring" and the E ring is represented as "E ring". [A24] The compound according to [A17], or a salt thereof, or a solvate thereof, wherein the E ring is unsubstituted or has one or more R E and one or more R E are each independently deuterium, halogen, cyano, nitro, hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, oxo, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, wherein the hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 The compound according to any one of [A14] to [A23], or a salt thereof, or a solvate thereof, wherein the aryl and the 5- to 10-membered heteroaryl are optionally further substituted. [A25] The compound according to any one of [A14] to [A23], or a salt thereof, or a solvate thereof, wherein the E ring is unsubstituted or substituted with one or more R E and one or more R E are each independently a halogen, C 1 -C6 Alkyl, C 1 -C 6 The compound according to any one of [A14] to [A23], or a salt thereof, or a solvate thereof, wherein the ring E is unsubstituted or contains one or more R E and one or more R E [A26] The compound according to any one of [A14] to [A23], or a salt thereof, or a solvate thereof, wherein R is independently selected from the group consisting of fluorine, chlorine, methoxy, dihydroxyboryl, methyl, and t-butyl. 4 is optionally substituted C 6 -C 10 Aryl (R 4A ) or optionally substituted 5- to 10-membered heteroaryl (R 4HA [A27] A compound according to any one of [A1] to [A25.5], a salt thereof, or a solvate thereof, wherein R 4 is optionally substituted C 6 -C 10 Aryl (R 4A [A28] The compound according to any one of [A1] to [A26], a salt thereof, or a solvate thereof, wherein 6 -C 10 Aryl (R 4A The compound according to [A26] or [A27], or a salt thereof, or a solvate of the compound or the salt, wherein C is phenyl. 6 -C 10 Aryl (R 4A ) is unsubstituted or contains one or more R a and one or more R a are each independently deuterium, halogen, cyano, nitro, hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, oxo, C 1 -C 6 Alkyl, C 2 -C6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, wherein the hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 The compound according to any one of [A26] to [A28], a salt thereof, or a solvate thereof, wherein the aryl and the 5- to 10-membered heteroaryl are optionally further substituted. [A30] C 6 -C 10 Aryl (R 4A ) is unsubstituted or contains one or more R a and one or more R a are each independently a halogen, a cyano, a hydroxy, an amino, 1 -C 6 Alkyl, haloC 1 -C 6 Alkyl, hydroxy C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, HaloC 1 -C 6 Alkoxy, and C 1 -C 6 The compound according to any one of [A26] to [A28], or a salt thereof, or a solvate thereof, selected from the group consisting of alkylsulfonylamino. [A31] C 6 -C 10Aryl (R 4A ) is unsubstituted or contains one or more R a and one or more R a are each independently halogen, hydroxy, haloC 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, HaloC 1 -C 6 Alkoxy, and C 1 -C 6 The compound according to any one of [A26] to [A28], or a salt thereof, or a solvate thereof, selected from the group consisting of alkylsulfonylamino. [A32] R 4 is an optionally substituted 5- to 10-membered heteroaryl (R 4HA [A33] A compound according to any one of [A1] to [A26], a salt thereof, or a solvate thereof, wherein R is a 5- to 10-membered heteroaryl (R 4HA The compound according to [A26] or [A32], or a salt thereof, or a solvate thereof, wherein R is selected from the group consisting of furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, benzofuranyl, benzothienyl, benzothiadiazolyl, benzothiazolyl, benzoxazolyl, benzoxadiazolyl, benzimidazolyl, benzotriazolyl, indolyl, isoindolyl, indazolyl, azaindolyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinyl, indolizinyl, imidazopyridyl, pyrazolopyridyl, triazolopyridyl, pyrrolopyrazinyl, and furopyridyl. [A34] 5- to 10-membered heteroaryl (R 4HA) is selected from the group consisting of furyl, thienyl, pyrrolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, benzofuranyl, benzothienyl, benzothiadiazolyl, benzothiazolyl, benzoxazolyl, benzoxadiazolyl, benzimidazolyl, benzotriazolyl, indolyl, isoindolyl, indazolyl, azaindolyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinyl, indolizinyl, imidazopyridyl, pyrazolopyridyl, triazolopyridyl, pyrrolopyrazinyl, and furopyridyl, or a salt thereof, or a solvate thereof, according to [A26] or [A32]. [A35] A compound according to [A26] or [A32], wherein 5- to 10-membered heteroaryl (R 4HA The compound according to [A26] or [A32], or a salt thereof, or a solvate thereof, wherein R 2 is selected from the group consisting of pyridyl, pyrimidyl, benzimidazolyl, indolyl, indazolyl, and pyrazolopyridyl. [A36] A compound according to [A26] or [A32], or a salt thereof, or a solvate thereof, wherein R 2 is selected from the group consisting of 5- to 10-membered heteroaryl (R 4HA The compound according to [A26] or [A32], or a salt thereof, or a solvate thereof, wherein R 1 is selected from the group consisting of pyrimidyl, benzimidazolyl, indolyl, indazolyl, and pyrazolopyridyl. [A37] A compound according to [A26] or [A32], or a salt thereof, or a solvate thereof, wherein R 1 is selected from the group consisting of 5- to 10-membered heteroaryl (R 4HA [A38] A compound according to [A26] or [A32], or a salt thereof, or a solvate of the compound or the salt, wherein R 1 is 1H-indazol-6-yl or 1H-indazol-4-yl. 4HA [A39] A compound according to [A26] or [A32], or a salt thereof, or a solvate of the compound or the salt, wherein R 1 is 1H-indazol-4-yl. 4HA ) is unsubstituted or contains one or more R a and one or more R a are each independently deuterium, halogen, cyano, nitro, hydroxy, thio, amino, C 1 -C 6 Alkoxy, C1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, oxo, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, wherein the hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 The compound according to any one of [A32] to [A38], or a salt thereof, or a solvate thereof, wherein the aryl and 5- to 10-membered heteroaryl are optionally further substituted. [A40] A compound according to any one of [A32] to [A38], or a salt thereof, or a solvate thereof, wherein the 5- to 10-membered heteroaryl (R 4HA ) is unsubstituted or contains one or more R a and one or more R a are each independently a halogen, a cyano, a hydroxy, an amino, 1 -C 6 Alkyl, haloC 1 -C 6 Alkyl, hydroxy C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, HaloC 1 -C 6 Alkoxy, and C 1 -C 6The compound according to any one of [A32] to [A38], or a salt thereof, or a solvate thereof, selected from the group consisting of alkylsulfonylamino. [A41] A 5- to 10-membered heteroaryl (R 4HA ) is unsubstituted or contains one or more R a and one or more R a are each independently a halogen, a cyano, an amino, or C 1 -C 6 Alkyl, and haloC 1 -C 6 [A42] A compound according to any one of [A32] to [A38], a salt thereof, or a solvate thereof, wherein R is selected from the group consisting of 5- to 10-membered heteroaryl (R 4HA [A43] A compound according to any one of [A32] to [A38], or a salt thereof, or a solvate of the compound or the salt, wherein R 1 is 1H-indazol-4-yl or 1H-indazol-4-yl substituted with one or more halogen atoms. 4HA [A44] A compound according to any one of [A32] to [A38], or a salt thereof, or a solvate of the compound or the salt, wherein R 1 is 1H-indazol-4-yl substituted with one or more halogen atoms. 4HA [A44.5] A compound according to any one of [A32] to [A38], or a salt thereof, or a solvate thereof, wherein R 1 is 1H-indazol-4-yl substituted with halogen at least at any one of the 5-, 6-, and 7-positions. 4HA ) has the following formula: [wherein * represents R in formula (1)] 4 represents the carbon atom to which R is bonded; a5 , R a6 and R a7 are independently hydrogen or halogen, and R a5 , R a6 and R a7 [A45] A compound according to any one of [A32] to [A38], or a salt thereof, or a solvate of the compound or the salt, wherein R4HA [A46] A compound according to any one of [A32] to [A38], a salt thereof, or a solvate of the compound or the salt, wherein R is 1H-indazol-4-yl substituted with a halogen atom at at least one of the 5-, 6-, and 7-positions, and the halogen atom is fluorine or chlorine. 4HA [A46.5] A compound according to any one of [A32] to [A38], a salt thereof, or a solvate thereof, wherein R is 1H-indazol-4-yl substituted with halogen at any one or two of the 5-, 6-, and 7-positions, and the halogen is selected from the group consisting of fluorine, chlorine, a combination of fluorine and fluorine, and a combination of fluorine and chlorine. [A46.6] A compound according to any one of [A32] to [A38], a salt thereof, or a solvate thereof, wherein R is 1H-indazol-4-yl substituted with halogen at any one or two of the 5-, 6-, and 7-positions, and the halogen is selected from the group consisting of fluorine, chlorine, a combination of fluorine and fluorine, and a combination of fluorine and chlorine. 4HA [B1] A compound according to any one of [A32] to [A38], a salt thereof, or a solvate of the compound or the salt, of formula (2): [In the formula, R 4 is an optionally substituted C 6 -C 10 Aryl (R 4A ), optionally substituted 4- to 10-membered heterocyclyl, and optionally substituted 5- to 10-membered heteroaryl (R 4HA X is selected from the group consisting of 5 is CR x5 or N, and X 6 is CR x6 or N, and X 10a is CR x10a or N, R x5、 R x6 , R 6a and R x10a are each independently hydrogen, deuterium, halogen, cyano, nitro, hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, C1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, wherein the hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 The aryl and 5- to 10-membered heteroaryl may be further substituted or R x5 and R x6 , R x6 and R 6a , or R 6a and R x10a may be taken together with the atom to which they are attached to form an optionally substituted ring E.] or a salt thereof, or a solvate thereof. [B2] A compound represented by the formula: X 5 is CR x5 or N, and X 6 is CR x6 and X 10a is CR x10a or N. [B3] The compound according to [B1], or a salt thereof, or a solvate of the compound or the salt, 5 is CH, and X 6 is CR x6 and X 10a is CR x10a[B4] The compound according to [B1] or [B2], or a salt thereof, or a solvate thereof, wherein R x6 is hydrogen, halogen, hydroxy, C 1 -C 6 Alkylthio, C 1 -C 6 Acylamino, Mono C 1 -C 6 Alkylamino, C 1 -C 6 Alkylsulfonylamino, C 3 -C 8 Cycloalkylsulfonylamino, C 1 -C 6 Alkoxy, HaloC 1 -C 6 Alkoxy, hydroxy C 1 -C 6 Alkoxy, C 1 -C 6 Alkoxy C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkoxy, 4- to 10-membered heterocyclyl C 1 -C 6 Alkoxy, C 3 -C 8 cycloalkoxy, 4- to 10-membered heterocyclyloxy, C 1 -C 6 Acyl, Mono C 3 -C 8 Cycloalkylaminocarbonyl, 4- to 8-membered cyclic aminocarbonyl, diC 1 -C 6 Alkylphosphoryl, C 1 -C 6 Alkyl, haloC 1 -C 6 Alkyl, hydroxy C 1 -C 6 Alkyl, diC 1 -C 6 Alkylaminocarbonyl C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl C 1-C 6 Alkyl, C 2 -C 6 Alkenyl, Hydroxy C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, hydroxy C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, 1 -C 6 Alkylthio, C 1 -C 6 Alkoxy, C 1 -C 6 Alkoxy C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkoxy, 4- to 10-membered heterocyclyl C 1 -C 6 Alkoxy, C 3 -C 8 cycloalkoxy, 4- to 10-membered heterocyclyloxy, C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 The aryl and 5- to 10-membered heteroaryl may further independently be selected from halogen, cyano, hydroxy, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, oxo, halo C 1 -C 6 Alkyl, and C 3 -C 8[B5] The compound according to any one of [B1] to [B3], or a salt thereof, or a solvate thereof, wherein R x6 But hydrogen, halogen, C 1 -C 6 Alkoxy, HaloC 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkoxy, C 1 -C 6 Alkyl, haloC 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkyl, and C 3 -C 8 [B6] The compound according to any one of [B1] to [B3], or a salt thereof, or a solvate thereof, wherein R is selected from the group consisting of cycloalkyl. x6 But hydrogen, C 1 -C 6 Alkoxy, C 1 -C 6 Alkyl, and C 3 -C 8 [B7] The compound according to any one of [B1] to [B3], or a salt thereof, or a solvate thereof, wherein R is selected from the group consisting of cycloalkyl. x6is selected from the group consisting of hydrogen, methoxy, ethoxy, propoxy, propan-2-yloxy, 3-methylbutoxy, [(2S)-butan-2-yl]oxy, [(2R)-butan-2-yl]oxy, methyl, ethyl, propyl, propan-2-yl, 2-methylpropyl, butan-2-yl, 3-methylbutyl, pentan-3-yl, cyclopropyl, cyclobutyl, cyclopentyl, 1-methylcyclopropyl, 3,3-dimethylcyclobutyl, and spiro[2.3]hexan-5-yl, or a salt thereof, or a solvate thereof according to any one of [B1] to [B3]. x10a But hydrogen, halogen, cyano, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, and C 3 -C 8 [B9] The compound according to any one of [B1] to [B7], or a salt thereof, or a solvate thereof, wherein R is selected from the group consisting of cycloalkyl. x10a [B10] The compound according to any one of [B1] to [B7], or a salt thereof, or a solvate thereof, wherein R is selected from the group consisting of hydrogen, chlorine, bromine, cyano, methyl, ethyl, propyl, propan-2-yl, vinyl, ethynyl, and cyclopropyl. 6a But hydrogen, halogen, cyano, halo C 1 -C 6 Alkoxy, and C 1 -C 6 [B11] The compound according to any one of [B1] to [B9], or a salt thereof, or a solvate thereof, wherein R is selected from the group consisting of alkyl. 6a [B12] The compound according to any one of [B1] to [B9], or a salt thereof, or a solvate thereof, wherein R is selected from the group consisting of hydrogen, fluorine, chlorine, bromine, cyano, difluoromethoxy, methyl, and ethyl. 6a and R x10aand R are taken together with the atom to which they are attached to form an optionally substituted ring E, or a salt thereof, or a solvate thereof, according to any one of [B1] to [B7]. [B13] The compound according to any one of [B1] to [B7], wherein ring E is a 3- to 10-membered monocyclic alicyclic ring, a benzene ring, a 3- to 12-membered monocyclic heterocyclic ring, and a 5- to 6-membered monocyclic aromatic heterocyclic ring (E HA [B14] The compound according to [B12], or a salt thereof, or a solvate thereof, wherein ring E is selected from the group consisting of a benzene ring or a 5- to 6-membered monocyclic aromatic heterocycle (E HA [B15] The compound according to [B12], or a salt thereof, or a solvate of the compound or the salt, wherein E HA [B16] The compound according to [B13] or [B14], or a salt thereof, or a solvate thereof, wherein E ) is selected from the group consisting of a thiophene ring, an imidazole ring, a pyrazole ring, a thiazole ring, an isothiazole ring, a pyridine ring, a pyrimidine ring, a pyridazine ring, and a pyrazine ring. HA [B17] The compound according to [B13] or [B14], or a salt thereof, or a solvate thereof, wherein E ) is selected from the group consisting of a pyridine ring, a pyrimidine ring, a pyridazine ring, and a pyrazine ring. HA [B18] The compound according to [B13] or [B14], or a salt thereof, or a solvate of the compound or the salt, wherein E ) is a pyridine ring or a pyrazine ring. HA [B19] The compound according to [B13] or [B14], or a salt thereof, or a solvate of the compound or the salt, wherein the E ring is a ring represented by the following formula: (where * represents R in formula (2) 6a is the carbon atom to which R is bonded, and ** is the carbon atom to which R is bonded in formula (2). x10a [B20] The compound according to [B12], or a salt thereof, or a solvate of the same, wherein the E ring is represented by the following formula: (where * represents R in formula (2) 6a is the carbon atom to which R is bonded, and ** is the carbon atom to which R is bonded in formula (2). x10aand each represent a carbon atom to which R is bonded. In the formula, the E ring is represented as "E ring". [B21] The compound according to [B12], or a salt thereof, or a solvate thereof, wherein the E ring is unsubstituted or is substituted with one or more R E and one or more R E are each independently deuterium, halogen, cyano, nitro, hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, oxo, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, wherein the hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 The compound according to any one of [B12] to [B20], or a salt thereof, or a solvate thereof, wherein the aryl and the 5- to 10-membered heteroaryl are optionally further substituted. [B22] The compound according to any one of [B12] to [B20], or a salt thereof, or a solvate thereof, wherein the E ring is unsubstituted or contains one or more R E and one or more R E are each independently a halogen, C 1 -C 6Alkoxy, boryl, and C 1 -C 6 [B23] The compound according to any one of [B12] to [B20], or a salt thereof, or a solvate thereof, wherein ring E is unsubstituted or contains one or more R E and one or more R E [B24] The compound according to any one of [B12] to [B20], or a salt thereof, or a solvate of the compound or the salt, wherein R is independently selected from the group consisting of fluorine, chlorine, methoxy, dihydroxyboryl, methyl, and t-butyl. 4 is optionally substituted C 6 -C 10 Aryl (R 4A ) or optionally substituted 5- to 10-membered heteroaryl (R 4HA [B25] The compound according to any one of [B1] to [B23], or a salt thereof, or a solvate of the compound or the salt, wherein R 4 is optionally substituted C 6 -C 10 Aryl (R 4A [B26] The compound according to any one of [B1] to [B23], or a salt thereof, or a solvate of the compound or the salt, wherein 6 -C 10 Aryl (R 4A The compound according to [B24] or [B25], or a salt thereof, or a solvate of the compound or the salt, wherein C is phenyl. 6 -C 10 Aryl (R 4A ) is unsubstituted or contains one or more R a and one or more R a are each independently deuterium, halogen, cyano, nitro, hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, oxo, C 1 -C 6 Alkyl, C 2 -C 6Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, wherein the hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 The compound according to any one of [B24] to [B26], a salt thereof, or a solvate thereof, wherein the aryl and 5- to 10-membered heteroaryl are optionally further substituted. [B28] C 6 -C 10 Aryl (R 4A ) is unsubstituted or contains one or more R a and one or more R a are each independently a halogen, a cyano, a hydroxy, an amino, 1 -C 6 Alkyl, haloC 1 -C 6 Alkyl, hydroxy C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, HaloC 1 -C 6 Alkoxy, and C 1 -C 6 The compound according to any one of [B24] to [B26], or a salt thereof, or a solvate thereof, selected from the group consisting of alkylsulfonylamino. [B29] C 6 -C 10 Aryl (R4A ) is unsubstituted or contains one or more R a and one or more R a are each independently halogen, hydroxy, haloC 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, HaloC 1 -C 6 Alkoxy and C 1 -C 6 [B30] The compound according to any one of [B24] to [B26], or a salt thereof, or a solvate thereof, wherein R is selected from the group consisting of alkylsulfonylamino. 4 is an optionally substituted 5- to 10-membered heteroaryl (R 4HA [B31] A compound according to any one of [B1] to [B23], a salt thereof, or a solvate thereof, wherein R is a 5- to 10-membered heteroaryl (R 4HA The compound or salt thereof according to [B24] or [B30], or a solvate thereof, wherein R is selected from the group consisting of furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, benzofuranyl, benzothienyl, benzothiadiazolyl, benzothiazolyl, benzoxazolyl, benzoxadiazolyl, benzimidazolyl, benzotriazolyl, indolyl, isoindolyl, indazolyl, azaindolyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinyl, indolizinyl, imidazopyridyl, pyrazolopyridyl, triazolopyridyl, pyrrolopyrazinyl, and furopyridyl. [B32] 5- to 10-membered heteroaryl (R 4HA) is selected from the group consisting of furyl, thienyl, pyrrolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, benzofuranyl, benzothienyl, benzothiadiazolyl, benzothiazolyl, benzoxazolyl, benzoxadiazolyl, benzimidazolyl, benzotriazolyl, indolyl, isoindolyl, indazolyl, azaindolyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinyl, indolizinyl, imidazopyridyl, pyrazolopyridyl, triazolopyridyl, pyrrolopyrazinyl, and furopyridyl, or a salt thereof, or a solvate thereof, according to [B24] or [B30]. [B33] A compound according to [B24] or [B30], wherein 5- to 10-membered heteroaryl (R 4HA [B34] A compound according to [B24] or [B30], or a salt thereof, or a solvate thereof, wherein 5- to 10-membered heteroaryl (R 4HA [B35] A compound according to [B24] or [B30], or a salt thereof, or a solvate thereof, wherein R 2 is selected from the group consisting of pyrimidyl, benzimidazolyl, indolyl, indazolyl, and pyrazolopyridyl. 4HA [B36] A compound according to [B24] or [B30], or a salt thereof, or a solvate of the compound or the salt, wherein R 1 is 1H-indazol-6-yl or 1H-indazol-4-yl. 4HA [B37] A compound according to [B24] or [B30], or a salt thereof, or a solvate of the compound or the salt, wherein R 1 is 1H-indazol-4-yl. 4HA ) is unsubstituted or contains one or more R a and one or more R a are each independently halogen, cyano, nitro, hydroxy, thio, amino, C 1 -C 6 Alkoxy, C1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, oxo, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, wherein the hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 The compound according to any one of [B31] to [B36], or a salt thereof, or a solvate thereof, wherein the aryl and the 5- to 10-membered heteroaryl are optionally further substituted. [B38] The compound according to any one of [B31] to [B36], or a salt thereof, or a solvate thereof, wherein the 5- to 10-membered heteroaryl (R 4HA ) is unsubstituted or contains one or more R a and one or more R a are each independently a halogen, a cyano, a hydroxy, an amino, 1 -C 6 Alkyl, haloC 1 -C 6 Alkyl, hydroxy C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, HaloC 1 -C 6 Alkoxy and C 1 -C 6The compound according to any one of [B31] to [B36], or a salt thereof, or a solvate thereof, wherein R is selected from the group consisting of alkylsulfonylamino. [B39] A 5- to 10-membered heteroaryl (R 4HA ) is unsubstituted or contains one or more R a and one or more R a are each independently a halogen, a cyano, an amino, or C 1 -C 6 Alkyl, haloC 1 -C 6 [B40] A compound according to any one of [B31] to [B36], or a salt thereof, or a solvate thereof, wherein R is selected from the group consisting of 5- to 10-membered heteroaryl (R 4HA [B41] A compound according to any one of [B31] to [B36], or a salt thereof, or a solvate of the compound or the salt, wherein R 1 is 1H-indazol-4-yl or 1H-indazol-4-yl substituted with one or more halogen atoms. 4HA [B42] A compound according to any one of [B31] to [B36], or a salt thereof, or a solvate of the compound or the salt, wherein R 1 is 1H-indazol-4-yl substituted with one or more halogen atoms. 4HA [B43] A compound according to any one of [B31] to [B36], or a salt thereof, or a solvate of the compound or the salt, wherein R 1 is 1H-indazol-4-yl substituted with a halogen atom at least at one of the 5-, 6-, and 7-positions. 4HA [B44] A compound according to any one of [B31] to [B36], a salt thereof, or a solvate thereof, wherein R is 1H-indazol-4-yl substituted with a halogen atom at at least one of the 5-, 6-, and 7-positions, and the halogen atom is fluorine or chlorine. 4HA[B44.5] A compound according to any one of [B31] to [B36], a salt thereof, or a solvate thereof, wherein 5- to 10-membered heteroaryl (R) is 1H-indazol-4-yl substituted with halogen at any one or two of the 5-, 6-, and 7-positions, and the halogen is selected from the group consisting of fluorine, chlorine, a combination of fluorine and fluorine, and a combination of fluorine and chlorine. 4HA [C1] A compound according to any one of [B31] to [B36], a salt thereof, or a solvate of the compound or the salt, of formula (3): [In the formula, R 4 is an optionally substituted C 6 -C 10 Aryl (R 4A ), optionally substituted 4- to 10-membered heterocyclyl, and optionally substituted 5- to 10-membered heteroaryl (R 4HA X is selected from the group consisting of 5 is CR x5 or N, and X 6 is CR x6 or N, and X 7 is CR x7 or N, and X 8 is CR x8 or N, and X 9 is CR x9 or N, and X 10 is CR x10 or N, R x5、 R x6 , R x7 , R x8 , R x9 and R x10 are each independently hydrogen, deuterium, halogen, cyano, nitro, hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, C 1 -C6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, wherein the hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 The aryl and 5- to 10-membered heteroaryl may be further substituted.] or a salt thereof, or a solvate thereof. [C2] X 5 is CR x5 or N, and X 6 is CR x6 and X 7 is CR x7 or N, and X 8 is CR x8 or N, and X 9 is CR x9 or N, and X 10 is CR x10 or N. [C3] The compound according to [C1], or a salt thereof, or a solvate of the compound or the salt, 5 is CH, and X 6 is CR x6 and X 7 is CR x7 or N, and X 8 is CR x8 or N, and X 9 is CRx9 or N, and X 10 is CR x10 or N. [C4] The compound according to [C1] or [C2], or a salt thereof, or a solvate thereof. 7 is N and X 8 is CR x8 and X 9 is CR x9 and X 10 is CR x10 Or X 7 is CR x7 and X 8 is N and X 9 is CR x9 and X 10 is CR x10 Or X 7 is CR x7 and X 8 is CR x8 and X 9 is N and X 10 is CR x10 Or X 7 is CR x7 and X 8 is CR x8 and X 9 is CR x9 and X 10 is N or X 7 is N and X 8 is CR x8 and X 9 is CR x9 and X 10 is N or X 7 is CR x7 and X 8 is N and X 9 is CR x9 and X 10 is N or X 7 is N and X 8 is N and X 9 is CR x9 and X 10 is CR x10 or a compound according to any one of [C1] to [C3], a salt thereof, or a solvate thereof. [C4.5] X 7is N and X 8 is CR x8 and X 9 is CR x9 and X 10 is CR x10 Or X 7 is CR x7 and X 8 is N and X 9 is CR x9 and X 10 is CR x10 Or X 7 is CR x7 and X 8 is CR x8 and X 9 is N and X 10 is CR x10 Or X 7 is CR x7 and X 8 is CR x8 and X 9 is CR x9 and X 10 [C5] The compound according to any one of [C1] to [C3], or a salt thereof, or a solvate of the compound or the salt, wherein R x6 is hydrogen, halogen, hydroxy, C 1 -C 6 Alkylthio, C 1 -C 6 Acylamino, Mono C 1 -C 6 Alkylamino, C 1 -C 6 Alkylsulfonylamino, C 3 -C 8 Cycloalkylsulfonylamino, C 1 -C 6 Alkoxy, HaloC 1 -C 6 Alkoxy, hydroxy C 1 -C 6 Alkoxy, C 1 -C 6 Alkoxy C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkyl C 1 -C6 Alkoxy, 4- to 10-membered heterocyclyl C 1 -C 6 Alkoxy, C 3 -C 8 cycloalkoxy, 4- to 10-membered heterocyclyloxy, C 1 -C 6 Acyl, Mono C 3 -C 8 Cycloalkylaminocarbonyl, 4- to 8-membered cyclic aminocarbonyl, diC 1 -C 6 Alkylphosphoryl, C 1 -C 6 Alkyl, haloC 1 -C 6 Alkyl, hydroxy C 1 -C 6 Alkyl, diC 1 -C 6 Alkylaminocarbonyl C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, Hydroxy C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, hydroxy C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, 1 -C 6 Alkylthio, C 1 -C 6 Alkoxy, C 1 -C 6 Alkoxy C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkoxy, 4- to 10-membered heterocyclyl C1 -C 6 Alkoxy, C 3 -C 8 cycloalkoxy, 4- to 10-membered heterocyclyloxy, C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 The aryl and 5- to 10-membered heteroaryl may further independently be selected from halogen, cyano, hydroxy, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, oxo, halo C 1 -C 6 Alkyl, and C 3 -C 8 [C5.1] The compound according to any one of [C1] to [C4], or a salt thereof, or a solvate thereof, wherein R x6 But hydrogen, halogen, C 1 -C 6 Alkoxy, HaloC 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkoxy, C 1 -C 6 Alkyl, haloC 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkyl, and C 3 -C 8 [C5.2] The compound according to any one of [C1] to [C3], or a salt thereof, or a solvate thereof, wherein R is selected from the group consisting of cycloalkyl.x6 But hydrogen, C 1 -C 6 Alkoxy, C 1 -C 6 Alkyl, and C 3 -C 8 [C6] The compound according to any one of [C1] to [C4], or a salt thereof, or a solvate thereof, wherein R is selected from the group consisting of cycloalkyl. x6 is selected from the group consisting of hydrogen, methoxy, ethoxy, propoxy, propan-2-yloxy, 3-methylbutoxy, [(2S)-butan-2-yl]oxy, [(2R)-butan-2-yl]oxy, methyl, ethyl, propyl, propan-2-yl, 2-methylpropyl, butan-2-yl, 3-methylbutyl, pentan-3-yl, cyclopropyl, cyclobutyl, cyclopentyl, 1-methylcyclopropyl, 3,3-dimethylcyclobutyl, and spiro[2.3]hexan-5-yl, or a salt thereof, or a solvate thereof, according to any one of [C1] to [C4]. [C6.5] A compound represented by formula (3): [In the formula, R 4 is an optionally substituted 5- to 10-membered heteroaryl (R 4HA ) and 5-10 membered heteroaryl (R 4HA ) is 1H-indazol-4-yl or 1H-indazol-4-yl substituted with one or more halogens, and X 5 is CR x5 or N, and X 6 is CR x6 and R x6 is selected from the group consisting of hydrogen, methoxy, ethoxy, propoxy, propan-2-yloxy, 3-methylbutoxy, [(2S)-butan-2-yl]oxy, [(2R)-butan-2-yl]oxy, methyl, ethyl, propyl, propan-2-yl, 2-methylpropyl, butan-2-yl, 3-methylbutyl, pentan-3-yl, cyclopropyl, cyclobutyl, cyclopentyl, 1-methylcyclopropyl, 3,3-dimethylcyclobutyl, and spiro[2.3]hexan-5-yl; 7 is CR x7 or N, and X8 is CR x8 or N, and X 9 is CR x9 or N, and X 10 is CR x10 or N, R x5、 R x7 , R x8 , R x9 and R x10 are each independently hydrogen, deuterium, halogen, cyano, nitro, hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, wherein the hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 The aryl and 5- to 10-membered heteroaryl may be further substituted.] or a salt thereof, or a solvate thereof. [C6.6] A compound represented by formula (3): [In the formula, R 4is 1H-indazol-4-yl or 1H-indazol-4-yl substituted with one or more halogens, and X 5 is CR x5 or N, and X 6 is CR x6 and R x6 is selected from the group consisting of hydrogen, methoxy, ethoxy, propoxy, propan-2-yloxy, 3-methylbutoxy, [(2S)-butan-2-yl]oxy, [(2R)-butan-2-yl]oxy, methyl, ethyl, propyl, propan-2-yl, 2-methylpropyl, butan-2-yl, 3-methylbutyl, pentan-3-yl, cyclopropyl, cyclobutyl, cyclopentyl, 1-methylcyclopropyl, 3,3-dimethylcyclobutyl, and spiro[2.3]hexan-5-yl; 7 is CR x7 or N, and X 8 is CR x8 or N, and X 9 is CR x9 or N, and X 10 is CR x10 or N, R x5、 R x7 , R x8 , R x9 and R x10 are each independently hydrogen, deuterium, halogen, cyano, nitro, hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, wherein the hydroxy, thio, amino, C 1 -C6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 The aryl and 5- to 10-membered heteroaryl may be further substituted.] or a salt thereof, or a solvate thereof. [C7] X 7 is CR x7 [C8] The compound according to any one of [C1] to [C6.5], or a salt thereof, or a solvate thereof, wherein R x7 is hydrogen, halogen, C 1 -C 6 Alkoxy or C 1 -C 6 [C9] The compound according to [C7], a salt thereof, or a solvate of the compound or the salt, wherein X is alkyl. 7 [C10] The compound according to any one of [C1] to [C6.5], or a salt thereof, or a solvate of the compound or the salt, wherein X is N. 8 is CR x8 [C11] The compound according to any one of [C1] to [C9], or a salt thereof, or a solvate thereof, wherein R x8 is hydrogen, halogen, C 1 -C 6 Alkoxy or C 1 -C 6 The compound according to [C10], a salt thereof, or a solvate thereof, wherein X is alkyl. 8 The compound according to any one of [C1] to [C9], a salt thereof, or a solvate of the compound or the salt, wherein X is N. [C13] 9 is CR x9 [C14] The compound according to any one of [C1] to [C12], a salt thereof, or a solvate thereof, wherein Rx9 is hydrogen, halogen, C 1 -C 6 Alkoxy, C 1 -C 6 The compound according to [C13], a salt thereof, or a solvate thereof, wherein X is selected from the group consisting of alkyl and boryl. 9 [C16] The compound according to any one of [C1] to [C12], a salt thereof, or a solvate of the compound or the salt, wherein X is N. 10 is CR x10 [C17] The compound according to any one of [C1] to [C15], or a salt thereof, or a solvate thereof, wherein R x10 is hydrogen, halogen, C 1 -C 6 Alkoxy or C 1 -C 6 The compound according to [C16], a salt thereof, or a solvate of the compound or the salt, wherein X is alkyl. 10 [C20] The compound according to any one of [C1] to [C12], a salt thereof, or a solvate of the compound or the salt, wherein R 4 is optionally substituted C 6 -C 10 Aryl (R 4A ) or optionally substituted 5- to 10-membered heteroaryl (R 4HA [C21] A compound according to any one of [C1] to [C18] (excluding [C6.5] and [C6.6]), or a salt thereof, or a solvate thereof, wherein R 4 is optionally substituted C 6 -C 10 Aryl (R 4A [C22] A compound according to any one of [C1] to [C18] (excluding [C6.5] and [C6.6]), or a salt thereof, or a solvate thereof. 6 -C 10 Aryl (R 4A [C23] The compound according to [C20] or [C21], or a salt thereof, or a solvate of the compound or the salt, wherein 6 -C 10 Aryl (R 4A) is unsubstituted or contains one or more R a and one or more R a are each independently deuterium, halogen, cyano, nitro, hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, oxo, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, wherein the hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 The compound according to any one of [C20] to [C22], a salt thereof, or a solvate thereof, wherein the aryl and the 5- to 10-membered heteroaryl are optionally further substituted. 6 -C 10 Aryl (R 4A ) is unsubstituted or contains one or more R a and one or more R a are each independently a halogen, a cyano, a hydroxy, an amino, 1 -C 6 Alkyl, haloC 1 -C6 Alkyl, hydroxy C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, HaloC 1 -C 6 Alkoxy, and C 1 -C 6 The compound according to any one of [C20] to [C22], or a salt thereof, or a solvate thereof, wherein the compound is selected from the group consisting of alkylsulfonylamino. [C25] 6 -C 10 Aryl (R 4A ) is unsubstituted or contains one or more R a and one or more R a are each independently halogen, hydroxy, haloC 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, HaloC 1 -C 6 [C26] The compound according to any one of [C20] to [C22], or a salt thereof, or a solvate thereof, wherein R is selected from the group consisting of alkoxy and alkylsulfonylamino. 4 is an optionally substituted 5- to 10-membered heteroaryl (R 4HA [C27] A compound according to any one of [C1] to [C18] (excluding [C6.5] and [C6.6]), or a salt thereof, or a solvate thereof, wherein R 4HAor a salt thereof, or a solvate thereof, according to [C20] or [C26], wherein R is selected from the group consisting of furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, benzofuranyl, benzothienyl, benzothiadiazolyl, benzothiazolyl, benzoxazolyl, benzoxadiazolyl, benzimidazolyl, benzotriazolyl, indolyl, isoindolyl, indazolyl, azaindolyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinyl, indolizinyl, imidazopyridyl, pyrazolopyridyl, triazolopyridyl, pyrrolopyrazinyl, and furopyridyl. [C28] 5- to 10-membered heteroaryl (R 4HA ) is selected from the group consisting of furyl, thienyl, pyrrolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, benzofuranyl, benzothienyl, benzothiadiazolyl, benzothiazolyl, benzoxazolyl, benzoxadiazolyl, benzimidazolyl, benzotriazolyl, indolyl, isoindolyl, indazolyl, azaindolyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinyl, indolizinyl, imidazopyridyl, pyrazolopyridyl, triazolopyridyl, pyrrolopyrazinyl, and furopyridyl, or a salt thereof, or a solvate thereof. [C29] A compound according to [C20] or [C26], wherein 5- to 10-membered heteroaryl (R 4HA The compound according to [C20] or [C26], or a salt thereof, or a solvate thereof, wherein R 2 is selected from the group consisting of pyridyl, pyrimidyl, benzimidazolyl, indolyl, indazolyl, and pyrazolopyridyl. [C30] A 5- to 10-membered heteroaryl (R 4HAThe compound according to [C20] or [C26], or a salt thereof, or a solvate thereof, wherein R 2 is selected from the group consisting of pyrimidyl, benzimidazolyl, indolyl, indazolyl, and pyrazolopyridyl. [C31] A 5- to 10-membered heteroaryl (R 4HA [C32] A compound according to [C20] or [C26], or a salt thereof, or a solvate of the compound or the salt, wherein R 1 is 1H-indazol-6-yl or 1H-indazol-4-yl. 4HA [C33] A compound according to [C20] or [C26], or a salt thereof, or a solvate of the compound or the salt, wherein R 4HA ) is unsubstituted or contains one or more R a and one or more R a are each independently deuterium, halogen, cyano, nitro, hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, oxo, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, wherein the hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 The compound according to any one of [C27] to [C32], or a salt thereof, or a solvate thereof, wherein the aryl and the 5- to 10-membered heteroaryl are optionally further substituted. [C34] A 5- to 10-membered heteroaryl (R 4HA ) is unsubstituted or contains one or more R a and one or more R a are each independently a halogen, a cyano, a hydroxy, an amino, 1 -C 6 Alkyl, haloC 1 -C 6 Alkyl, hydroxy C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, HaloC 1 -C 6 The compound according to any one of [C27] to [C32], or a salt thereof, or a solvate thereof, wherein R is selected from the group consisting of alkoxy and alkylsulfonylamino. [C35] 5- to 10-membered heteroaryl (R 4HA ) is unsubstituted or contains one or more R a and one or more R a are each independently a halogen, a cyano, an amino, or C 1 -C 6 Alkyl, and haloC 1 -C 6 The compound according to any one of [C27] to [C32], or a salt thereof, or a solvate thereof, wherein R is selected from the group consisting of 5- to 10-membered heteroaryl (R 4HA [C37] A compound according to any one of [C27] to [C32], or a salt thereof, or a solvate of the compound or the salt, wherein R 1 is 1H-indazol-4-yl or 1H-indazol-4-yl substituted with one or more halogens. 4HA[C38] A compound according to any one of [C27] to [C32], or a salt thereof, or a solvate of the compound or the salt, wherein R 1 is 1H-indazol-4-yl substituted with one or more halogen atoms. 4HA [C39] A compound according to any one of [C27] to [C32], or a salt thereof, or a solvate of the compound or the salt, wherein R 1 is 1H-indazol-4-yl substituted with a halogen atom at at least one of the 5-, 6-, and 7-positions. 4HA [C40] A compound according to any one of [C27] to [C32], a salt thereof, or a solvate thereof, wherein R is 1H-indazol-4-yl substituted with a halogen atom at at least one of the 5-, 6-, and 7-positions, and the halogen atom is fluorine or chlorine. 4HA [C40.5] A compound according to any one of [C27] to [C32], a salt thereof, or a solvate thereof, wherein R is 1H-indazol-4-yl substituted with halogen at any one or two of the 5-, 6-, and 7-positions, and the halogen is selected from the group consisting of fluorine, chlorine, a combination of fluorine and fluorine, and a combination of fluorine and chlorine. 4HA) is 1H-indazol-4-yl substituted with halogen at any one or two of the 5-, 6-, and 7-positions, and the halogen is independently fluorine or chlorine, or a salt thereof, or a solvate thereof according to any one of [C27] to [C32]. [D1] A compound selected from the following compounds, a salt thereof, or a solvate thereof: 3-amino-7-chloro-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-benzo[h]quinolin-2-one, 3-amino-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-benzo[h]quinolin-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methyl-1H-benzo[h]quinolin-2-one, 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-cyclopropyl-1H-benzo[h]quinolin-2-one, 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-methyl-1H-benzo[h]quinolin-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-propan-2-yl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-propan-2-yloxy-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-cyclopropyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-cyclobutyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-ethyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(5-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-6-cyclopropyl-4-(5-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one,(S)-3-amino-6-cyclopropyl-4-(5-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-6-cyclopropyl-4-(6,7-difluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-ethyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-chloro-6-fluoro-1H-indazol-4-yl)-6-ethoxy-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-chloro-6-fluoro-1H-indazol-4-yl)-6-propan-2-yloxy-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-chloro-6-fluoro-1H-indazol-4-yl)-6-cyclopropyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-chloro-6-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-propoxy-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-ethoxy-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-propan-2-yloxy-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-chloro-6-fluoro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthrolin-2-one,3-amino-6-ethoxy-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one, 3-amino-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-6-ethyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one, 3-amino-6-cyclobutyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methoxy-1H-1,10-phenanthrolin-2-one, 3-amino-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,10-phenanthrolin-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,10-phenanthrolin-2-one, 3-amino-6-ethyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,10-phenanthrolin-2-one, 3-amino-9-fluoro-4-(7-fluoro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthrolin-2-one, 3-amino-9-fluoro-4-(7-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-9-fluoro-6-methoxy-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-9-fluoro-6-methyl-1H-1,7-phenanthrolin-2-one, 8-amino-7-(7-fluoro-1H-indazol-4-yl)-5-methoxy-10H-pyrido[2,3-f]quinoxalin-9-one, 8-amino-7-(7-fluoro-1H-indazol-4-yl)-5-propan-2-yloxy-10H-pyrido[2,3-f]quinoxalin-9-one,8-amino-7-(7-fluoro-1H-indazol-4-yl)-5-methyl-10H-pyrido[2,3-f]quinoxalin-9-one, 8-amino-5-cyclopropyl-7-(7-fluoro-1H-indazol-4-yl)-10H-pyrido[2,3-f]quinoxalin-9-one, 8-amino-7-(7-fluoro-1H-indazol-4-yl)-5-methyl-10H-pyrido[3,2-h]quinazolin-9-one, 8-amino-5-cyclopropyl-7-(7-fluoro-1H-indazol-4-yl)-10H-pyrido[3,2-h]quinazolin-9-one, 3-amino-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,8-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-5,6-dimethyl-1H-1,7-phenanthrolin-2-one, 3-amino-6-cyclopropyl-4-(6,7-difluoro-1H-indazol-4-yl)-5-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-5-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-5-fluoro-6-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-6-cyclopropyl-4-(6,7-difluoro-1H-indazol-4-yl)-5-fluoro-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-5-fluoro-1H-1,7-phenanthrolin-2-one, 3-amino-4-(5,7-difluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-6-methyl-4-(1H-pyrazolo[4,3-c]pyridin-4-yl)-1H-1,7-phenanthrolin-2-one, 3-amino-4-(1H-benzotriazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one, and 3-amino-6-(tert-butyl)-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one. [D2][D2] 3-amino-7-chloro-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-benzo[h]quinolin-2-one or a salt thereof or a solvate thereof. [D3] 3-amino-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-benzo[h]quinolin-2-one or a salt thereof or a solvate thereof. [D4] 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methyl-1H-benzo[h]quinolin-2-one or a salt thereof or a solvate thereof. [D5] 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-cyclopropyl-1H-benzo[h]quinolin-2-one or a salt thereof or a solvate thereof. [D6] 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-methyl-1H-benzo[h]quinolin-2-one or a salt thereof or a solvate thereof. [D7] 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-propan-2-yl-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D8] 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-propan-2-yloxy-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D9] 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-cyclopropyl-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D10] 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-cyclobutyl-1H-1,7-phenanthrolin-2-one, a salt thereof, or a solvate thereof. [D11] 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-ethyl-1H-1,7-phenanthrolin-2-one, a salt thereof, or a solvate thereof. [D12] 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one, a salt thereof, or a solvate thereof. [D13]3-Amino-4-(5-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D14] 3-Amino-6-cyclopropyl-4-(5-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D15] (S)-3-Amino-6-cyclopropyl-4-(5-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D16] 3-Amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D16.5] 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one hydrochloride monohydrate. [D17] 3-amino-6-cyclopropyl-4-(6,7-difluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D18] 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-ethyl-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D19] 3-amino-4-(7-chloro-6-fluoro-1H-indazol-4-yl)-6-ethoxy-1H-1,7-phenanthrolin-2-one, a salt thereof, or a solvate thereof. [D20] 3-amino-4-(7-chloro-6-fluoro-1H-indazol-4-yl)-6-propan-2-yloxy-1H-1,7-phenanthrolin-2-one, a salt thereof, or a solvate thereof. [D21] 3-amino-4-(7-chloro-6-fluoro-1H-indazol-4-yl)-6-cyclopropyl-1H-1,7-phenanthrolin-2-one, a salt thereof, or a solvate thereof. [D22] 3-amino-4-(7-chloro-6-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one or a salt thereof, or a solvate thereof. [D23]3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthrolin-2-one or a salt thereof, or a solvate thereof. [D23.5] 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthrolin-2-one hydrochloride. [D24] 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-propoxy-1H-1,7-phenanthrolin-2-one or a salt thereof, or a solvate thereof. [D25] 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthrolin-2-one or a salt thereof, or a solvate thereof. [D26] 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-ethoxy-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D27] 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-propan-2-yloxy-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D28] 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D29] 3-amino-4-(7-chloro-6-fluoro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthrolin-2-one or a salt thereof, or a solvate thereof. [D30] 3-amino-6-ethoxy-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one or a salt thereof, or a solvate thereof. [D31] 3-amino-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one or a salt thereof, or a solvate thereof. [D31.5] Solvate of 3-amino-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one. [D32]3-Amino-4-(7-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one or a salt thereof, or a solvate thereof. [D32.5] 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one hydrochloride monohydrate. [D33] 3-amino-6-ethyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one or a salt thereof, or a solvate thereof. [D34] 3-amino-6-cyclobutyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one or a salt thereof, or a solvate thereof. [D35] 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methoxy-1H-1,10-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D36] 3-amino-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,10-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D37] 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,10-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D38] 3-amino-6-ethyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,10-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D39] 3-amino-9-fluoro-4-(7-fluoro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthrolin-2-one, a salt thereof, or a solvate thereof. [D40] 3-amino-9-fluoro-4-(7-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one, a salt thereof, or a solvate thereof. [D41] 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-9-fluoro-6-methoxy-1H-1,7-phenanthrolin-2-one, a salt thereof, or a solvate thereof. [D42]3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-9-fluoro-6-methyl-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D43] 8-amino-7-(7-fluoro-1H-indazol-4-yl)-5-methoxy-10H-pyrido[2,3-f]quinoxalin-9-one or a salt thereof or a solvate thereof. [D44] 8-amino-7-(7-fluoro-1H-indazol-4-yl)-5-propan-2-yloxy-10H-pyrido[2,3-f]quinoxalin-9-one or a salt thereof or a solvate thereof. [D45] 8-amino-7-(7-fluoro-1H-indazol-4-yl)-5-methyl-10H-pyrido[2,3-f]quinoxalin-9-one or a salt thereof or a solvate thereof. [D46] 8-amino-5-cyclopropyl-7-(7-fluoro-1H-indazol-4-yl)-10H-pyrido[2,3-f]quinoxalin-9-one or a salt thereof or a solvate thereof. [D47] 8-amino-7-(7-fluoro-1H-indazol-4-yl)-5-methyl-10H-pyrido[3,2-h]quinazolin-9-one or a salt thereof or a solvate thereof. [D48] 8-amino-5-cyclopropyl-7-(7-fluoro-1H-indazol-4-yl)-10H-pyrido[3,2-h]quinazolin-9-one or a salt thereof or a solvate thereof. [D49] 3-amino-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,8-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D49.1] 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-5,6-dimethyl-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D49.2] 3-amino-6-cyclopropyl-4-(6,7-difluoro-1H-indazol-4-yl)-5-methyl-1H-1,7-phenanthrolin-2-one or a salt thereof, or a solvate thereof. [D49.3]3-Amino-4-(6,7-difluoro-1H-indazol-4-yl)-5-methyl-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D49.4] 3-Amino-4-(6,7-difluoro-1H-indazol-4-yl)-5-fluoro-6-methyl-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D49.5] 3-Amino-6-cyclopropyl-4-(6,7-difluoro-1H-indazol-4-yl)-5-fluoro-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D49.6] 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-5-fluoro-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D49.7] 3-amino-4-(5,7-difluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D49.8] 3-amino-6-methyl-4-(1H-pyrazolo[4,3-c]pyridin-4-yl)-1H-1,7-phenanthrolin-2-one or a salt thereof or a solvate thereof. [D49.9] 3-amino-4-(1H-benzotriazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one or a salt thereof, or a solvate thereof. [D49.10] 3-amino-6-(tert-butyl)-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one or a salt thereof, or a solvate thereof. [D50] A compound or a salt thereof, or a solvate thereof according to any one of [A1] to [A46], [B1] to [B44], and [C1] to [C40], wherein the compound represented by formula (1), formula (2), or formula (3), or a salt thereof, or a solvate thereof is a compound represented by formula (1), formula (2), or formula (3), or a salt thereof. [D51]The compound, a salt thereof, or a solvate thereof according to any one of [A1] to [A46], [B1] to [B44], and [C1] to [C40], wherein the compound represented by formula (1), formula (2), and formula (3), a salt thereof, or a solvate thereof is the compound represented by formula (1), formula (2), and formula (3). [D52] The compound, a salt thereof, or a solvate thereof according to any one of [A1] to [A46], [B1] to [B44], and [C1] to [C40], wherein the compound represented by formula (1), formula (2), and formula (3), a salt thereof, or a solvate thereof is a salt of the compound represented by formula (1), formula (2), and formula (3). [D53] A compound or a salt thereof, or a solvate thereof according to any one of [A1] to [A46], [B1] to [B44], and [C1] to [C40], wherein the compound represented by formula (1), formula (2), and formula (3), or a salt thereof, or a solvate thereof is a solvate of the compound represented by formula (1), formula (2), and formula (3), or a salt thereof. [D54] A compound or a salt thereof, or a solvate thereof according to any one of [A1] to [A46], [B1] to [B44], and [C1] to [C40], wherein the compound represented by formula (1), formula (2), and formula (3), or a salt thereof, or a solvate thereof is a compound represented by formula (1), formula (2), and formula (3), or a salt thereof, or a hydrate thereof. [D55] A compound or a salt thereof, or a solvate thereof according to any one of [A1] to [A46], [B1] to [B44], and [C1] to [C40], wherein the compound represented by formula (1), formula (2), and formula (3), or a salt thereof, or a solvate thereof is a hydrate of the compound represented by formula (1), formula (2), and formula (3), or a salt thereof. [D56] A compound or a salt thereof, or a solvate thereof according to any one of [D1] to [D49], wherein the compound or a salt thereof, or a solvate thereof is a compound or a salt thereof according to any one of [D1] to [D49]. [D57][D1] - [D49] A compound according to any one of [D1] - [D49], a salt thereof, or a solvate thereof, wherein the compound according to any one of [D1] - [D49], a salt thereof, or a solvate thereof is the compound according to any one of [D1] - [D49]. [D58] A compound according to any one of [D1] - [D49], a salt thereof, or a solvate thereof is the salt of the compound according to any one of [D1] - [D49]. [D59] A compound according to any one of [D1] - [D49], a salt thereof, or a solvate thereof is the solvate of the compound according to any one of [D1] - [D49]. [D60] A compound, a salt thereof, or a solvate thereof according to any one of [D1] to [D49], wherein the compound, a salt thereof, or a solvate thereof according to any one of [D1] to [D49] is a compound, a salt thereof, or a hydrate thereof according to any one of [D1] to [D49]. [D61] A compound, a salt thereof, or a solvate thereof according to any one of [D1] to [D49], wherein the compound, a salt thereof, or a solvate thereof according to any one of [D1] to [D49] is a hydrate of the compound or a salt thereof according to any one of [D1] to [D49]. [E1] A pharmaceutical composition comprising, as an active ingredient, a compound, a salt thereof, or a solvate thereof according to any one of [A1] to [A46], [B1] to [B44], [C1] to [C40] and [D1] to [D61]. [E2] A cancer preventive and / or therapeutic agent comprising, as an active ingredient, a compound according to any one of [A1] to [A46], [B1] to [B44], [C1] to [C40] and [D1] to [D61] or a salt thereof, or a solvate thereof. [E3] A MYT1 inhibitor comprising a compound according to any one of [A1] to [A46], [B1] to [B44], [C1] to [C40] and [D1] to [D61] or a salt thereof, or a solvate thereof. [E4]A method for preventing and / or treating cancer, comprising administering to a subject an effective amount of a compound described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40] and [D1] to [D61], or a salt thereof, or a solvate thereof. [E5] A compound described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40] and [D1] to [D61], or a salt thereof, or a solvate thereof, for use in the prevention and / or treatment of cancer. [E6] Use of a compound described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40] and [D1] to [D61], or a salt thereof, or a solvate thereof, for the manufacture of a pharmaceutical composition for the prevention and / or treatment of cancer. [E6.2] A pharmaceutical composition, a cancer preventive and / or therapeutic agent, a MYT1 inhibitor, a method, a compound or a salt thereof, or a solvate thereof, described in any one of [E1] to [E6], used in combination with a chemotherapeutic agent, described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40], and [D1] to [D61] for use in combination with a chemotherapeutic agent, or a compound or a salt thereof, or a solvate thereof. [E7] A pharmaceutical composition, in combination with a chemotherapeutic agent, for treating or preventing cancer in a cancer patient who has been detected to be positive for an RB1 gene mutation or reduced expression of the RB1 gene or protein, comprising a MYT1 inhibitor as an active ingredient, wherein the MYT1 inhibitor is a compound or a salt thereof, or a solvate thereof, described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40], and [D1] to [D61]. [E7.2] A pharmaceutical composition comprising as an active ingredient a MYT1 inhibitor for use in combination with a chemotherapeutic agent to treat or prevent cancer in a cancer patient who is positive for RB1 gene mutation or has reduced expression of the RB1 gene or protein, wherein the MYT1 inhibitor is a compound described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40], and [D1] to [D61], or a salt thereof, or a solvate thereof. [E7.5] A pharmaceutical composition comprising as an active ingredient a chemotherapeutic agent for use in combination with a MYT1 inhibitor to treat or prevent cancer in a cancer patient who is positive for RB1 gene mutation or has reduced expression of the RB1 gene or protein, wherein the MYT1 inhibitor is a compound described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40], and [D1] to [D61], or a salt thereof, or a solvate thereof.[E7.7] A pharmaceutical composition comprising, as an active ingredient, a chemotherapeutic agent for treating or preventing cancer in a cancer patient who is positive for an RB1 gene mutation or has reduced expression of the RB1 gene or protein, in combination with a MYT1 inhibitor, wherein the MYT1 inhibitor is a compound described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40] and [D1] to [D61], or a salt thereof, or a solvate thereof. [E8] A method for treating or preventing cancer in a cancer patient in which a positive RB1 gene mutation or decreased expression of the RB1 gene or protein has been detected, the method comprising administering to the cancer patient a combination of a chemotherapeutic agent and a MYT1 inhibitor, wherein the MYT1 inhibitor is a compound according to any one of [A1] to [A46], [B1] to [B44], [C1] to [C40], and [D1] to [D61], or a salt thereof, or a solvate thereof. [E8.1] A method for treating or preventing cancer, comprising detecting, or having a third party detect, in a biological sample derived from a cancer patient whether the cancer patient has a positive RB1 gene mutation or whether the expression of the RB1 gene or protein is reduced; and administering to the cancer patient a combination of a chemotherapeutic agent and a MYT1 inhibitor, wherein the MYT1 inhibitor is a compound described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40], and [D1] to [D61], or a salt thereof, or a solvate thereof. [E8.2] A method for treating or preventing cancer in a cancer patient who is positive for an RB1 gene mutation or has reduced expression of the RB1 gene or protein, comprising administering to the cancer patient a combination of a chemotherapeutic agent and a MYT1 inhibitor, wherein the MYT1 inhibitor is a compound according to any one of [A1] to [A46], [B1] to [B44], [C1] to [C40], and [D1] to [D61], or a salt thereof, or a solvate thereof. [E9]A method for suppressing the proliferation of cancer cells in a cancer patient in which a positive RB1 gene mutation or decreased expression of the RB1 gene or protein has been detected, the method comprising contacting the cancer cells with a MYT1 inhibitor and a chemotherapeutic agent, wherein the MYT1 inhibitor is a compound set forth in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40], and [D1] to [D61], or a salt thereof, or a solvate thereof. [E9.1] A method for suppressing the proliferation of cancer cells, comprising detecting, or having a third party detect, in a biological sample derived from a cancer patient whether the cancer patient has a positive RB1 gene mutation or whether the expression of the RB1 gene or protein is reduced; and contacting the cancer cells with a MYT1 inhibitor and a chemotherapeutic agent, wherein the MYT1 inhibitor is a compound described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40], and [D1] to [D61], or a salt thereof, or a solvate thereof. [E9.2] A method for suppressing the proliferation of cancer cells in a cancer patient who is positive for an RB1 gene mutation or has reduced expression of the RB1 gene or protein, the method comprising contacting the cancer cells with a MYT1 inhibitor and a chemotherapeutic agent, wherein the MYT1 inhibitor is a compound selected from any one of [A1] to [A46], [B1] to [B44], [C1] to [C40], and [D1] to [D61], or a salt thereof, or a solvate thereof. [E10] A method for improving responsiveness to cancer treatment with a chemotherapeutic agent, wherein the cancer is cancer in a cancer patient in which a positive RB1 gene mutation or a decreased expression of the RB1 gene or protein has been detected, and the method comprises administering a MYT1 inhibitor to the cancer patient together with a chemotherapeutic agent, wherein the MYT1 inhibitor is a compound described in any of [A1] to [A46], [B1] to [B44], [C1] to [C40] and [D1] to [D61] or a salt thereof, or a solvate of any of them. [E10.1] A method for improving responsiveness to cancer treatment with a chemotherapeutic agent, comprising detecting, or having a third party detect, in a biological sample derived from the cancer patient, a positive RB1 gene mutation in the cancer patient or a decreased expression of the RB1 gene or protein;[E10.1] A method for improving responsiveness to cancer treatment with a chemotherapeutic agent, wherein the cancer is a cancer of a patient who is positive for an RB1 gene mutation or has reduced expression of the RB1 gene or protein, and the method comprises administering a MYT1 inhibitor to the cancer patient together with a chemotherapeutic agent, wherein the MYT1 inhibitor is a compound of any of [A1] to [A46], [B1] to [B44], [C1] to [C40] and [D1] to [D61] or a salt thereof, or a solvate of either. [E10.2] A method for improving responsiveness to cancer treatment with a chemotherapeutic agent, wherein the cancer is a cancer of a patient who is positive for an RB1 gene mutation or has reduced expression of the RB1 gene or protein, and the method comprises administering a MYT1 inhibitor to the cancer patient together with a chemotherapeutic agent, and the MYT1 inhibitor is a compound of any of [A1] to [A46], [B1] to [B44], [C1] to [C40] and [D1] to [D61] or a salt thereof, or a solvate of either. [E11] A method for predicting responsiveness to cancer treatment with a combination of a MYT1 inhibitor and a chemotherapeutic agent, comprising: detecting, or having a third party detect, in a biological sample derived from a cancer patient, the presence or absence of an RB1 gene mutation or the presence or absence of reduced expression of the RB1 gene or protein; and determining that the patient will be responsive to cancer treatment with a combination of a MYT1 inhibitor and a chemotherapeutic agent if the RB1 gene mutation is positive or if the expression of the RB1 gene or protein is reduced, wherein the MYT1 inhibitor is a compound according to any one of [A1] to [A46], [B1] to [B44], [C1] to [C40], and [D1] to [D61], or a salt thereof, or a solvate thereof. [E12] A method for selecting a cancer patient for whom administration of a combination of a MYT1 inhibitor and a chemotherapeutic agent is more effective than administration of a MYT1 inhibitor or / and a chemotherapeutic agent alone, comprising: detecting, or having a third party detect, in a biological sample derived from the cancer patient, the presence or absence of an RB1 gene mutation or the presence or absence of reduced expression of the RB1 gene or protein; and determining, based on the presence of the mutation or the reduced expression, that the cancer patient is one for whom administration of a combination of a MYT1 inhibitor and a chemotherapeutic agent is more effective than administration of a MYT1 inhibitor or / and a chemotherapeutic agent alone;[E13] A method for screening for a compound effective for treating or preventing cancer in a cancer patient who has been detected as positive for an RB1 gene mutation or as having reduced expression of the RB1 gene or protein, the method comprising measuring the MYT1 inhibitory activity of a candidate compound and selecting a candidate compound having MYT1 inhibitory activity as a compound effective for treating cancer. [E13.2] A method for screening for a compound effective for treating or preventing cancer in a cancer patient who has been detected as positive for an RB1 gene mutation or as having reduced expression of the RB1 gene or protein, the method comprising measuring the MYT1 inhibitory activity of a candidate compound and selecting a candidate compound having MYT1 inhibitory activity as a compound effective for treating cancer. [E14] A MYT1 inhibitor for use in combination with a chemotherapeutic agent in the treatment or prevention of cancer in a cancer patient who has been detected as positive for an RB1 gene mutation or as having reduced expression of the RB1 gene or protein, wherein the MYT1 inhibitor is a compound described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40], and [D1] to [D61], or a salt thereof, or a solvate thereof. [E14.2] A MYT1 inhibitor for use in combination with a chemotherapeutic agent in the treatment or prevention of cancer in a cancer patient who has been detected as positive for an RB1 gene mutation or as having reduced expression of the RB1 gene or protein, wherein the MYT1 inhibitor is a compound described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40], and [D1] to [D61], or a salt thereof, or a solvate thereof. [E15] A chemotherapeutic agent for use in combination with a MYT1 inhibitor in the treatment or prevention of cancer in a cancer patient in which RB1 gene mutation or reduced expression of the RB1 gene or protein has been detected, comprising:A chemotherapeutic agent, wherein the MYT1 inhibitor is a compound according to any one of [A1] to [A46], [B1] to [B44], [C1] to [C40] and [D1] to [D61], or a salt thereof, or a solvate thereof. [E15.2] A chemotherapeutic agent for use in combination with a MYT1 inhibitor in the treatment or prevention of cancer in cancer patients who are positive for RB1 gene mutation or have reduced expression of the RB1 gene or protein, wherein the MYT1 inhibitor is a compound according to any one of [A1] to [A46], [B1] to [B44], [C1] to [C40] and [D1] to [D61], or a salt thereof, or a solvate thereof. [E16] Use of a MYT1 inhibitor for the manufacture of a pharmaceutical composition to be administered in combination with a chemotherapeutic agent for the treatment or prevention of cancer in a cancer patient who has been detected as having a positive RB1 gene mutation or reduced expression of the RB1 gene or protein, wherein the MYT1 inhibitor is a compound described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40], and [D1] to [D61], or a salt thereof, or a solvate thereof. [E16.2] Use of a MYT1 inhibitor for the manufacture of a pharmaceutical composition to be administered in combination with a chemotherapeutic agent for the treatment or prevention of cancer in a cancer patient who has been detected as having a positive RB1 gene mutation or reduced expression of the RB1 gene or protein, wherein the MYT1 inhibitor is a compound described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40], and [D1] to [D61], or a salt thereof, or a solvate thereof. [E17] Use of a chemotherapeutic agent for the manufacture of a pharmaceutical composition for treating or preventing cancer in a cancer patient who has been detected to be positive for an RB1 gene mutation or reduced expression of the RB1 gene or protein, the pharmaceutical composition being administered in combination with a MYT1 inhibitor, wherein the MYT1 inhibitor is a compound according to any one of [A1] to [A46], [B1] to [B44], [C1] to [C40], and [D1] to [D61], or a salt thereof, or a solvate thereof. [E17.2]Use of a chemotherapeutic agent for the manufacture of a pharmaceutical composition for treating or preventing cancer in a cancer patient who is positive for an RB1 gene mutation or has reduced expression of the RB1 gene or protein, to be administered in combination with a MYT1 inhibitor, wherein the MYT1 inhibitor is a compound described in any one of [A1] to [A46], [B1] to [B44], [C1] to [C40], and [D1] to [D61], or a salt thereof, or a solvate thereof. [E18] The pharmaceutical composition, method, MYT1 inhibitor for use, chemotherapeutic agent for use, or use described in any one of [E7] to [E17], wherein the chemotherapeutic agent is an antimetabolite. [E19] The pharmaceutical composition, method, MYT1 inhibitor for use, chemotherapeutic agent for use, or use described in [E18], wherein the antimetabolite is an antifolate. [E20] The pharmaceutical composition, method, use of a MYT1 inhibitor, use of a chemotherapeutic agent, or use according to [E19], wherein the antifolate is pemetrexed. [E21] The pharmaceutical composition, method, use of a MYT1 inhibitor, use of a chemotherapeutic agent, or use according to any of [E7] to [E20], wherein the cancer is lung cancer.
[0007] In the above numbering scheme, unless otherwise specified, the numbers referred to in the dependent claims include numbers with different decimal points. For example, [C6] referred to in the dependent claims indicates that it includes [C6] as well as [C6.5]. The same applies to other numbering schemes.
[0008] According to the present invention, it is possible to provide a novel compound having MYT1 inhibitory activity, or a salt thereof, or a solvate thereof, and also to provide a pharmaceutical agent containing the compound or salt as an active ingredient, which is useful for treating and preventing cancer.
[0009] 1 is a graph showing the cell viability calculated in a pemetrexed-induced cytotoxicity test when example compounds (A12, A59, B3, B22, B23, B24, B32, B35, and B37) are added. 2 is a graph showing the cell viability calculated in a pemetrexed-induced cytotoxicity test when example compounds (B46, B47, B48, B49, C1, C4, C8, C13, and C64) are added. 3 is a graph showing the cell viability calculated in a pemetrexed-induced cytotoxicity test when example compounds (C65, C67, C69, C76, C78, C83, C84, C85, and C86) are added. 1 is a graph showing the cell viability calculated in a pemetrexed-induced cytotoxicity test when example compounds (C88, C90, C91, C92, C98, C100, C101, C102, and C134) were added. 2 is a graph showing the cell viability calculated in a pemetrexed-induced cytotoxicity test when example compounds (C135, C136, C137, C138, C139, C140, C141, C143, and C144) were added. 3 is a graph showing the cell viability calculated in a pemetrexed-induced cytotoxicity test when example compounds (C146, C155, C156, C185, C190, C195, C200, D2, and F2) were added. 1 is a graph showing the cell viability calculated in a pemetrexed-induced cell injury test when example compounds (G16, H3, K4, L3, M4, N2, O1, P1, and P4) were added. FIG. 2 is a graph showing the cell viability calculated in a pemetrexed-induced cell injury test when example compound (Q1) was added. The graph shows the results of simultaneous measurements of thermogravimetry, differential scanning calorimetry, and mass spectrometry for Sample A. The horizontal axis is temperature (°C). The left vertical axis is the weight change (%) of the sample in thermogravimetry. The right vertical axis is the heat flow (mW / mg) observed in differential thermal analysis (left) and the peak intensity observed in mass spectrometry (right). The graph shows the results of simultaneous measurements of thermogravimetry, differential scanning calorimetry, and mass spectrometry for Sample A-1. The horizontal axis is temperature (°C). The left vertical axis is the weight change (%) of the sample in thermogravimetry (these results are for reference only, as the samples were directly measured after filtering and drying through a mesh).The right vertical axis shows the heat flow (mW / mg) observed in differential thermal analysis (left) and the peak intensity (right) observed in mass analysis. The results of simultaneous thermogravimetry and differential thermal analysis for sample A-2 are shown. The horizontal axis shows temperature (°C). The right vertical axis shows the weight change (%) of the sample in thermogravimetry. The left vertical axis shows the heat flow (μV) observed in differential thermal analysis. The results of simultaneous thermogravimetry, differential scanning calorimetry, and mass analysis for sample B are shown. The horizontal axis shows temperature (°C). The left vertical axis shows the weight change (%) of the sample in thermogravimetry. The right vertical axis shows the heat flow (mW / mg) observed in differential thermal analysis (left) and the peak intensity (right) observed in mass analysis. The results of simultaneous thermogravimetry and differential thermal analysis for sample B-2 are shown. The horizontal axis shows temperature (°C). The right vertical axis shows the weight change (%) of the sample in thermogravimetry. The left vertical axis shows the heat flow observed in differential thermal analysis. The results of simultaneous measurements of thermogravimetry, differential scanning calorimetry, and mass spectrometry for sample B-3 are shown. The horizontal axis is temperature (°C). The left vertical axis is the weight change (%) of the sample in thermogravimetry (these results are for reference only, as the sample was directly measured after filtering and drying through a mesh). The right vertical axis is the heat flow (mW / mg) observed in differential thermal analysis (left) and the peak intensity observed in mass analysis (right). The results of simultaneous measurements of thermogravimetry, differential scanning calorimetry, and mass spectrometry for sample C are shown. The horizontal axis is temperature (°C). The left vertical axis is the weight change (%) of the sample in thermogravimetry. The right vertical axis is the heat flow (mW / mg) observed in differential thermal analysis (left) and the peak intensity observed in mass analysis (right). The results of simultaneous measurements of thermogravimetry, differential scanning calorimetry, and mass spectrometry for sample C-1 are shown. The horizontal axis is temperature (°C). The left vertical axis is the weight change (%) of the sample in thermogravimetric analysis (this is a reference value because the sample was directly measured after filtering through a mesh and drying). The right vertical axis is the heat flow (mW / mg) observed in differential thermal analysis (left) and the peak intensity observed in mass spectrometry (right). The results of simultaneous measurements of thermogravimetry, differential scanning calorimetry, and mass spectrometry for sample C-2 are shown. The horizontal axis is temperature (°C). The left vertical axis is the weight change (%) of the sample in thermogravimetric analysis (this is a reference value because the sample was directly measured after filtering through a mesh and drying).The right vertical axis represents the heat flow (mW / mg) observed in differential thermal analysis (left) and the peak intensity (right) observed in mass spectrometry. The results of simultaneous thermogravimetry and differential thermal analysis of sample D are shown. The horizontal axis represents temperature (°C). The right vertical axis represents the weight change (%) of the sample in thermogravimetry. The left vertical axis represents the heat flow (μV) observed in differential thermal analysis. The asymmetric unit of the crystal structure of sample E is shown. The plot is based on the Ellipsoid model (probability level: 50%).
[0010] The present invention will be described in detail below by showing definitions of symbols, terms, etc. used in this specification, and embodiments of the present invention.
[0011] As used herein, "halogen" means fluorine, chlorine, bromine, or iodine.
[0012] As used herein, "thio(thiol)" refers to --SH.
[0013] As used herein, "amino" refers to -NRR', where R and R' are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, or R and R' are taken together with the nitrogen atom to which they are attached to form a ring. As amino, -NH 2 , Mono C 1 -C 6 alkylamino (hereinafter referred to as "C p -C q " means that the number of carbon atoms is p to q), diC 1 -C 6 Examples thereof include alkylamino and 4- to 8-membered cyclic amino.
[0014] As used herein, "alkoxy" refers to an oxy group to which an "alkyl" as defined herein is bonded. As the alkoxy, C 1 -C 6 Alkoxy, more preferably C 1 -C 4Specific examples of the alkoxy include methoxy, ethoxy, 1-propoxy, 2-propoxy, n-butoxy, i-butoxy, s-butoxy, t-butoxy, pentyloxy, and 3-methylbutoxy.
[0015] As used herein, "alkylthio" refers to a "thio" group to which an "alkyl" as defined herein is bonded. As alkylthio, C 1 -C 6 alkylthio, more preferably C 1 -C 4 Specific examples of alkylthio include methylthio, ethylthio, 1-propylthio, 2-propylthio, n-butylthio, i-butylthio, s-butylthio, and t-butylthio.
[0016] As used herein, "sulfonyl" refers to -S(=O) 2 -R, where R is selected from the group consisting of hydroxy, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl. As sulfonyl, preferably C 1 -C 6 Alkylsulfonyl is exemplified.
[0017] As used herein, "phosphoryl" refers to -P(=O)RR', where R and R' are each independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl. As phosphoryl, preferably mono-C 1 -C 6 Alkylphosphoryl, diC 1 -C 6 Examples include alkylphosphoryl.
[0018] As used herein, "boryl" refers to -BRR', where R and R' are each independently selected from the group consisting of hydrogen, hydroxy, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, or R and R' together with the boron atom to which they are attached form a ring. Preferred boryls include dihydroxyboryl, monoC 1 -C 6 Alkylboryl, diC 1 -C 6 Examples of the boryl include alkylboryl and 4- to 8-membered cyclic boryl. Specific examples of the boryl include a dihydroxyboryl group, a pinacolatoboryl group, a neopentanediolateboryl group, a catecholateboryl group, and a 9-borabicyclo[3.3.1]nonan-9-yl group.
[0019] As used herein, "alkyl" refers to a monovalent group derived from an aliphatic hydrocarbon by removing any one hydrogen atom, and does not contain heteroatoms (atoms other than carbon and hydrogen atoms) or unsaturated carbon-carbon bonds in the skeleton, but has a subset of hydrocarbyl or hydrocarbon group structures containing hydrogen and carbon atoms. Alkyl includes not only linear but also branched chain alkyls. As alkyl, C is preferred. 1 -C 6 Alkyl, more preferably C 1 -C 4Specific examples of the alkyl include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, isobutyl (2-methylpropyl), n-pentyl, s-pentyl (1-methylbutyl), t-pentyl (1,1-dimethylpropyl), neopentyl (2,2-dimethylpropyl), isopentyl (3-methylbutyl), 3-pentyl (1-ethylpropyl), 1,2-dimethylpropyl, 2-methylbutyl, n-hexyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1,1,2,2-tetramethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, and 2-ethylbutyl.
[0020] As used herein, "alkenyl" refers to an alkyl group having at least one double bond (two adjacent sp 2 Depending on the configuration of the double bond and the substituents (if any), the geometry of the double bond can be in the Entgegen (E) or Zusammen (Z), cis or trans configuration. Alkenyl includes not only straight chains but also branched chains. As alkenyl, C is preferably used. 2 -C 6 alkenyl, more preferably C 2 -C 4 Specific examples of alkenyl include vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl (including cis and trans), 3-butenyl, pentenyl, 3-methyl-2-butenyl, and hexenyl.
[0021] As used herein, "alkynyl" refers to a monovalent group having at least one triple bond (two adjacent SP carbon atoms). Alkynyl includes not only straight chain but also branched chain. C 2 -C 6 Alkynyl, more preferably C 2 -C 4Specific examples of the alkynyl include ethynyl, 1-propynyl, propargyl, 3-butynyl, pentynyl, hexynyl, 3-phenyl-2-propynyl, 3-(2'-fluorophenyl)-2-propynyl, 2-hydroxy-2-propynyl, 3-(3-fluorophenyl)-2-propynyl, and 3-methyl-(5-phenyl)-4-pentynyl.
[0022] As used herein, the term "cycloalkyl" refers to a saturated or partially saturated cyclic monovalent aliphatic hydrocarbon group, including monocyclic, bicyclic, and spirocyclic rings. 3 -C 8 Cycloalkyl, more preferably C 3 -C 6 Specific examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]heptyl, spiro[3.3]heptyl, spiro[2.3]hexyl, spiro[4.5]decyl, and the like.
[0023] As used herein, the term "aryl" refers to a monovalent aromatic hydrocarbon ring, i.e., an aromatic hydrocarbon ring group. The aryl is preferably C 6 -C 10 Specific examples of the aryl include phenyl and naphthyl (for example, 1-naphthyl and 2-naphthyl).
[0024] As used herein, the term "heterocyclyl" refers to a non-aromatic, cyclic, monovalent group containing 1 to 5 heteroatoms in addition to carbon atoms. A heterocyclyl may have a double and / or triple bond within the ring, and a carbon atom within the ring may be oxidized to form a carbonyl. The heterocyclyl includes a monocyclic, fused, or spiro ring. In the case of a fused ring, an aromatic ring such as a benzene ring, a pyridine ring, or a pyrimidine ring may be fused with a saturated alicyclic ring such as a cyclopentane ring or a cyclohexane ring, or with a saturated heterocyclic ring such as a tetrahydropyran ring, a dioxane ring, or a pyrrolidine ring. The number of atoms constituting the heterocyclyl ring is preferably 4 to 10 (4- to 10-membered heterocyclyl), more preferably 4 to 7 (4- to 7-membered heterocyclyl).Specific examples of heterocyclyl include azetidinyl, oxoazetidinyl, oxiranyl, oxetanyl, azetidinyl, dihydrofuryl, tetrahydrofuryl (oxolan-2-yl, oxolan-3-yl), dihydropyranyl, tetrahydropyranyl (oxan-4-yl), tetrahydropyridyl, tetrahydropyrimidyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, oxopyrrolidinyl, piperidinyl, piperazinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, oxa Zolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, 1,2-thiazinane, thiadiazolidinyl, oxazolidonyl, benzodioxanyl, benzoxazolyl, dioxolanyl, dioxanyl, tetrahydropyrrolo[1,2-c]imidazole, thietanyl, 3,6-diazabicyclo[3.1.1]heptanyl, 2,5-diazabicyclo[2.2.1]heptanyl, 3-oxa-8-azabicyclo[3.2.1]octanyl, 2,4,5-trimethylpiperazin-1-yl, sultam , 2-oxaspiro[3.3]heptyl, 6,7-dihydro-pyrrolo[1,2-a]imidazolyl, 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazinyl, azepanyl, dioxepanyl, 5,9-dioxaspiro[3.5]nonanyl, 1,1-dioxo-1,4-thiazinan-4-yl, carbonylazetidinyl, acetylpiperidinyl, 2-oxa-6-azaspiro[3.3]heptan-6-yl, 2-oxa-7-azaspiro[3.4]octan-7-yl, 3-oxa-6-azabicyclo[ 3.1.1]heptan-6-yl, 6-oxa-3-azabicyclo[3.1.1]heptan-3-yl, (9aR)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazin-8-yl, 3-(azetidin-1-yl)azetidin-1-yl, 1-(oxetan-3-yl)piperidin-4-yl, 1-(oxan-4-yl)piperidin-4-yl, 4-pyrrolidin-1-ylpiperidin-1-yl, 4-morpholin-4-ylpiperidin-1-yl, and the like.
[0025] As used herein, the term "heteroaryl" refers to an aromatic monovalent cyclic group containing 1 to 5 heteroatoms in addition to carbon atoms, i.e., an aromatic heterocyclic group. The ring may be a single ring or a condensed ring with another ring. The number of atoms constituting the heteroaryl ring is preferably 5 to 10 (5- to 10-membered heteroaryl), and more preferably 5 to 7 (5- to 7-membered heteroaryl). Specific examples of heteroaryl include furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, benzofuranyl, benzothienyl, benzothiadiazolyl, benzothiazolyl, benzoxazolyl, benzoxadiazolyl, benzimidazolyl, benzotriazolyl, indolyl, isoindolyl, indazolyl, azaindolyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinyl, indolizinyl, imidazopyridyl, pyrazolopyridyl, triazolopyridyl, pyrrolopyrazinyl, and furopyridyl.
[0026] As used herein, "alkylsulfonyl" refers to a "sulfonyl" group to which an "alkyl" or "cycloalkyl" as defined herein is bonded. As the alkylsulfonyl, C 1 -C 6 Alkylsulfonyl, C 3 -C 8 Cycloalkylsulfonyl, more preferably C 1 -C 4 Alkylsulfonyl, C 3 -C 6 Specific examples of the alkylsulfonyl include methylsulfonyl, ethylsulfonyl, 1-propylsulfonyl, 2-propylsulfonyl, n-butylsulfonyl, i-butylsulfonyl, s-butylsulfonyl, and t-butylsulfonyl.
[0027] As used herein, "acylamino" refers to a group in which R is hydrogen and R' is "acyl" as defined herein, among "amino" as defined herein. As acylamino, C 1 -C 6 acylamino, more preferably C 1 -C 4 Specific examples of acylamino include acetylamino.
[0028] As used herein, "monoalkylamino" refers to a group in which R is hydrogen and R' is an "alkyl" as defined herein, among "amino" as defined herein. As the monoalkylamino, preferably mono C 1 -C 6 Alkylamino, more preferably mono C 1 -C 4 Specific examples of monoalkylamino include methylamino, ethylamino, n-propylamino, i-propylamino, n-butylamino, s-butylamino, and t-butylamino.
[0029] As used herein, "alkylsulfonylamino" refers to a group in which R is hydrogen and R' is "alkylsulfonyl" as defined herein, among "amino" as defined herein. As alkylsulfonylamino, C 1 -C 6 Alkylsulfonylamino, C 3 -C 8 Cycloalkylsulfonylamino, more preferably C 1 -C 4 Alkylsulfonylamino, C 3 -C 6 Specific examples of alkylsulfonylamino include methylsulfonylamino, ethylsulfonylamino, and cyclopropylsulfonylamino.
[0030] As used herein, "haloalkoxy" refers to a group in which one or more hydrogen atoms of an "alkoxy" as defined herein are substituted with "halogen". As the haloalkoxy, halo C 1 -C 6 Alkoxy, more preferably haloC 1 -C 4 Specific examples of haloalkoxy include difluoromethoxy, trifluoromethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 3-fluoropropoxy, 2,2-difluoropropoxy, 3,3-difluoropropoxy, (2R)-2-fluoropropoxy, [(2S)-1,1,1-trifluoropropan-2-yl]oxy, [(2R)-1,1,1-trifluoropropan-2-yl]oxy, 3,3,3-trifluoro-2,2-dimethylpropoxy, and the like.
[0031] As used herein, "hydroxyalkoxy" refers to a group in which one or more hydrogen atoms of an "alkoxy" as defined herein are substituted with a hydroxyl group (hydroxy group). As the hydroxyalkoxy, hydroxy C is preferred. 1 -C 6 Alkoxy, more preferably hydroxy C 1 -C 4 Specific examples of hydroxyalkoxy include 2-hydroxy-2-methylpropoxy, 3-hydroxy-3-methylbutoxy, and 4-hydroxybutoxy.
[0032] As used herein, "alkoxyalkoxy" refers to a group in which an "alkoxy" is bonded to an "alkoxy" as defined herein. As the alkoxyalkoxy, C 1 -C 6 Alkoxy C 1 -C 6 Alkoxy, more preferably C 1 -C 4 Alkoxy C 1 -C 4Specific examples of alkoxyalkoxy include 2-methoxyethoxy, (2S)-2-methoxypropoxy, (2R)-2-methoxypropoxy, etc.
[0033] As used herein, "cycloalkylalkoxy" refers to an oxy group to which a "cycloalkylalkyl" as defined herein is bonded. As the cycloalkylalkoxy, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkoxy, more preferably C 3 -C 6 Cycloalkyl C 1 -C 4 Specific examples of cycloalkylalkoxy include cyclopropylmethoxy, cyclobutanylmethoxy, cyclopentylmethoxy, cyclohexylmethoxy, 1-bicyclo[1.1.1]pentanylmethoxy, and the like.
[0034] As used herein, "heterocyclylalkoxy" refers to an oxy group in which a "heterocyclyl" as defined herein is bonded via an "alkyl". Heterocyclylalkoxy is preferably a 4- to 10-membered heterocyclyl C 1 -C 6 Alkoxy, more preferably 4- to 7-membered heterocyclyl C 1 -C 4 Specific examples of heterocyclylalkoxy include (1,1-dioxothian-4-yl)oxy, oxolan-2-ylmethoxy, oxolan-3-ylmethoxy, oxan-4-ylmethoxy, 1,4-dioxan-2-ylmethoxy, (1-methylpiperidin-4-yl)methoxy, 3-morpholin-4-ylpropoxy, and (oxetan-3-yl)methoxy.
[0035] As used herein, "cycloalkoxy" refers to an oxy group to which a "cycloalkyl" as defined herein is bonded. As the cycloalkoxy, C 3 -C 8 Cycloalkoxy, more preferably C3 -C 6 Specific examples of cycloalkoxy include cyclopropoxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.
[0036] As used herein, "heterocyclyloxy" refers to an oxy group bonded to a "heterocyclyl" as defined herein. The number of atoms constituting the heterocyclyl ring is preferably 4 to 10 (4- to 10-membered heterocyclyloxy), more preferably 4 to 7 (4- to 7-membered heterocyclyloxy). Specific examples of heterocyclyloxy include azetidinyloxy, oxiranyloxy, oxetanyloxy, azetidinyloxy, dihydrofuryloxy, tetrahydrofuryloxy ([(3R)-oxolan-3-yl]oxy, [(3S)-oxolan-3-yl]oxy), dihydropyranyloxy, tetrahydropyranyloxy (oxan-4-yloxy), [(3S)-oxan-3-yl]oxy, [(3R)-oxan-3-yl]oxy), tetrahydropyridyloxy, tetrahydropyrimidyloxy, morpholinyloxy, thiomorpholinyloxy, pyrrolidinyloxy, piperidinyloxy, piperazinyloxy, pyrazolidinyloxy, imidazolinyloxy, and methyl. midazolidinyloxy, oxazolidinyloxy, isoxazolidinyloxy, thiazolidinyloxy, isothiazolidinyloxy, 1,2-thiazinaneoxy, thiadiazolidinyloxy, oxazolidonyloxy, benzodioxanyloxy, benzoxazolyloxy, dioxolanyloxy, dioxanyloxy, tetrahydropyrrolo[1,2-c]imidazoloxy, thietanyloxy, 3,6-diazabicyclo[3.1.1]heptanyloxy, 2,5-diazabicyclo[2.2.1]heptanyloxy, 3-oxa-8-azabicyclo[3.2.1]octanyloxy, sultamoxy, 2-oxaspiro[3.3]heptyloxy, tetrahydrothiopyranyloxy, and the like.
[0037] As used herein, "acyl (alkanoyl)" refers to a group in which a carbonyl group is bonded to hydrogen or an "alkyl" as defined herein. As the acyl, C 1 -C 6 Acyl, more preferably C 2 -C 4 Specific examples of acyl include formyl, acetyl, propionyl, butanoyl, etc.
[0038] As used herein, "aminocarbonyl" refers to a carbonyl group to which "amino" as defined herein is bonded. The aminocarbonyl is preferably -CONH 2 , Mono C 1 -C 6 Alkylaminocarbonyl, mono C 3 -C 8 Cycloalkylaminocarbonyl, diC 1 -C 6 Examples of the aminocarbonyl include alkylaminocarbonyl and 4- to 8-membered cyclic aminocarbonyl. Specific examples of the aminocarbonyl include -CONH 2 , dimethylaminocarbonyl, 1-azetidinylcarbonyl, 1-pyrrolidinylcarbonyl, 1-piperidinylcarbonyl, 1-piperazinylcarbonyl, 4-morpholinylcarbonyl, 3-oxazolidinylcarbonyl, 1,1-dioxidethiomorpholinyl-4-ylcarbonyl, 3-oxa-8-azabicyclo[3.2.1]octan-8-ylcarbonyl, N-cyclopropylaminocarbonyl, and the like.
[0039] As used herein, "alkylphosphoryl" refers to a "phosphoryl" bonded to an "alkyl" as defined herein. As the alkylphosphoryl, mono C 1 -C 6 Alkylphosphoryl, diC 1 -C 6 Alkylphosphoryl, more preferably mono C 1 -C 4 Alkylphosphoryl, diC 1 -C 4Specific examples of alkylphosphoryls include methylphosphoryl, ethylphosphoryl, dimethylphosphoryl, and diethylphosphoryl.
[0040] As used herein, "haloalkyl" refers to a group in which one or more hydrogen atoms of an "alkyl" as defined herein are substituted with "halogen". As a haloalkyl, haloC 1 -C 6 Alkyl, more preferably haloC 1 -C 4 Specific examples of haloalkyl include difluoromethyl, trifluoromethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 3-fluoropropyl, 3,3-difluoropropyl, 3,3,3-trifluoropropyl, 1,1,1-trifluoro-2-propyl, 4,4-difluorobutyl, and 5,5-difluoropentyl.
[0041] As used herein, "hydroxyalkyl" refers to a group in which one or more hydrogen atoms of an "alkyl" as defined herein are replaced with a hydroxyl group (hydroxy group). As the hydroxyalkyl, a hydroxy C 1 -C 6 Alkyl, more preferably hydroxy C 1 -C 4 Specific examples of hydroxyalkyl include hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 2-hydroxy-2-methylpropyl, and 5-hydroxypentyl.
[0042] As used herein, "aminocarbonylalkyl" refers to a group in which one or more hydrogen atoms of an "alkyl" as defined herein are substituted with an "aminocarbonyl" as defined herein. As the aminocarbonylalkyl, preferably, an aminocarbonyl C 1 -C 6 Alkyl, mono C 1 -C 6 Alkylaminocarbonyl C 1 -C 6 Alkyl, diC1 -C 6 Alkylaminocarbonyl C 1 -C 6 Alkyl, more preferably aminocarbonyl C 1 -C 4 Alkyl, mono C 1 -C 4 Alkylaminocarbonyl C 1 -C 4 Alkyl, diC 1 -C 4 Alkylaminocarbonyl C 1 -C 4 Specific examples of aminocarbonylalkyl include methylaminocarbonylmethyl, dimethylaminocarbonylmethyl, t-butylaminocarbonylmethyl, 1-azetidinylcarbonylmethyl, 1-pyrrolidinylcarbonylmethyl, 1-piperidinylcarbonylmethyl, 4-morpholinylcarbonylmethyl, 2-(methylaminocarbonyl)ethyl, 2-(dimethylaminocarbonyl)ethyl, 2-(1-azetidinylcarbonyl)ethyl, 2-(1-pyrrolidinylcarbonyl)ethyl, 2-(4-morpholinylcarbonyl)ethyl, 3-(dimethylaminocarbonyl)propyl, and 4-(dimethylaminocarbonyl)butyl.
[0043] As used herein, "cycloalkylalkyl" refers to a group in which one or more hydrogen atoms of an "alkyl" as defined above are substituted with a "cycloalkyl" as defined above. As the cycloalkylalkyl, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkyl, more preferably C 3 -C 6 Cycloalkyl C 1 -C 4 Specific examples of cycloalkylalkyl include cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, and the like.
[0044] As used herein, "hydroxyalkenyl" refers to a group in which one or more hydrogen atoms of an "alkenyl" as defined herein are substituted with a hydroxyl group (hydroxy group). As the hydroxyalkenyl, hydroxy C 2 -C 6 Alkenyl, more preferably hydroxy C 2 -C 4 Specific examples of hydroxyalkenyl include (E)-4-hydroxybut-1-enyl.
[0045] As used herein, "hydroxyalkynyl" refers to a group in which one or more hydrogen atoms of an "alkynyl" as defined herein are replaced with a hydroxyl group (hydroxy group). As the hydroxyalkynyl, hydroxy C is preferred. 2 -C 6 Alkynyl, more preferably hydroxy C 2 -C 4 Specific examples of hydroxyalkynyl include 3-hydroxy-3-methylbut-1-ynyl.
[0046] As used herein, the term "alicyclic ring" refers to a non-aromatic hydrocarbon ring. The alicyclic ring may have an unsaturated bond within the ring. A carbon atom constituting the ring may be oxidized to form a carbonyl. The alicyclic ring may be a monocyclic ring (referred to as a monocyclic alicyclic ring in this specification) or may form a condensed ring with a saturated alicyclic ring such as a cyclopentane ring or a cyclohexane ring, or an aromatic hydrocarbon ring such as a benzene ring or a naphthalene ring. Preferred examples of the alicyclic ring include 3- to 10-membered alicyclic rings. Specific examples of the alicyclic ring include a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, a cyclohexane ring, a cycloheptane ring, a cyclooctane ring, and a bicyclo[2.2.1]heptane ring.
[0047] As used herein, the term "aromatic hydrocarbon ring" refers to a hydrocarbon ring composed of a single ring or fused rings that exhibits aromaticity. Preferred examples of the aromatic hydrocarbon ring include 6- to 10-membered aromatic hydrocarbon rings. Specific examples of the aromatic hydrocarbon ring include a benzene ring and a naphthalene ring.
[0048] As used herein, the term "heterocycle" refers to a non-aromatic heterocycle containing preferably 1 to 5, and more preferably 1 to 3, heteroatoms among the atoms constituting the ring. The heterocycle may have a double and / or triple bond in the ring, and a carbon atom in the ring may be oxidized to form a carbonyl. The heterocycle may be a monocycle (referred to as a monocyclic heterocycle in this specification) or may form a fused ring or a spiro ring with a saturated alicyclic ring such as a cyclopentane ring or a cyclohexane ring, or a saturated heterocycle such as a tetrahydropyran ring, a dioxane ring, or a pyrrolidine ring. The number of atoms constituting the heterocycle ring is preferably 3 to 12 (3- to 12-membered heterocycle), more preferably 4 to 10 (4- to 10-membered heterocycle). Specific examples of heterocyclic rings include an azetidine ring, an oxetane ring, a tetrahydrofuran ring, a tetrahydropyran ring, a morpholine ring, a thiomorpholine ring, a pyrrolidine ring, a 4-oxopyrrolidine ring, a piperidine ring, a 4-oxopiperidine ring, a piperazine ring, a pyrazolidine ring, an imidazolidine ring, an oxazolidine ring, an isoxazolidine ring, a thiazolidine ring, an isothiazolidine ring, a thiadiazolidine ring, and an oxazolidone ring. , a dioxolane ring, a dioxane ring, a thietane ring, an octahydroindole ring, a 6,7-dihydro-pyrrolo[1,2-a]imidazole ring, an azocane ring, a 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine ring, an azepane ring, a dioxepane ring, a 5,9-dioxaspiro[3.5]nonane ring, or a ring in which one or more single bonds in these saturated heterocycles are replaced with double bonds or triple bonds.
[0049] As used herein, the term "aromatic heterocycle" refers to a cyclic compound composed of a single ring or fused rings containing one or more heteroatoms and exhibiting aromaticity. In this specification, a cyclic compound composed of a single ring exhibiting aromaticity is referred to as a monocyclic aromatic heterocycle. Preferred examples of aromatic heterocycles include 5- to 10-membered aromatic heterocycles. Specific examples of the aromatic heterocycle include a furan ring, a thiophene ring, a pyrrole ring, an imidazole ring, a pyrazole ring, a thiazole ring, an isothiazole ring, an oxazole ring, an isoxazole ring, an oxadiazole ring, a thiadiazole ring, a triazole ring, a tetrazole ring, a pyridine ring, a pyrimidine ring, a pyridazine ring, a pyrazine ring, a triazine ring, a benzofuran ring, a benzothiophene ring, a benzothiadiazoline ring, a benzothiazoline ring, a benzoxazoline ring, a benzoxadiazoline ring, a benzimidazole ring, a benzotriazole ring, an indole ring, an isoindole ring, an indazole ring, an azaindole ring, a quinoline ring, an isoquinoline ring, a cinnoline ring, a quinazoline ring, a quinoxaline ring, a benzodioxole ring, an indolizine ring, an imidazopyridine ring, a pyrazolopyridine ring, an imidazopyridine ring, a triazolopyridine ring, a pyrrolopyrazine ring, and a furopyridine ring.
[0050] In this specification, "optionally substituted" means that a group is unsubstituted or substituted with one or more substituents, and when substituted with multiple substituents, the substituents may be the same or different from each other. Furthermore, each of these may be given a substituent, and the substituents are not limited, and for example, one or more may be independently selected from any substituents containing a halogen atom, an oxygen atom, a sulfur atom, a nitrogen atom, a boron atom, a silicon atom, or a phosphorus atom. Examples of the substituent include deuterium, halogen, cyano, nitro, hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, oxo, C 1 -C 6 Alkyl, C 2 -C6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 Examples include aryl and 5- to 10-membered heteroaryl.
[0051] As used herein, "one or more" means one or more than one. When "one or more" is used in the context of substituents on a group, the term means a number from one to the maximum number of substituents permitted by the group.
[0052] In this specification, the term "to" indicating a numerical range includes both ends of the range. For example, "A to B" means a numerical range that is equal to or greater than A and equal to or less than B.
[0053] As used herein, the term "about" when used in conjunction with a numerical value means a range of values of plus and minus 10% of that numerical value.
[0054] As used herein, the term "and / or" includes any combination of "and" and "or." Specifically, for example, "A, B, and / or C" includes the following seven variations: (i) A, (ii) B, (iii) C, (iv) A and B, (v) A and C, (vi) B and C, and (vii) A, B, and C.
[0055] One embodiment of the present invention is a compound represented by general formula (1) (hereinafter also referred to as "compound (1)"), a salt thereof, or a solvate thereof.
[0056] In compound (1), R 4 is an optionally substituted C 6 -C 10 Aryl (R 4A ), optionally substituted 4- to 10-membered heterocyclyl, and optionally substituted 5- to 10-membered heteroaryl (R 4HA ) is selected from the group consisting of
[0057] R 4Preferably, optionally substituted C 6 -C 10 Aryl (R 4A ) or optionally substituted 5- to 10-membered heteroaryl (R 4HA )
[0058] R 4 is optionally substituted C 6 -C 10 Aryl (R 4A ), then R 4A is preferably phenyl.
[0059] C 6 -C 10 Aryl (R 4A As a preferred embodiment (i) of R 4A is unsubstituted or contains one or more R a and one or more R a are each independently deuterium, halogen, cyano, nitro, hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, oxo, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl; 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3-C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 The aryl and 5- to 10-membered heteroaryl may be further substituted.
[0060] C 6 -C 10 Aryl (R 4A As a preferred embodiment (ii) of R 4A is unsubstituted or contains one or more R a and one or more R a are each independently a halogen, a cyano, a hydroxy, an amino, 1 -C 6 Alkyl, haloC 1 -C 6 Alkyl, hydroxy C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, HaloC 1 -C 6 Alkoxy, and C 1 -C 6 alkylsulfonylamino.
[0061] C 6 -C 10 Aryl (R 4A As a preferred embodiment (iii) of R 4A is unsubstituted or contains one or more R a and one or more R a are each independently halogen, hydroxy, haloC 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, HaloC 1 -C 6 Alkoxy, and C 1 -C 6 alkylsulfonylamino.
[0062] R 4 optionally substituted 5- to 10-membered heteroaryl (R 4HA ), then R 4HAPreferred examples of the alkyl group include furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, benzofuranyl, benzothienyl, benzothiadiazolyl, benzothiazolyl, benzoxazolyl, benzoxadiazolyl, benzimidazolyl, benzotriazolyl, indolyl, and iodo. isoindolyl, indazolyl, azaindolyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinyl, indolizinyl, imidazopyridyl, pyrazolopyridyl, triazolopyridyl, pyrrolopyrazinyl, and furopyridyl, and more preferably furyl, thienyl, pyrrolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl ... imidyl, pyridazinyl, pyrazinyl, triazinyl, benzofuranyl, benzothienyl, benzothiadiazolyl, benzothiazolyl, benzoxazolyl, benzoxadiazolyl, benzimidazolyl, benzotriazolyl, indolyl, isoindolyl, indazolyl, azaindolyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinyl, indolizinyl, imidazopyridyl, pyrazolopyridyl, triazolopyridyl, pyrrolopyrazinyl and It is preferably selected from the group consisting of pyridyl, pyrimidyl, benzimidazolyl, indolyl, indazolyl, and pyrazolopyridyl, more preferably selected from the group consisting of pyrimidyl, benzimidazolyl, indolyl, indazolyl, and pyrazolopyridyl, and is particularly preferably 1H-indazol-6-yl or 1H-indazol-4-yl, and most preferably 1H-indazol-4-yl.
[0063] 5- to 10-membered heteroaryl (R 4HA As a preferred embodiment (i) of R 4HA is unsubstituted or contains one or more R a and one or more R aare each independently deuterium, halogen, cyano, nitro, hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, oxo, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl; 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 The aryl and 5- to 10-membered heteroaryl may be further substituted.
[0064] 5- to 10-membered heteroaryl (R 4HA As a preferred embodiment (ii) of R 4HA is unsubstituted or contains one or more R a and one or more R a are each independently a halogen, a cyano, a hydroxy, an amino, 1 -C 6 Alkyl, haloC 1 -C 6 Alkyl, hydroxy C 1 -C 6 Alkyl, C 1 -C 6Alkoxy, HaloC 1 -C 6 Alkoxy, and C 1 -C 6 alkylsulfonylamino.
[0065] 5- to 10-membered heteroaryl (R 4HA As a preferred embodiment (iii) of R 4HA is unsubstituted or contains one or more R a and one or more R a are each independently a halogen, a cyano, an amino, or C 1 -C 6 Alkyl, and haloC 1 -C 6 alkyl.
[0066] 5- to 10-membered heteroaryl (R 4HA As a preferred embodiment (iv) of R 4HA is 1H-indazol-4-yl or 1H-indazol-4-yl substituted with one or more halogens.
[0067] 5- to 10-membered heteroaryl (R 4HA As a preferred embodiment (v) of R 4HA is 1H-indazol-4-yl substituted with one or more halogens.
[0068] 5- to 10-membered heteroaryl (R 4HA As a preferred embodiment (vi) of R 4HA is 1H-indazol-4-yl substituted with halogen at least one of the 5-, 6-, and 7-positions.
[0069] 5- to 10-membered heteroaryl (R 4HA As a preferred embodiment (vii) of R 4HA is 1H-indazol-4-yl substituted with a halogen at least one of the 5-, 6-, and 7-positions, and the halogen is fluorine or chlorine.
[0070] 5- to 10-membered heteroaryl (R 4HA As a preferred embodiment (viii) of the formula (viii), R4HA is 1H-indazol-4-yl substituted with a halogen at any one or two of the 5-, 6-, and 7-positions, and the halogen is selected from the group consisting of fluorine, chlorine, a combination of fluorine and fluorine, and a combination of fluorine and chlorine.
[0071] In compound (1), R 5 and R 6 are taken together with the atom to which they are attached to form an optionally substituted D ring, and the D ring is a 3- to 10-membered monocyclic alicyclic ring, a benzene ring, a 3- to 12-membered monocyclic heterocyclic ring, and a 5- to 6-membered monocyclic aromatic heterocyclic ring (D HA and any two adjacent substituents on ring D may be taken together with the atoms to which they are attached to form an optionally substituted ring E.
[0072] The D ring is preferably a benzene ring or a 5- to 6-membered monocyclic aromatic heterocycle (D HA )
[0073] Ring D is a 5- to 6-membered monocyclic aromatic heterocycle (D HA ), then D HA is preferably selected from the group consisting of a furan ring, a thiophene ring, a pyrrole ring, an imidazole ring, a pyrazole ring, a thiazole ring, an isothiazole ring, an oxazole ring, an isoxazole ring, an oxadiazole ring, a thiadiazole ring, a triazole ring, a tetrazole ring, a pyridine ring, a pyrimidine ring, a pyridazine ring, a pyrazine ring, and a triazine ring, more preferably selected from the group consisting of a pyridine ring, a pyrimidine ring, a pyridazine ring, and a pyrazine ring, and even more preferably a pyridine ring.
[0074] In a preferred embodiment (i) of the D ring, the D ring is unsubstituted or contains one or more R D and one or more R D are each independently deuterium, halogen, cyano, nitro, hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, oxo, C1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl; 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 The aryl and 5- to 10-membered heteroaryl may be further substituted.
[0075] In a preferred embodiment (ii) of the D ring, the D ring is unsubstituted or contains one or more R D and one or more R D are each independently a halogen, a cyano, a hydroxy, 1 -C 6 Alkylthio, C 1 -C 6 Acylamino, Mono C 1 -C 6 Alkylamino, C 1 -C 6 Alkylsulfonylamino, C 3 -C 8 Cycloalkylsulfonylamino, C 1 -C 6 Alkoxy, HaloC 1 -C 6 Alkoxy, hydroxy C 1 -C 6 Alkoxy, C 1 -C6 Alkoxy C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkoxy, 4- to 10-membered heterocyclyl C 1 -C 6 Alkoxy, C 3 -C 8 cycloalkoxy, 4- to 10-membered heterocyclyloxy, C 1 -C 6 Acyl, Mono C 3 -C 8 Cycloalkylaminocarbonyl, 4- to 8-membered cyclic aminocarbonyl, diC 1 -C 6 Alkylphosphoryl, C 1 -C 6 Alkyl, haloC 1 -C 6 Alkyl, hydroxy C 1 -C 6 Alkyl, diC 1 -C 6 Alkylaminocarbonyl C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, Hydroxy C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, hydroxy C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, 1 -C 6 Alkylthio, C 1 -C 6 Alkoxy, C 1 -C 6 Alkoxy C 1 -C6 Alkoxy, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkoxy, 4- to 10-membered heterocyclyl C 1 -C 6 Alkoxy, C 3 -C 8 cycloalkoxy, 4- to 10-membered heterocyclyloxy, C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 The aryl and 5- to 10-membered heteroaryl may further independently be selected from halogen, cyano, hydroxy, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, oxo, halo C 1 -C 6 Alkyl, and C 3 -C 8 It may be optionally substituted with one or more substituents selected from the group consisting of cycloalkyl.
[0076] In a preferred embodiment (iii) of the D ring, the D ring is unsubstituted or contains one or more R D and one or more R D are each independently a halogen, C 1 -C 6 Alkoxy, HaloC 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkoxy, C 1 -C 6 Alkyl, haloC 1 -C 6 Alkyl, C 3 -C 8Cycloalkyl C 1 -C 6 Alkyl, and C 3 -C 8 cycloalkyl.
[0077] In a preferred embodiment (iv) of the D ring, the D ring is unsubstituted or contains one or more R D and one or more R D are each independently C 1 -C 6 Alkoxy, C 1 -C 6 Alkyl, and C 3 -C 8 cycloalkyl.
[0078] In a preferred embodiment (v) of the D ring, the D ring is unsubstituted or substituted with one or more R D and one or more R D are each independently selected from the group consisting of methoxy, ethoxy, propoxy, propan-2-yloxy, 3-methylbutoxy, [(2S)-butan-2-yl]oxy, [(2R)-butan-2-yl]oxy, methyl, ethyl, propyl, propan-2-yl, 2-methylpropyl, butan-2-yl, 3-methylbutyl, pentan-3-yl, cyclopropyl, cyclobutyl, cyclopentyl, 1-methylcyclopropyl, 3,3-dimethylcyclobutyl, and spiro[2.3]hexan-5-yl.
[0079] In one embodiment of compound (1), any two adjacent substituents on ring D, together with the atoms to which they are attached, form ring E, which may be substituted. In this case, ring E is preferably a 3- to 10-membered monocyclic alicyclic ring, a benzene ring, a 3- to 12-membered monocyclic heterocyclic ring, or a 5- to 6-membered monocyclic aromatic heterocyclic ring (E HA ), more preferably a benzene ring or a 5- to 6-membered monocyclic aromatic heterocycle (E HA )
[0080] In the compound (1), the ring E is a 5- to 6-membered monocyclic aromatic heterocycle (E HA ), then E HAis preferably selected from the group consisting of a furan ring, a thiophene ring, a pyrrole ring, an imidazole ring, a pyrazole ring, a thiazole ring, an isothiazole ring, an oxazole ring, an isoxazole ring, an oxadiazole ring, a thiadiazole ring, a triazole ring, a tetrazole ring, a pyridine ring, a pyrimidine ring, a pyridazine ring, a pyrazine ring, and a triazine ring, more preferably selected from the group consisting of a thiophene ring, an imidazole ring, a pyrazole ring, a thiazole ring, an isothiazole ring, a pyridine ring, a pyrimidine ring, a pyridazine ring, and a pyrazine ring, even more preferably selected from the group consisting of a pyridine ring, a pyrimidine ring, a pyridazine ring, and a pyrazine ring, particularly preferably a pyridine ring or a pyrazine ring, and most preferably a pyridine ring.
[0081] In one embodiment of the present invention, the D ring and the E ring in compound (1) are represented by the following formula: (where * represents R in formula (1) 5 is the carbon to which R is bonded, and ** is the carbon to which R is bonded in formula (1). 6 In the formula, the D ring is represented as the "D ring" and the E ring is represented as the "E ring".
[0082] In a preferred embodiment of the present invention, the D ring and the E ring in compound (1) are represented by the following formula: (where * represents R in formula (1) 5 is the carbon to which R is bonded, and ** is the carbon to which R is bonded in formula (1). 6 In the formula, the D ring is represented as the "D ring" and the E ring is represented as the "E ring".
[0083] In a preferred embodiment (i) of the ring E in the compound (1), the ring E is unsubstituted or is substituted with one or more R E and one or more R E are each independently deuterium, halogen, cyano, nitro, hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, oxo, C 1-C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl; 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 The aryl and 5- to 10-membered heteroaryl may be further substituted.
[0084] In a preferred embodiment (ii) of the E ring in compound (1), the E ring is unsubstituted or has one or more R E and one or more R E are each independently a halogen, C 1 -C 6 Alkyl, C 1 -C 6 The alkyl group is selected from the group consisting of alkoxy, and boryl.
[0085] In a preferred embodiment (iii) of the E ring in compound (1), the E ring is unsubstituted or contains one or more R E and one or more R E are each independently selected from the group consisting of fluorine, chlorine, methoxy, dihydroxyboryl, methyl, and t-butyl.
[0086] Another embodiment of the present invention is a compound represented by general formula (2) (hereinafter also referred to as "compound (2)"), a salt thereof, or a solvate thereof.
[0087] R in compound (2) 4 is R in the above-mentioned compound (1). 4 is synonymous with.
[0088] In compound (2), X 5 is CR x5 Or N. X 5 Preferably, CR x5 and more preferably CH.
[0089] In compound (2), X 6 is CR x6 Or N. X 6 Preferably, CR x6 is.
[0090] In compound (2), X 10a is CR x10a Or N. X 10a Preferably, CR x10a is.
[0091] In compound (2), R x5、 R x6 , R 6a and R x10a are each independently hydrogen, deuterium, halogen, cyano, nitro, hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl;1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 The aryl and 5- to 10-membered heteroaryl may be further substituted or R x5 and R x6 , R x6 and R 6a , or R 6a and R x10a may be taken together with the atom to which they are attached to form an optionally substituted E ring.
[0092] R x6 As a preferred embodiment (i) of R x6 is hydrogen, halogen, hydroxy, C 1 -C 6 Alkylthio, C 1 -C 6 Acylamino, Mono C 1 -C 6 Alkylamino, C 1 -C 6 Alkylsulfonylamino, C 3 -C 8 Cycloalkylsulfonylamino, C 1 -C 6 Alkoxy, HaloC 1 -C 6 Alkoxy, hydroxy C 1 -C 6 Alkoxy, C 1 -C 6 Alkoxy C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkyl C 1 -C 6Alkoxy, 4- to 10-membered heterocyclyl C 1 -C 6 Alkoxy, C 3 -C 8 cycloalkoxy, 4- to 10-membered heterocyclyloxy, C 1 -C 6 Acyl, Mono C 3 -C 8 Cycloalkylaminocarbonyl, 4- to 8-membered cyclic aminocarbonyl, diC 1 -C 6 Alkylphosphoryl, C 1 -C 6 Alkyl, haloC 1 -C 6 Alkyl, hydroxy C 1 -C 6 Alkyl, diC 1 -C 6 Alkylaminocarbonyl C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, Hydroxy C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, hydroxy C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, 1 -C 6 Alkylthio, C 1 -C 6 Alkoxy, C 1 -C 6 Alkoxy C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkoxy, 4- to 10-membered heterocyclyl C 1 -C6 Alkoxy, C 3 -C 8 cycloalkoxy, 4- to 10-membered heterocyclyloxy, C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 The aryl and 5- to 10-membered heteroaryl may further independently be selected from halogen, cyano, hydroxy, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, oxo, halo C 1 -C 6 Alkyl, and C 3 -C 8 It may be optionally substituted with one or more substituents selected from the group consisting of cycloalkyl.
[0093] R x6 As a preferred embodiment (ii) of R x6 is hydrogen, halogen, C 1 -C 6 Alkoxy, HaloC 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkoxy C 3 -C 8 Cycloalkyl, C 3 -C 8 Cycloalkoxy, C 1 -C 6 Alkyl, haloC 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkyl, and C 3 -C 8 cycloalkyl.
[0094] Rx6 As a preferred embodiment (iii) of R x6 is hydrogen, C 1 -C 6 Alkoxy, C 1 -C 6 Alkyl, and C 3 -C 8 cycloalkyl.
[0095] R x6 As a preferred embodiment (iv) of R x6 is selected from the group consisting of hydrogen, methoxy, ethoxy, propoxy, propan-2-yloxy, 3-methylbutoxy, [(2S)-butan-2-yl]oxy, [(2R)-butan-2-yl]oxy, methyl, ethyl, propyl, propan-2-yl, 2-methylpropyl, butan-2-yl, 3-methylbutyl, pentan-3-yl, cyclopropyl, cyclobutyl, cyclopentyl, 1-methylcyclopropyl, 3,3-dimethylcyclobutyl, and spiro[2.3]hexan-5-yl.
[0096] R x10a As a preferred embodiment (i) of R x10a is hydrogen, halogen, cyano, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, and C 3 -C 8 cycloalkyl.
[0097] R x10a As a preferred embodiment (ii) of R x10a is selected from the group consisting of hydrogen, chlorine, bromine, cyano, methyl, ethyl, propyl, propan-2-yl, vinyl, ethynyl, and cyclopropyl.
[0098] R 6a As a preferred embodiment (i) of R 6a is hydrogen, halogen, cyano, haloC 1 -C 6 Alkoxy, and C 1 -C 6alkyl.
[0099] R 6a As a preferred embodiment (ii) of R 6a is selected from the group consisting of hydrogen, fluorine, chlorine, bromine, cyano, difluoromethoxy, methyl, and ethyl.
[0100] In one embodiment of the compound (2), R 6a and R x10a are taken together with the atoms to which they are attached to form an optionally substituted ring E. In this case, ring E is preferably a 3- to 10-membered monocyclic alicyclic ring, a benzene ring, a 3- to 12-membered monocyclic heterocyclic ring, or a 5- to 6-membered monocyclic aromatic heterocyclic ring (E HA ), more preferably a benzene ring or a 5- to 6-membered monocyclic aromatic heterocycle (E HA )
[0101] Ring E is a 5- to 6-membered monocyclic aromatic heterocycle (E HA ), then E HA is preferably selected from the group consisting of a thiophene ring, an imidazole ring, a pyrazole ring, a thiazole ring, an isothiazole ring, a pyridine ring, a pyrimidine ring, a pyridazine ring, and a pyrazine ring, more preferably selected from the group consisting of a pyridine ring, a pyrimidine ring, a pyridazine ring, and a pyrazine ring, even more preferably a pyridine ring or a pyrazine ring, and most preferably a pyridine ring.
[0102] In a preferred embodiment of the present invention, the E ring in compound (2) is represented by the following formula: (where * represents R in formula (2) 6a is the carbon atom to which R is bonded, and ** is the carbon atom to which R is bonded in formula (2). x10a In the formula, the E ring is represented as "E ring".
[0103] In a preferred embodiment of the present invention, the E ring in compound (2) is represented by the following formula: (where * represents R in formula (2) 6a is the carbon atom to which R is bonded, and ** is the carbon atom to which R is bonded in formula (2). x10a In the formula, the E ring is represented as "E ring".
[0104] In a preferred embodiment (i) of the ring E in the compound (2), the ring E is unsubstituted or is substituted with one or more R E and one or more R E are each independently deuterium, halogen, cyano, nitro, hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, oxo, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl; 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 The aryl and 5- to 10-membered heteroaryl may be further substituted.
[0105] In a preferred embodiment (ii) of the ring E in the compound (2), the ring E is unsubstituted or is substituted with one or more R E and one or more R E are each independently a halogen, C 1 -C 6 Alkoxy, boryl, and C 1 -C 6alkyl.
[0106] In a preferred embodiment (iii) of the E ring in compound (2), the E ring is unsubstituted or contains one or more R E and one or more R E are each independently selected from the group consisting of fluorine, chlorine, methoxy, dihydroxyboryl, methyl, and t-butyl.
[0107] Another embodiment of the present invention is a compound represented by general formula (3) (hereinafter also referred to as "compound (3)"), a salt thereof, or a solvate thereof.
[0108] R in compound (3) 4 is R in the above-mentioned compound (1). 4 and X in compound (3) has the same meaning as 5 and X 6 is the X in the above-mentioned compound (2). 5 and X 6 is synonymous with.
[0109] In compound (3), X 7 is CR x7 Or N.
[0110] In compound (3), X 8 is CR x8 Or N.
[0111] In compound (3), X 9 is CR x9 Or N.
[0112] In compound (3), X 10 is CR x10 Or N.
[0113] In compound (3), X 7 , X 8 , X 9 and X 10 The combination of X 7 is N and X 8 is CR x8 and X 9 is CR x9 and X 10 is CR x10Or X 7 is CR x7 and X 8 is N and X 9 is CR x9 and X 10 is CR x10 Or X 7 is CR x7 and X 8 is CR x8 and X 9 is N and X 10 is CR x10 Or X 7 is CR x7 and X 8 is CR x8 and X 9 is CR x9 and X 10 is N or X 7 is N and X 8 is CR x8 and X 9 is CR x9 and X 10 is N or X 7 is CR x7 and X 8 is N and X 9 is CR x9 and X 10 is N or X 7 is N and X 8 is N and X 9 is CR x9 and X 10 is CR x10 It is preferable that:
[0114] In compound (3), X 7 , X 8 , X 9 and X 10 The combination of X 7 is N and X 8 is CR x8 and X 9 is CR x9 and X 10 is CR x10 Or X 7 is CR x7 and X 8 is N and X9 is CR x9 and X 10 is CR x10 Or X 7 is CR x7 and X 8 is CR x8 and X 9 is N and X 10 is CR x10 Or X 7 is CR x7 and X 8 is CR x8 and X 9 is CR x9 and X 10 More preferably, is N.
[0115] In compound (3), R x7 , R x8 , R x9 and R x10 are each independently hydrogen, deuterium, halogen, cyano, nitro, hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, wherein the hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C3 -C 8 cycloalkyl, 4- to 10-membered heterocyclyl, C 6 -C 10 The aryl and 5- to 10-membered heteroaryl may be further substituted.
[0116] R x7 is preferably hydrogen, halogen, C 1 -C 6 Alkoxy and C 1 -C 6 alkyl.
[0117] R x8 is preferably hydrogen, halogen, C 1 -C 6 Alkoxy and C 1 -C 6 alkyl.
[0118] R x9 is preferably hydrogen, halogen, C 1 -C 6 Alkoxy, C 1 -C 6 The alkyl group is selected from the group consisting of alkyl, and boryl.
[0119] R x10 is preferably hydrogen, halogen, C 1 -C 6 Alkoxy and C 1 -C 6 alkyl.
[0120] Another embodiment of the present invention is a compound or salt or solvate thereof set forth in Table 11 below.
[0121] As used herein, the term "compound or a salt thereof, or a solvate thereof" includes the compound, a salt of the compound, a solvate of the compound, and a solvate of a salt of the compound. The compounds described herein can be in the form of a salt thereof, preferably a pharmaceutically acceptable salt thereof. The compounds described herein or a salt thereof can be in the form of a solvate thereof, preferably a pharmaceutically acceptable solvate thereof. Salts of the compounds include, for example, hydrochloride; hydrobromide; hydroiodide; phosphate; phosphonate; sulfate; sulfonate such as methanesulfonate or p-toluenesulfonate; carboxylate such as acetate, citrate, malate, tartrate, succinate, or salicylate; alkali metal salts such as sodium salt or potassium salt; alkaline earth metal salts such as magnesium salt or calcium salt; ammonium salts such as ammonium salt, alkylammonium salt, dialkylammonium salt, trialkylammonium salt, or tetraalkylammonium salt. These salts are prepared, for example, by contacting the compound with an acid or a base. As used herein, the term "solvate" refers to a compound formed with a solvent to form a single molecular group, and is not particularly limited as long as it is a solvate formed with a solvent that is acceptable for ingestion accompanying pharmaceutical administration. Examples of solvates include solvates with a single solvent such as hydrates, alcoholates (ethanol solvates, methanol solvates, 1-propanol solvates, 2-propanol solvates, etc.), and dimethyl sulfoxide, as well as solvates formed with multiple solvents per compound molecule, or solvates formed with multiple types of solvents per compound molecule. A solvate is referred to as a hydrate when the solvent is water. As the solvate of the compound of the present invention, a hydrate is preferred, and specific examples of such hydrates include mono- to decahydrates, preferably mono- to pentahydrates, and more preferably mono- to trihydrates.
[0122] When the compound according to the present invention is obtained in a free form, the compound can be converted into a salt thereof or a hydrate or solvate thereof according to a conventional method. Examples include hydrates and ethanolates of the compound represented by formula (1) or its salts. Specific examples include, but are not limited to, the hemihydrate, monohydrate, dihydrate, trihydrate, tetrahydrate, pentahydrate, hexahydrate, heptahydrate, octahydrate, nodahydrate, decahydrate, or monoethanolate of the compound represented by formula (1), or the hemihydrate, monohydrate, dihydrate, trihydrate, tetrahydrate, pentahydrate, hexahydrate, heptahydrate, octahydrate, nodahydrate, decahydrate, or monoethanolate of the sodium salt of the compound represented by formula (1), or the hydrate or ethanolate of the hydrochloride of the compound represented by formula (1). The hydrate or solvate may be produced in a crystalline or amorphous form, and in the case of a crystalline form, it may take the form of a crystalline polymorph. As a method for producing the hydrate or solvate, for example, the hydrate or solvate can be obtained by a conventional method, such as adding a solvent such as ethanol and / or water to the compound represented by formula (1), and stirring, cooling, concentrating, and / or drying.
[0123] Furthermore, when the compound according to the present invention is obtained as a salt, hydrate, or solvate of the compound, the compound can be converted into its free form by a conventional method.
[0124] The compounds described herein may contain unnatural proportions of isotope atoms in one or more atoms constituting such compounds. The present invention also includes compounds in which any atom in a compound is substituted with another isotope atom having the same atomic number (number of protons) but a different mass number (sum of the number of protons and neutrons), thereby replacing the isotope with an abundance ratio different from the abundance ratio of the isotopes in nature, i.e., compounds labeled with isotope atoms. Examples of isotope elements contained in the compounds of the present specification include hydrogen atoms, carbon atoms, nitrogen atoms, oxygen atoms, phosphorus atoms, sulfur atoms, fluorine atoms, chlorine atoms, etc., and each of these isotopes is 2 H, 3 H, 13 C. 14 C. 15 N, 17 O.18 O. 32 P, 35 S, 18 F, 36 Isotopically labeled compounds include Cl and the like. Compounds labeled with isotope atoms are useful as therapeutic or preventive agents, research reagents (e.g., assay reagents), and diagnostic agents (e.g., in vivo imaging diagnostic agents). Compounds herein containing radioactive or non-radioactive isotopes in all proportions are encompassed within the scope of the present invention. Compounds labeled with isotope atoms can be produced using reagents and solvents containing the corresponding isotope atoms in the same manner as for producing unlabeled compounds.
[0125] The compounds described herein, their salts, or solvates thereof include all stereoisomers thereof (e.g., enantiomers, diastereomers (including cis and trans geometric isomers)), racemates of said isomers, and other mixtures thereof. For example, the compounds of the present invention may have one or more asymmetric centers, and the present invention includes racemic mixtures, diastereomeric mixtures, and enantiomers of such compounds. Furthermore, for example, the compounds of the present invention may have axial chirality, and the present invention includes each stereoisomer of such compounds and mixtures thereof.
[0126] <General Manufacturing Methods> Examples of manufacturing methods for the compounds represented by formulas (1) to (3), or salts thereof, or solvates thereof, are explained using the following group of schemes. The compounds of the present invention can be synthesized by various methods, and the manufacturing methods below are illustrative, and the present invention is not limited to the chemical reactions and conditions explicitly stated. In the manufacturing method schemes below, some substituents are omitted for clarity, but these are not intended to limit the disclosure of the schemes. Representative compounds of the present invention can be synthesized using appropriate intermediates, known compounds, and reagents. In the formulas in the general synthesis methods below, R 1 , R 2 Variables such as n and n are, unless otherwise specified, the same as R 1 , R 2and variables represented by n, etc. Note that if the starting material or target product of a certain step undergoes an undesired chemical transformation under the reaction conditions of that step, the target product of that step can be obtained, for example, by protecting and deprotecting functional groups. Regarding the selection of protecting groups and the selection of protection and deprotection methods, see, for example, TW Greene, PGM Wuts, Protective Groups in Organic Synthesis (5th Edition, John Wiley & Sons 2014) (Non-Patent Document 6). Some of the protection and deprotection of functional groups are also described in the following schemes. The compounds obtained in each step may be isolated by a conventional technique and, if necessary, purified by crystallization or chromatography.
[0127] Examples of abbreviations used herein are listed below along with their meanings: Boc: tert-butoxycarbonyl DCM: dichloromethane DMA: N,N-dimethylacetamide DMF: N,N-dimethylformamide DMSO: dimethyl sulfoxide EtOH: ethanol MeOH: methanol NMP: N-methyl-2-pyrrolidone TFA: trifluoroacetic acid THF: tetrahydrofuran TBME: tert-butyl methyl ether TFE: 2,2,2-trifluoroethanol HATU: O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate DIPEA: N,N-diisopropylethylamine XPhos Pd G3: (2-Dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)(2-(2'-amino-1,1'-biphenyl))palladium(II) methanesulfonic acid (CAS number: 1445085-55-1) XPhos Pd G4: (2-Dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)(2-(2'-(N-methyl)amino-1,1'-biphenyl))palladium(II) methanesulfonic acid (CAS number: 1599466-81-5) DPPF Pd G4: (1,1'-Bis(diphenylphosphino)ferrocene)(2-(2'-(N-methyl)amino-1,1'-biphenyl))palladium(II) Methanesulfonic acid (CAS number: 1621274-17-6) CPhos Pd G3: (2-dicyclohexylphosphino-2',6'-bis(N,N-dimethylamino)biphenyl)(2-(2'-amino-1,1-biphenyl))palladium(II) Methanesulfonic acid (CAS number: 1447963-73-6) CPhos Pd G2: Chloro[(2-dicyclohexylphosphino-2',6'-bis(N,N-dimethylamino)-1,1'-biphenyl)-2-(2'-amino-1,1'-biphenyl)]palladium(II) (CAS number: 2230788-62-0) tBuBrettPhos Pd G3: [(2-di-tert-butylphosphino-3,6-dimethoxy-2',4',6'-triisopropyl-1,BINAP Pd G4: [(±)-2,2'-bis(diphenylphosphino)-1,1'-binaphthalene] (2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) methanesulfonic acid (CAS number: 1599466-90-6) Xantphos Pd G3: [9,9-dimethyl-4,5-bis(diphenylphosphino)xanthene] (2'-amino-1,1'-biphenyl-2-yl)palladium(II) methanesulfonic acid (CAS number: 1445085-97-1) Xantphos Pd G4: [9,9-dimethyl-4,5-bis(diphenylphosphino)xanthene](2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) methanesulfonic acid (CAS number: 1621274-19-8) tBuXPhos Pd G3: [(2-di-tert-butylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)-2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonic acid (CAS number: 1447963-75-8) DCC: N,N'-dicyclohexylcarbodiimide EDC: N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide COMU: (1-cyano-2-ethoxy-2-oxoethylideneaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate LiHMDS: Lithium hexamethyldisilazide NaHMDS: Sodium hexamethyldisilazide KHMDS: Potassium hexamethyldisilazide LDA: Lithium diisopropylamide DIAD: Diisopropyl azodicarboxylate CMMP: (cyanomethylene)trimethylphosphorane CMBP: (cyanomethylene)tributylphosphorane DCE: 1,2-dichloroethane FA: Formic acid,
[0128] The compounds of the present invention can be synthesized, for example, by the following production methods.
[0129] (General Production Method 1-1) General Production Method 1-1 is a method for producing a compound represented by any one of the general formulae (1) to (3), wherein R4 is optionally substituted C 6 -C 10 This is a preferred method for producing a compound which is an aryl or an optionally substituted 5- to 10-membered heteroaryl.
[0130] Step 1-1 This step is a formylation step of aromatic bromide 1a. Compound 1b can be produced by reacting aromatic bromide 1a with a metal species, followed by a reaction with a formylating reagent. Examples of metal species include magnesium, lithium, and other metals, and organometallic reagents. Examples of organometallic reagents include isopropylmagnesium bromide, isopropylmagnesium chloride-lithium chloride complex, n-butyllithium, and sec-butyllithium, with isopropylmagnesium chloride-lithium chloride complex being preferred. The formylating reagent is selected from N-formamides and orthoformates, with DMF being preferred as the N-formamide and trimethyl orthoformate being preferred as the orthoformates. Examples of the solvent used in this step include aprotic solvents such as n-hexane, cyclohexane, ethers (examples include dialkyl ethers such as diethyl ether, and cyclic ethers such as 1,2-dimethoxyethane, THF, and 2-methyltetrahydrofuran), toluene, and mixed solvents thereof, and THF, 1,2-dimethoxyethane, toluene, and mixed solvents thereof are preferred.
[0131] Step 1-2 This step is a step of producing an aromatic ester from aromatic bromide 1a. Aromatic ester 1c (wherein R is C 1 -C 6The aromatic bromide 1a (representing alkyl, 2,4,6-trichlorophenyl, or 2,5-dioxopyrrolidin-1-yl) can be produced by reacting aromatic bromide 1a with a carbonylation reagent in the presence of a Pd catalyst and a base. This step can be carried out with reference to the method described in, for example, Tetrahedron Lett., 2019 vol. 60, 151147 (Non-Patent Document 7). Examples of the carbonylation reagent include formate esters, oxalate esters, and salts thereof, with 2,4,6-trichlorophenyl formate being preferred. Examples of the base include tertiary amines, with triethylamine and DIPEA being preferred. Examples of the solvent used in this step include aprotic solvents such as toluene, acetonitrile, THF, and DMF, and mixed solvents thereof, with toluene being preferred. Preferred Pd catalysts include a combination of palladium acetate and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene, Xantphos Pd G4, and Xantphos Pd G3. This step can be carried out at a reaction temperature of from −20° C. to about the boiling point of the solvent, preferably from 60° C. to about the boiling point of the solvent.
[0132] Step 1-3 This step is a hydrolysis step of aromatic ester 1c. Aromatic carboxylic acid 1d can be produced by reacting aromatic ester 1c with a hydroxide. The hydroxide can be selected from the group consisting of sodium hydroxide, lithium hydroxide, potassium hydroxide, and barium hydroxide. Solvents used in this step include polar solvents such as water, ethers, alcohols, and DMSO, and mixed solvents thereof, and a mixed solvent of THF and water and a mixed solvent of methanol and water are preferred.
[0133] Step 1-4: This step is the amidation step of aromatic carboxylic acid 1d. Aromatic amide 1e (wherein X represents methyl(methoxy)amino or morpholinyl) can be produced by reacting aromatic carboxylic acid 1d with an amine or an amine salt in the presence of a condensing agent. Examples of the condensing agent include DCC, EDC, EDC hydrochloride, HATU, COMU, and propylphosphonic anhydride (cyclic trimer), with HATU being preferred. A base may also be used as an additive in this step. Examples of the base include DIPEA, triethylamine, and diazabicycloundecene, with DIPEA being preferred. Examples of the solvent used in this step include DMF, DMA, NMP, DCM, THF, 1,4-dioxane, 1,2-dimethoxyethane, ethyl acetate, acetonitrile, and mixtures thereof. Examples of amines or amine salts include N,O-dimethylhydroxylamine hydrochloride and morpholine, with N,O-dimethylhydroxylamine hydrochloride being preferred.
[0134] Step 1-5: This step is an alternative method for synthesizing aromatic amide 1e, and involves an ester-amide exchange reaction of aromatic ester 1c. This step can be performed when R in aromatic ester 1c is 2,4,6-trichlorophenyl, 2,5-dioxopyrrolidin-1-yl, or the like. Aromatic amide 1e (wherein X represents methyl(methoxy)amino or morpholinyl) can be produced by reacting aromatic ester 1c with an amine. Morpholine is preferred as the amine. Examples of solvents used in this step include toluene, DMF, DMA, THF, 1,4-dioxane, 1,2-dimethoxyethane, acetonitrile, and mixed solvents thereof, with toluene being preferred. This step can be performed at a reaction temperature of -20°C to near the boiling point of the solvent, preferably at a temperature of 60°C or higher to near the boiling point of the solvent.
[0135] (General Production Method 1-2) General Production Method 1-2 is a method for producing a compound represented by any one of the general formulae (1) to (3), wherein R 4 is optionally substituted C 6 -C 10This is a preferred method for producing a compound which is an aryl or an optionally substituted 5- to 10-membered heteroaryl.
[0136] Step 1-6: This step is a step of iodinating aromatic amine 1f. Aromatic amine 1g can be produced by reacting aromatic amine 1f with an iodinating reagent. Examples of iodinating reagents include iodine, N-iodosuccinimide, 1,3-diiodo-5,5-dimethylhydantoin, N-iodosaccharin, and iodine chloride, with N-iodosuccinimide being preferred. Solvents used in this step include DCM, acetonitrile, ethyl acetate, DMSO, and acetic acid, with DCM and DMSO being preferred. Acids such as TFA, acetic acid, sulfuric acid, methanesulfonic acid, and trifluoromethanesulfonic acid may be used as appropriate as additives in this step.
[0137] Step 1-7: This step involves converting the amino group of aromatic amine 1g using an N,N-dimethylformamidination reagent. Aromatic iodine compound 1h can be produced by converting the amino group of aromatic amine 1g to an N,N-dimethylformamidino group. Examples of N,N-dimethylformamidination reagents include N,N-dimethylformamide dimethyl acetal, N,N-dimethylformamide di-tert-butyl acetal, and a combination of DMF and phosphorus(V) oxychloride, with N,N-dimethylformamide dimethyl acetal being preferred. Solvents used in this step include alcohols, DMSO, THF, DMF, DMA, NMP, toluene, 1,4-dioxane, 1,2-dimethoxyethane, ethyl acetate, acetonitrile, and mixed solvents thereof, with ethanol and DMSO being preferred. This step can be carried out at a reaction temperature of from −20° C. to about the boiling point of the solvent, preferably from 40° C. to about the boiling point of the solvent.
[0138] Step 1-8: This step involves reacting aromatic iodine compound 1h with a metal species, followed by reaction with aromatic amide 1e (wherein X represents methyl(methoxy)amino or morpholinyl), to synthesize ketone 1i. Examples of metal species include magnesium and lithium, as well as organometallic reagents. Examples of organometallic reagents include isopropylmagnesium bromide, isopropylmagnesium chloride-lithium chloride complex, n-butyllithium, and sec-butyllithium, with isopropylmagnesium chloride-lithium chloride complex being preferred. Examples of solvents used in this step include aprotic solvents such as n-hexane, cyclohexane, ethers, and toluene, as well as mixed solvents thereof. Preferred are THF, 1,2-dimethoxyethane, toluene, and mixed solvents thereof. Furthermore, additives such as hexamethylphosphoric triamide, N,N'-dimethylpropylene urea, or crown ether may be added as desired, with N,N'-dimethylpropylene urea being preferred.
[0139] Step 1-9: This step is a step of converting dimethylformamidine 1i to aniline 1j by hydrolysis. Aniline 1j can be produced by reacting dimethylformamidine compound 1i with a hydroxide. Examples of hydroxides include sodium hydroxide, lithium hydroxide, potassium hydroxide, and barium hydroxide, with sodium hydroxide being preferred. Solvents used in this step include polar solvents such as THF, alcohol, and DMSO, with DMSO being preferred.
[0140] Step 1-10: This step involves reacting aromatic iodine compound 1h with a metal species, followed by reaction with aromatic aldehyde 1b to produce an alcohol. Examples of metal species include magnesium, lithium, and other metals, as well as organometallic reagents. Examples of organometallic reagents include isopropylmagnesium bromide, isopropylmagnesium chloride-lithium chloride complex, n-butyllithium, and sec-butyllithium, with isopropylmagnesium chloride-lithium chloride complex being preferred. Examples of solvents used in this step include aprotic solvents such as n-hexane, cyclohexane, ethers, and toluene, as well as mixed solvents thereof. Preferred are THF, 1,2-dimethoxyethane, toluene, and mixed solvents thereof. Additionally, additives such as hexamethylphosphoric triamide, N,N'-dimethylpropylene urea, or crown ether may be added, with N,N'-dimethylpropylene urea being preferred. Furthermore, the N,N-dimethylformamidino group can be converted to an amino group by sequentially adding an acid and a base to the reaction mixture. The acid is preferably formic acid, and the base is preferably ethylenediamine.
[0141] Step 1-11: This step is a step of converting benzyl alcohol 1o into a ketone by oxidation. Aromatic amine 1j can be produced by reacting benzyl alcohol 1o with an oxidizing agent. Examples of the oxidizing agent include manganese dioxide, Dess-Martin periodinane, chromium (IV) oxide, and pyridinium dichromate, with manganese dioxide being preferred. Solvents used in this step include aprotic solvents such as DCM, chloroform, acetonitrile, and ethyl acetate, as well as mixed solvents thereof, with DCM being preferred.
[0142] Step 1-12: This step involves haloacetylating aromatic amine 1j. This step can be carried out according to the following Method-1 or Method-2. Method-1: Haloacetamide 1k (wherein Y represents a halogen) can be produced by reacting aromatic amine 1j with a haloacetylating agent. Examples of the haloacetylating agent that can be used include chloroacetyl chloride and bromoacetyl chloride. In this step, a base may be used as appropriate, and examples of the base that can be used include organic bases such as DIPEA, triethylamine, and pyridine. Examples of solvents used in this step include DCM, acetonitrile, THF, DMF, DMA, and NMP, with DCM and DMA being preferred. Method-2: Haloacetamide 1k (wherein Y represents a halogen) can be produced by reacting aromatic amine 1j with a haloacetic acid in the presence of a condensing agent. Examples of the haloacetic acid that can be used include chloroacetic acid and bromoacetic acid. Condensing agents include, for example, DCC, EDC, EDC hydrochloride, HATU, COMU, and propylphosphonic anhydride (cyclic trimer), with HATU and propylphosphonic anhydride (cyclic trimer) being preferred. Bases include, for example, DIPEA and triethylamine, with DIPEA being preferred. Solvents used in this step include, for example, DMF, DMA, NMP, DCM, acetone, THF, 1,4-dioxane, 1,2-dimethoxyethane, ethyl acetate, acetonitrile, and mixed solvents thereof, with DMF being preferred.
[0143] Step 1-13: This step is a step of constructing a pyridone skeleton from haloacetamide 1k (wherein Y represents a halogen) by a cyclization reaction. Pyridinium ylide 1l (wherein Y represents a halogen) can be produced by reacting haloacetamide 1k with pyridine. Pyridine may be used as a solvent in this step. Alternatively, the reaction mixture from step 1-12 may be reacted with pyridine. This step can be performed at a reaction temperature of -20°C to near the boiling point of the solvent, preferably at a temperature of 40°C to near the boiling point of the solvent.
[0144] Step 1-14: This step is a deprotection step of pyridinium ylide 1l. 3-Aminopyridone compound 1n1 can be produced by reacting pyridinium ylide 1l with a nucleophile. Examples of nucleophiles include hydrazine, hydrazine hydrochloride, hydrazine monohydrate, and hydroxylamine, with hydrazine monohydrate and hydrazine hydrochloride being preferred. Alternatively, the reaction mixture from Step 1-13 may be used as is. This step can be performed at a reaction temperature of -20°C to about the boiling point of the solvent, preferably 40°C to about the boiling point of the solvent.
[0145] Step 1-15 This step is carried out by reacting R of 3-aminopyridone compound 1n1 4 In the case where 3-aminopyridone compound 1n1 has an acid-removable protecting group such as 2-tetrahydropyranyl, this step involves adding an acid to the 3-aminopyridone compound 1n1 to remove the acid-removable protecting group such as 2-tetrahydropyranyl. Examples of acids include sulfuric acid, hydrochloric acid, sulfonic acids, and carboxylic acids, with TFA being preferred. Examples of solvents used in this step include alcohols (such as alkyl alcohols and fluoroalkyl alcohols), water, and DCM. Alternatively, an acid may be generated using, for example, chlorotrimethylsilane (TMSCl) in the alcohol solvent to remove the acid-removable protecting group such as 2-tetrahydropyranyl. Preferred combinations of acids and solvents include, for example, a combination of TMSCl and TFE, a combination of TFA and DCM, and a combination of TFA and water.
[0146] (General Production Method 2) General Production Method 2 is another preferred method for synthesizing 3-aminopyridone compound 1n2. General Production Method 2 is a method for synthesizing 3-aminopyridone compound 1n2 by synthesizing 3-aminopyridone compound 1n2. 4 is optionally substituted C 6 -C 10 This is a preferred method for producing a compound which is an aryl or an optionally substituted 5- to 10-membered heteroaryl.
[0147] Step 2-1 Step 2-1 is a step of condensing an acid chloride 2a-1 (wherein X represents chlorine) or a carboxylic acid 2a-2 (wherein X represents hydroxy) with a glycine alkyl ester or a salt of a glycine alkyl ester. This step can be carried out according to the following Method-1 or Method-2. Method-1: Amide 2b can be prepared by condensing an acid chloride 2a-1 with a glycine alkyl ester or a salt of a glycine alkyl ester (wherein R represents C 1 -C 6 The amide 2b can be prepared by reacting the carboxylic acid 2a-2 with a glycine alkyl ester or a salt of a glycine alkyl ester in the presence of a condensing agent. The salt of a glycine alkyl ester is preferably glycine alkyl ester hydrochloride. Examples of the base include organic bases such as DIPEA, triethylamine, and pyridine, as well as inorganic bases such as carbonates and sodium hydroxide, with triethylamine or DIPEA being preferred. Solvents used in this step include DCM, acetonitrile, THF, DMF, DMA, NMP, and water, with DCM and THF being preferred. Method 2: Amide 2b can be prepared by reacting carboxylic acid 2a-2 with a glycine alkyl ester or a salt of a glycine alkyl ester in the presence of a condensing agent. The salt of a glycine alkyl ester is preferably glycine alkyl ester hydrochloride. Examples of the condensing agent include DCC, EDC, EDC hydrochloride, HATU, COMU, and propylphosphonic anhydride (cyclic trimer), with HATU and propylphosphonic anhydride (cyclic trimer) being preferred. A base may be used as an additive in this step, and examples of the base include DIPEA and triethylamine, with DIPEA being preferred. Examples of the solvent used in this step include a solvent selected from the group consisting of DMF, DMA, NMP, DCM, acetone, THF, 1,4-dioxane, 1,2-dimethoxyethane, ethyl acetate, and acetonitrile, or a mixed solvent thereof, with DMF being preferred.
[0148] Step 2-2 This step is a step of protecting amide 2b with Boc. Boc-protected compound 2c can be produced by reacting amide 2b with a Boc-modification reagent. In this step, a base and a catalyst can be used as appropriate. Examples of the base include DIPEA, triethylamine, and diazabicycloundecene. Examples of the catalyst include DMAP. Examples of the solvent used in this step include a solvent selected from the group consisting of DMF, DMA, DCM, acetone, THF, 1,4-dioxane, 1,2-dimethoxyethane, ethyl acetate, and acetonitrile, or a mixed solvent thereof, and DMF is preferred.
[0149] Step 2-3: This step involves rearranging the acyl group of Boc-protected compound 2c in the presence of a base. Examples of the base include sodium tert-butoxide, potassium tert-butoxide, LiHMDS, NaHMDS, KHMDS, and LDA, which can be used alone or in combination. Potassium tert-butoxide, LiHMDS, and mixtures thereof are preferred. Examples of the solvent used in this step include solvents selected from the group consisting of toluene, xylene, n-hexane, cyclohexane, THF, 1,2-dimethoxyethane, N,N'-dimethylpropyleneurea, and hexamethylphosphoric triamide, or mixed solvents thereof, with THF being preferred.
[0150] Step 2-4: This step involves tosylation of ketone compound 2d using a base. Examples of the base include a base selected from the group consisting of sodium tert-butoxide, potassium tert-butoxide, LiHMDS, NaHMDS, KHMDS, LDA, DIPEA, triethylamine, and diazabicycloundecene, or a combination of these bases. LDA, LiHMDS, DIPEA, and triethylamine are preferred. Examples of the solvent used in this step include a solvent selected from the group consisting of toluene, xylene, n-hexane, cyclohexane, THF, 1,2-dimethoxyethane, acetonitrile, and DCM, or a mixed solvent thereof, with THF being preferred. Alternatively, the reaction mixture from Step 2-3 may be used directly to carry out the reaction.
[0151] Step 2-5 This step is a Pd-catalyzed cross-coupling step and a cyclocondensation step. In the presence of a Pd catalyst, compound 2e is reacted with a corresponding organoboron compound (wherein R' is exemplified by hydrogen, alkyl, or alkylene) or an organotin compound (wherein R' is exemplified by hydrogen, alkyl, or alkylene). The organoboron compound or organotin compound used has an amino group at the ortho position of the boron or tin, and the cross-coupling step is followed by a cyclocondensation step. This step can be carried out according to the following Method-1 or Method-2. Method-1 (Suzuki-Miyaura cross-coupling): Method-1 is described, for example, in Chem. Rev. 1995, vol. 95, no. 7, pp. 2457-2483 (Non-Patent Document 8), Acc. Chem. Res. 2008, vol. 41, no. 11, pp. 1461-1473. (Non-Patent Document 9). Examples of bases used in this method include inorganic salts such as carbonates, phosphates, and hydroxides, and amines such as triethylamine and DIPEA, with cesium carbonate, potassium carbonate, and triethylamine being preferred. Examples of solvents used in this method include polar solvents such as toluene, xylene, THF, 2-methyltetrahydrofuran, 4-methyltetrahydropyran, 1,4-dioxane, DMF, DMA, NMP, and water, as well as mixed solvents thereof, with mixed solvents of 2-methyltetrahydrofuran and 4-methyltetrahydropyran with water being preferred. Examples of Pd catalysts include PdCl 2 (PPh 3 ) 2 , Pd(PPh 3 ) 4[1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride, 1,4-bis(diphenylphosphino)butane]palladium(II) dichloride, XPhos Pd G3, and XPhos Pd G4 are examples. [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride, 1,4-bis(diphenylphosphino)butane]palladium(II) dichloride, XPhos Pd G3, and XPhos Pd G4 are preferred. This step can be carried out at a reaction temperature of -20°C to near the boiling point of the solvent, preferably at a temperature of 80°C or higher to near the boiling point of the solvent. Method 2 (Stille cross-coupling): Method 2 is described, for example, in Synthesis 1992, vol. 9, pp. 803-815. The method can be carried out by the method described in (Non-Patent Document 10). As the Pd catalyst, for example, PdCl 2 (PPh 3 ) 2 , Pd(PPh 3 ) 4 , and [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride, and 1,4-bis(diphenylphosphino)butane]palladium(II) dichloride, and Pd(PPh 3 ) 4 Examples of solvents used in this method include toluene, xylene, THF, 2-methyltetrahydrofuran, 4-methyltetrahydropyran, 1,4-dioxane, DMF, DMA, and NMP, with toluene being preferred. This step can be carried out at a reaction temperature of from −20° C. to about the boiling point of the solvent, preferably from 80° C. to about the boiling point of the solvent.
[0152] Step 2-6 This step is a step of deprotecting the Boc of the Boc-protected compound 2f, and can be performed under the same conditions as in Step 1-15.
[0153] Step 2-7: This step involves carrying out a Wittig reaction on the formyl compound 2g. The α,β-unsaturated ester compound 2h can be produced by reacting the formyl compound 2g with a phosphorus reagent in the presence of a base. Examples of the phosphorus reagent include 2-(BOC-amino)-2-(dimethoxyphosphoryl)acetic acid ester and its equivalents (wherein R is C 1 -C 6 Examples of suitable bases include methyl 2-(BOC-amino)-2-(dimethoxyphosphoryl)acetate, with 2-(BOC-amino)-2-(dimethoxyphosphoryl)acetate being preferred. Examples of suitable bases include those selected from the group consisting of sodium tert-butoxide, potassium tert-butoxide, LiHMDS, NaHMDS, KHMDS, LDA, and 1,4-diazabicyclo[2.2.2]octane, or mixtures thereof. Examples of suitable solvents for use in this method include toluene, THF, 1,2-dimethoxyethane, acetonitrile, DCM, and the like.
[0154] Step 2-8: This step is a bromination step of the α,β-unsaturated ester compound 2h. The aromatic nitro compound 2i can be produced by reacting the α,β-unsaturated ester 2h with a bromination reagent and then isomerizing it in the presence of a base. Examples of the bromination reagent include NBS, 1,3-dibromo-5,5'-dimethylhydantoin, and N-bromosaccharin, with NBS being preferred. Examples of the base include 1,4-diazabicyclo[2.2.2]octane, diazabicycloundecene, sodium tert-butoxide, potassium tert-butoxide, LiHMDS, NaHMDS, and KHMDS, with 1,4-diazabicyclo[2.2.2]octane and diazabicycloundecene being preferred. Solvents used in this method include acetonitrile and DCM.
[0155] Step 2-9: This step is a reduction step of aromatic nitro compound 2i and a subsequent cyclization step. The reduction step can be carried out, for example, by the method described in Org. Process Res. Dev. 2018, vol. 22, no. 4, pp. 430-445 (Non-Patent Document 11). In particular, the reduction step can be carried out by using Pd(OH) 2 / H 2or a combination of Fe / NH in ethanol 4 It is preferable to carry out the reaction using a combination of Cl. The cyclization step can be carried out continuously by carrying out the reaction at a temperature ranging from room temperature to a temperature close to the boiling point of the solvent.
[0156] Step 2-10: This step is a Pd-catalyzed cross-coupling step. Compound 2i or 2j is reacted with the corresponding organoboron compound (R 4 -B (OR) 2 , R 4 -BF 3 K) or organotin compounds (R 4 -SnR 3 ) (wherein R is exemplified by hydrogen and alkyl) can be reacted under the same conditions as in step 2-5.
[0157] (General Production Method 3) General Production Method 3 is a method for preparing 3-aminopyridone compound 1n1 or 1n2 by reacting 3-aminopyridone compound 1n1 or 1n2 with a compound represented by the formula: X 6 is CR x6 and R x6 is a halogen.
[0158] Step 3-1 In this step, a 3-aminopyridone compound 1n1 or 1n2 is reacted with a substituent R x6 This step can be carried out according to any of the following methods 1 to 6. Method 1 (Suzuki-Miyaura cross-coupling): 3-aminopyridone compound 1n1 or 1n2 is introduced into a corresponding organoboron compound (R x6 -B (OR) 2 , R x6 -BF 3 K) or organotin compounds (R x6 -SnR 3 ) (wherein R is exemplified by hydrogen or alkyl). This can be carried out under the same conditions as in Method-1 of Step 2-5. Method-2 (Alkylation or alkenylation by Negishi cross-coupling): 3-aminopyridone compound 3a can be prepared by reacting 3-aminopyridone compound 1n1 or 1n2 with the corresponding organozinc reagent (R x6-ZnX) (wherein X is a halogen). Method-2 can be carried out, for example, by the method described in Tetrahedron. 1992, vol. 48, no. 44, pp. 9577-9648 (Non-Patent Document 12) or Aldrichimica Acta. 2005, vol. 38, pp. 71-88 (Non-Patent Document 13). Solvents used in this step include polar solvents such as THF, 1,4-dioxane, DMF, DMA, NMP, etc., or mixed solvents thereof, with THF being preferred. Pd or Ni can be used, for example, as described in Tetrahedron. 1992, vol. 48, no. 44, pp. 9577-9648. (Non-Patent Document 12) or Aldrichimica Acta. 2005, vol. 38, pp. 71-88. (Non-Patent Document 13), as well as PdCl 2 (PPh 3 ) 2 , Pd(PPh 3 ) 4 and [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride, PdCl 2 (PPh 3 ) 2 , Pd(PPh 3 ) 4 and [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride are preferred. Method 3 (Sonogashira cross-coupling): 3-aminopyridone compound 3a can be prepared by reacting 3-aminopyridone compound 1n1 or 1n2 with a corresponding alkyne (R-C≡C-H, where R-C≡C- is R x6 -). Method-3 can be carried out, for example, by the method described in Chem. Soc. Rev. 2011, vol. 40, pp. 5084-5121. (Non-Patent Document 14). The corresponding alkyne may have a silyl group, for example, trimethylsilylacetylene. Examples of the base include amines such as triethylamine, DIPEA, diazabicycloundecene, and inorganic bases such as sodium acetate, with triethylamine and DIPEA being preferred. Examples of Pd include, for example, PdCl 2 (PPh3 ) 2 , Pd(PPh 3 ) 4 , [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride, Pd(OAc) 2 , and Pd 2 (dba) 3 and PdCl 2 (PPh 3 ) 2 , Pd(PPh 3 ) 4 , and [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride are preferred. Examples of Cu include copper iodide, copper bromide, and copper chloride, with copper iodide being preferred. Solvents used in this step include polar solvents such as THF, 1,4-dioxane, DMF, DMA, NMP, DMSO, methanol, ethanol, and 2-propanol, as well as mixed solvents thereof, with DMSO, DMF, DMA, and NMP being preferred. Method 4 (Thioetherification): 3-aminopyridone compound 3a can be produced by reacting 3-aminopyridone compound 1n1 or 1n2 with the corresponding mercaptan or mercaptan salt in the presence of Pd and a base. Examples of mercaptans include 2-ethylhexyl and 3-mercaptopropionic acid. Examples of the base include amines such as triethylamine, DIPEA, diazabicycloundecene, and piperidine, and triethylamine and DIPEA are preferred. Examples of Pd include Pd(PPh 3 ) 4Examples of the solvent used in this step include polar solvents such as THF, 1,4-dioxane, DMF, DMA, NMP, DMSO, methanol, ethanol, and 2-propanol, as well as mixed solvents thereof, with 1,4-dioxane being preferred. Method 5 (Etherification or Hydroxylation): 3-aminopyridone compound 3a can be produced by reacting 3-aminopyridone compound 1n1 or 1n2 with the corresponding alcohol or water in the presence of Pd. In the case of etherification, for example, sodium salts and potassium salts of the corresponding alcohols can be used as bases. In the case of hydroxylation, for example, sodium hydroxide and potassium hydroxide can be used. Examples of Pd include Pd(PPh 3 ) 4 Examples of the zero-valent Pd complex include tBuBrettPhos Pd G3, with tBuBrettPhos Pd G3 being preferred. Examples of the solvent used in this step include polar solvents such as THF, 1,4-dioxane, DMF, DMA, and NMP, with 1,4-dioxane being preferred. Method 6 (amination): 3-aminopyridone compound 3a can be produced by reacting 3-aminopyridone compound 1n1 or 1n2 with the corresponding amine in the presence of Pd or Cu and a base. When Pd is used, the method described in Chem. Rev. 2016, vol. 116, pp. 12564-12649 (Non-Patent Document 15) can be used. Pd can be, for example, Pd(PPh 3 ) 4Examples of the base include zero-valent Pd complexes such as those described above, with Xantphos Pd G3, Xantphos Pd G4, and tBuXPhos Pd G3 being preferred. Examples of the base include carbonates, phosphates, sodium tert-butoxide, potassium tert-butoxide, and the like, with sodium tert-butoxide being preferred. Examples of the solvent used in this step include polar solvents such as THF, 1,4-dioxane, DMF, DMA, NMP, and DMSO, as well as mixed solvents thereof, with 1,4-dioxane being preferred. Furthermore, when Cu is used, the process can be carried out by the method described in Org. Process Res. Dev. 2022, vol. 26, no. 6, pp. 1690-1750. (Non-Patent Document 16). Examples of Cu include copper iodide, copper bromide, and copper chloride, with copper iodide being preferred. Examples of Cu ligands include 1,10-phenanthroline, L-proline, and 2-((2,6-dimethylphenyl)amino)-2-oxoacetic acid (DMPAO), with 2-((2,6-dimethylphenyl)amino)-2-oxoacetic acid (DMPAO) being preferred. Examples of bases include carbonates, phosphates, sodium tert-butoxide, and potassium tert-butoxide, with cesium carbonate, potassium carbonate, and tripotassium phosphate being preferred. Examples of solvents used in this step include polar solvents such as THF, 1,4-dioxane, DMF, DMA, NMP, and DMSO, as well as mixed solvents thereof, with DMSO being preferred.
[0159] Step 3-2: When the 3-aminopyridone compound 3a has a Boc group, a 2-tetrahydropyranyl group, or both, this step is to deprotect the Boc group, the 2-tetrahydropyranyl group, or both. This step can be performed under the same conditions as in Step 1-15.
[0160] Step 3-3-1, Step 3-3-2, and Step 3-3-3 are all steps for protecting the 3-aminopyridone compound 1n1 or 1n2 with a protecting group.
[0161] Step 3-3-1: Protection by Boc Derivatization This step is a step of protecting 3-aminopyridone compound 1n1 or 1n2 with a Boc group. Protected 3-aminopyridone compound 3c can be produced by reacting 3-aminopyridone compound 1n1 or 1n2 with a Boc-derivatization reagent. In this step, a base and a catalyst can be used as appropriate. In this step, in the formula, P 1 is a Boc group, and P 3 is a Boc group or H. This step can be carried out under the same conditions as in step 2-2.
[0162] Step 3-3-2: Protection by para-methoxybenzylation This step involves reacting 3-aminopyridone compound 1n1 or 1n2 with a p-methoxybenzylation reagent in the presence of a base to perform para-methoxybenzylation. 1 is a p-methoxybenzyl group, and P 3 is H. Examples of p-methoxybenzylation reagents include p-methoxybenzyl chloride and p-methoxybenzyl bromide. Examples of bases include inorganic bases such as potassium carbonate, silver carbonate, cesium carbonate, and sodium hydride, with potassium carbonate and silver carbonate being preferred. Examples of solvents used in this step include aprotic solvents such as DMF, DMA, NMP, THF, DCM, and DCE, with DMF, DMA, or DCE being preferred.
[0163] Step 3-3-3: Protection by 2-(trimethylsilyl)ethoxymethylation In this step, 3-aminopyridone compound 1n1 or 1n2 is reacted with a 2-(trimethylsilyl)ethoxymethylating reagent in the presence of a base to perform 2-(trimethylsilyl)ethoxymethylation. 1 is a 2-(trimethylsilyl)ethoxymethyl group, and P 3is H. Examples of 2-(trimethylsilyl)ethoxymethylating reagents include 2-(trimethylsilyl)ethoxymethyl chloride. Examples of bases include inorganic bases such as potassium carbonate, silver carbonate, cesium carbonate, and sodium hydride, with potassium carbonate or cesium carbonate being preferred. Examples of solvents used in this step include aprotic solvents such as DMF, DMA, NMP, THF, DCM, and 1,2-dichloroethane, with DMF and DMA being preferred.
[0164] Step 3-4 This step is a step of alkylating the protected 3-aminopyridone 3c. In the presence of a photoredox catalyst, the protected 3-aminopyridone 3c is alkylated with an alcohol (R x6 —OH) or haloalkyl (R x6 -X, where X is a halogen), and alkylation can be performed. JACS. 2016, vol. 138, no. 26, pp. 8084-8087. (Non-Patent Document 17), ACS Med. Chem. Lett. 2020, 11, 597-604. (Non-Patent Document 18) and Nature 2021, vol. 598, pp. 451-456. (Non-Patent Document 19) It can be carried out with reference to the methods described therein.
[0165] Step 3-5: When the 3-aminopyridone 3d has a Boc group or a 2-tetrahydropyranyl group, this step is for deprotecting the Boc group or the 2-tetrahydropyranyl group. This step can be performed under the same conditions as in Step 1-15.
[0166] Step 3-6 This step is a hydroxylation step of the protected 3-aminopyridone 3c, which can be carried out under the same conditions as in the hydroxylation of Method 5 in Step 3-1.
[0167] Step 3-7: This step is an alkylation step of hydroxyl compound 3e. This step can be carried out according to the following Method-1 or Method-2. Method-1 (nucleophilic substitution reaction): alkylation of hydroxyl compound 3f (wherein R x6a O is R x6The alkylated compound 3f (wherein R x6a O is R x6 (representing the formula:) can be prepared by reacting hydroxyl compound 3e with the corresponding alcohol in the presence of a Mitsunobu reagent. Examples of Mitsunobu reagents include a combination of triphenylphosphine and DIAD, CMMP, and CMBP. Examples of solvents used in this step include aprotic solvents such as toluene, DCM, THF, n-hexane, cyclohexane, ethyl acetate, DMA, DMF, NMP, and 1,4-dioxane, with DCM and THF being preferred.
[0168] Step 3-8: When alkylated compound 3f has a 2-(trimethylsilyl)ethoxymethyl group, a p-methoxybenzyl group, or a 2-tetrahydropyranyl group, this step is for deprotecting the 2-(trimethylsilyl)ethoxymethyl group, the p-methoxybenzyl group, or the 2-tetrahydropyranyl group. This step can be performed under the same conditions as in Step 1-15.
[0169] Step 3-9 This step is a p-methoxybenzylation step of 3-aminopyridone compound 1n1 or 1n2. Step 3-9 can be carried out under the same conditions as in Step 3-3-2. 2 represents a p-methoxybenzyl group.
[0170] Step 3-10 This step is a hydroxylation step of the p-methoxybenzyl-protected compound 3g, which can be carried out under the same conditions as in the hydroxylation of Method 5 in Step 3-1.
[0171] Step 3-11 This step is an alkylation step of the hydroxyl compound 3h. It can be carried out under the same conditions as in Step 3-7. (In the formula of compound 3i, R x6a O is R x6(represents
[0172] Step 3-12: When Compound 3i has a p-methoxybenzyl group or a 2-tetrahydropyranyl group, this step is for deprotecting the p-methoxybenzyl group or the 2-tetrahydropyranyl group. This step can be carried out under the same conditions as in Step 1-15.
[0173] (General Production Method 4) General Production Method 4 is a method for producing a compound represented by any one of the general formulae (1) to (3), in which R 4 is an optionally substituted 4- to 10-membered heterocyclyl.
[0174] Step 4-1 This step is a nitration step of 4-hydroxylpyridone compound 4a. 3-Nitropyridone compound 4b can be produced by reacting 4-hydroxylpyridone compound 4a with a nitrating reagent under acidic conditions. Examples of the nitrating reagent include nitric acid and nitrates. Examples of the solvent used in this step include acetic acid, sulfuric acid, and nitric acid.
[0175] Step 4-2 This step is a chlorination step of 3-nitropyridone compound 4b. 4-Chloropyridone compound 4c can be produced by reacting 3-nitropyridone compound 4b with a chlorinating reagent. Examples of the chlorinating reagent include phosphorus oxychloride, thionyl chloride, and oxalyl chloride, and these chlorinating reagents may be used in a solvent amount. DMF may be used as a catalyst in this step.
[0176] Step 4-3: This step involves carrying out an aromatic nucleophilic substitution reaction of the 4-chloropyridone compound 4c. The 3-nitropyridone compound 4d can be produced by reacting the 4-chloropyridone compound 4c with the corresponding amine (e.g., piperidine). Examples of the solvent used in this step include aprotic solvents such as toluene, THF, n-hexane, cyclohexane, ethyl acetate, DMA, DMF, NMP, 1,4-dioxane, and DMSO, with DMF being preferred.
[0177] Step 4-4 This step is a reduction step of 3-nitropyridone compound 4d. 3-Aminopyridone compound 4e can be produced by reacting 3-nitropyridone compound 4d with a reducing reagent. This step can be carried out, for example, by the method described in Org. Process Res. Dev. 2018, vol. 22, no. 4, pp. 430-445. (Non-Patent Document 11). The reduction step involves reducing 3-nitropyridone compound 4d with Pd(OH) 2 / H 2 or a combination of Fe / NH in ethanol 4 The combination of Cl is preferred.
[0178] <Pharmaceutical Composition> The present invention provides a pharmaceutical composition (hereinafter also referred to as the "pharmaceutical composition of the present invention") containing the compound represented by formula (1) of the present invention, or a salt thereof, or a solvate thereof (first component). The pharmaceutical composition of the present invention can be formulated by known methods by incorporating a pharmaceutically acceptable carrier in addition to the compound represented by formula (1) of the present invention, or a salt thereof, or a solvate thereof. For formulation, commonly used excipients, binders, lubricants, colorants, flavorings, and, if necessary, stabilizers, emulsifiers, absorption enhancers, surfactants, pH adjusters, preservatives, antioxidants, etc. can be used, and the composition is formulated by conventional methods by blending ingredients generally used as raw materials for pharmaceutical formulations. For formulation, the active ingredient used in pharmaceuticals can be processed by known methods into an optimal shape or form, i.e., dosage form, suited to the method and purpose of use. Examples of commonly used dosage forms include liquid pharmaceutical preparations (liquid preparations) such as injections, suspensions, emulsions, and eye drops, and solid pharmaceutical preparations (solid preparations) such as tablets, powders, fine granules, granules, coated tablets, capsules, dry syrups, troches, and suppositories, but are not limited to these.
[0179] For example, to prepare a liquid formulation, a pharmacologically acceptable carrier or vehicle, specifically, pharmaceutically acceptable additives commonly used in the field of pharmaceutical formulations, such as sterile water, physiological saline, vegetable oil, emulsifier, suspending agent, surfactant, stabilizer, flavoring agent, excipient, vehicle, preservative, binder, etc., are added in appropriate combination to the compound represented by formula (1) of the present invention or its salt, or a solvate thereof, and then the mixture is mixed to form a unit dose required for generally accepted pharmaceutical practice. Alternatively, a solid formulation prepared for liquid formulation can be dissolved as needed by adding an appropriate solvent, such as sterile water or physiological saline, before administration, and then used for administration.
[0180] Such liquid preparations can also be used parenterally, for example, in the form of a sterile solution or suspension injection in water or other pharmaceutically acceptable liquid. For example, they can be formulated by appropriately combining them with pharmacologically acceptable carriers or vehicles, specifically, sterile water, physiological saline, vegetable oils, emulsifiers, suspending agents, surfactants, stabilizers, flavoring agents, excipients, vehicles, preservatives, binders, etc., and blending them in a unit dosage form required for generally accepted pharmaceutical practice. Specific examples of carriers include light anhydrous silicic acid, lactose, crystalline cellulose, mannitol, starch, carmellose calcium, carmellose sodium, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinyl acetal diethylaminoacetate, polyvinylpyrrolidone, gelatin, medium-chain fatty acid triglycerides, polyoxyethylene hydrogenated castor oil 60, sucrose, carboxymethylcellulose, cornstarch, inorganic salts, etc. The amount of active ingredient in these preparations is such that an appropriate dose within the indicated range can be obtained. Sterile compositions for injection can be formulated according to conventional pharmaceutical practice using a vehicle such as distilled water for injection.
[0181] Examples of aqueous solutions for injection include isotonic solutions containing physiological saline or other adjuvants, such as D-sorbitol, D-mannose, D-mannitol, and sodium chloride, and may be used in combination with an appropriate solubilizing agent, such as alcohol, specifically ethanol, polyalcohols such as propylene glycol and polyethylene glycol, or nonionic surfactants such as Polysorbate 80 (registered trademark) and HCO-50.
[0182] Examples of oily liquids include sesame oil and soybean oil, and they may be used in combination with solubilizing agents such as benzyl benzoate and benzyl alcohol. They may also contain buffers such as phosphate buffer and sodium acetate buffer, soothing agents such as procaine hydrochloride, stabilizers such as benzyl alcohol, phenol, and antioxidants. The prepared injection solution is usually filled into suitable ampoules.
[0183] For example, to produce a solid preparation, an excipient and, if necessary, pharmaceutically acceptable additives commonly used in the field of pharmaceutical preparations such as a binder, a disintegrant, a lubricant, a colorant, a flavoring agent, etc. are added appropriately in combination to the compound represented by formula (1) of the present invention, or a salt thereof, or a solvate thereof, and then the mixture is made into tablets, powders, fine granules, granules, coated tablets, capsules, dry syrup, troches, suppositories, etc. by a conventional method.
[0184] Examples of pharmaceutically acceptable additives used in such solid preparations include animal and vegetable oils such as soybean oil, beef tallow, and synthetic glycerides; hydrocarbons such as liquid paraffin, squalane, and solid paraffin; ester oils such as octyldodecyl myristate and isopropyl myristate; higher alcohols such as cetostearyl alcohol and behenyl alcohol; silicone resins; silicone oils; surfactants such as polyoxyethylene fatty acid esters, sorbitan fatty acid esters, glycerin fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene hydrogenated castor oil, and polyoxyethylene polyoxypropylene block copolymers; water-soluble polymers such as hydroxyethyl cellulose, polyacrylic acid, carboxyvinyl polymers, polyethylene glycol, polyvinylpyrrolidone, and methylcellulose; lower alcohols such as ethanol and isopropanol; polyhydric alcohols such as glycerin, propylene glycol, dipropylene glycol, and sorbitol; sugars such as lactose, lactose hydrate, fructose, and sucrose; inorganic powders such as silicic anhydride, aluminum magnesium silicate, and aluminum silicate; and purified water.
[0185] Examples of excipients include sugars (e.g., lactose, lactose hydrate, fructose, sucrose, etc.), sugar alcohols (e.g., mannitol, etc.), starches (corn starch, potato starch, wheat starch, rice starch, partially pregelatinized starch, pregelatinized starch, etc.), celluloses (e.g., crystalline cellulose), inorganic salts (e.g., calcium silicate, anhydrous calcium hydrogen phosphate, precipitated calcium carbonate, etc.), etc.
[0186] Examples of binders include polyvinyl alcohol, polyvinyl ether, methyl cellulose, ethyl cellulose, gum arabic, tragacanth, gelatin, shellac, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, polypropylene glycol-polyoxyethylene block polymers, and the like.
[0187] Examples of disintegrants include croscarmellose sodium, carmellose sodium, hydroxypropyl cellulose, carmellose, carmellose calcium, methylcellulose, crystalline cellulose, sodium lauryl sulfate, povidone, and polysorbate.
[0188] Examples of lubricants include magnesium stearate, calcium stearate, talc, sucrose fatty acid esters, sodium stearyl fumarate, and hardened oils.
[0189] Coloring agents that are permitted to be added to pharmaceuticals are used, and flavoring agents include cocoa powder, peppermint, aromatic powder, peppermint oil, borneol, cinnamon powder, etc.
[0190] These tablets and granules may be coated with sugar or other suitable coatings as necessary. When producing liquid preparations such as syrups and injection preparations, the compound of the present invention or a pharmacologically acceptable salt thereof is formulated in a conventional manner by adding a pH adjuster, a solubilizer, an isotonicity agent, etc., and, if necessary, a solubilizing agent, a stabilizer, etc.
[0191] <Treatment or prevention of cancer in cancer patients who have been detected as having a positive RB1 gene mutation or reduced expression of the RB1 gene or protein, and in cancer patients who have been detected as having a positive RB1 gene mutation or reduced expression of the RB1 gene or protein> The MYT1 inhibitor can be used alone or in combination with a chemotherapeutic agent for the purpose of treating or preventing cancer in cancer patients who have been detected as having a positive RB1 gene mutation or reduced expression of the RB1 gene or protein, or in cancer patients who have been detected as having a positive RB1 gene mutation or reduced expression of the RB1 gene or protein.
[0192] The term "combination" refers to the use of two or more components in combination. For example, a combination of a MYT1 inhibitor (hereinafter sometimes referred to as the "first component") and a chemotherapeutic agent (hereinafter sometimes referred to as the "second component") includes "administration as a single formulation containing the first component and the second component" (i.e., administration of the first component and the second component as a combined drug) and "administration of the first component and the second component as separate formulations, either simultaneously or separately." In the latter embodiment, the formulation containing the first component may be administered first, or the formulation containing the second component may be administered first. The latter embodiment may be any of "an embodiment in which the first component and the second component are formulated separately and administered simultaneously via the same administration route," "an embodiment in which the first component and the second component are formulated separately and administered separately via the same administration route at different times," "an embodiment in which the first component and the second component are formulated separately and administered simultaneously via different administration routes (administered from different sites on the same patient)," and "an embodiment in which the first component and the second component are formulated separately and administered separately via different administration routes at different times." In the case of "an embodiment in which the first component and the second component are formulated separately and administered simultaneously via the same administration route," the two formulations may be mixed immediately before administration. "Separately" means that one formulation is administered before or after the other formulation.
[0193] In other words, "combined use" can also be said to be a method of use in which one component is present in the patient's body while the other component is present in the patient's body. That is, a preferred embodiment is one in which the first component and the second component are administered so that they are simultaneously present in the patient's body, for example, in the blood, and a preferred embodiment is one in which one formulation is administered to the patient simultaneously, or one formulation is administered to the patient within 48 hours of the other formulation being administered.
[0194] "Cancer treatment" in the present invention means a reduction in the number of cancer cells in an individual, inhibition of cancer cell proliferation, reduction in tumor volume, reduction in tumor weight, inhibition of cancer cell metastasis, or amelioration of various symptoms caused by cancer, or a combination thereof. Furthermore, "cancer prevention" in the present invention means preventing the development of new cancer cells, preventing an increase in the number of cancer cells due to the re-proliferation of reduced cancer cells, preventing the regrowth of cancer cells whose proliferation has been inhibited, preventing a re-increase in the volume or weight of reduced tumors, or a combination thereof.
[0195] [First embodiment related to the treatment or prevention of cancer] One embodiment of the present invention is a pharmaceutical composition comprising an MYT1 inhibitor as an active ingredient, for use in combination with a chemotherapeutic agent to treat or prevent cancer in patients who have been detected as having a positive RB1 gene mutation or reduced expression of the RB1 gene or protein. One embodiment of the present invention is a pharmaceutical composition comprising an MYT1 inhibitor as an active ingredient, for use in combination with a chemotherapeutic agent to treat or prevent cancer in patients who have been detected as having a positive RB1 gene mutation or reduced expression of the RB1 gene or protein.
[0196] RB1 (retinoblastoma gene, also known as Rb or RB) is a gene encoding the RB1 protein, a representative cell cycle regulator, and is involved in the G1 / S checkpoint. The RB1 protein (also known as RB1 or pRb) forms a complex with E2F, a transcription factor responsible for inducing the expression of genes involved in the transition from the G1 phase to the S phase of the cell cycle, thereby suppressing the activity of E2F. When E2F activity is suppressed, the transition from the G1 phase to the S phase is inhibited.
[0197] During the cell cycle, cyclin D is generally synthesized in response to cell proliferation stimuli and binds to CDK4 to form a complex. The complex is phosphorylated (activated) by CAK, phosphorylating the RB protein. When the RB protein is phosphorylated, the transcription factor E2F bound to the RB protein is released, inducing the expression of a group of genes required for S phase progression or DNA replication. Among the induced genes is cyclin E, which forms a complex with CDK2 and further promotes the phosphorylation of RB1, thereby further inactivating the RB1 protein. If there is a mutation in the RB1 gene (particularly a mutation that reduces the function of the RB1 protein) or if the expression level of the RB1 gene or protein is reduced, the cell cycle will progress.
[0198] As used herein, "positive for RB1 gene mutation" means that, when the nucleotide sequence corresponding to the RB1 gene of interest is analyzed, some mutation (e.g., a mutation resulting in the insertion, substitution, deletion, and / or addition of at least one amino acid residue relative to the wild-type RB1 protein) is found in the nucleotide sequence compared to the nucleotide sequence of the wild-type RB1 gene, or, if a mutation in the nucleotide sequence of the RB1 gene is reflected in a base change in a transcription product or an amino acid change in a translation product, the change is detected in the transcription product or translation product. In certain embodiments, a positive RB1 gene mutation is detected in a biological sample (e.g., cancer cells) derived from a cancer patient. As used herein, "detecting a mutation" generally means detecting a mutation in genomic DNA, but also includes detecting the change in the transcription product or translation product (i.e., indirect detection) when the mutation in the genomic DNA is reflected in a base change in a transcription product or an amino acid change in a translation product. A preferred embodiment of the method herein is a method of detecting a mutation by directly determining the nucleotide sequence of the RB1 gene region in a cancer cell. There are no particular limitations on the method for detecting a positive RB1 gene mutation, and for example, confirmation and determination can be performed by NGS (next generation sequencer).
[0199] In the present invention, the term "RB1 gene region" refers to a certain region on genomic DNA that contains the RB1 gene. This region independently includes, in addition to the translated region, untranslated regions such as expression control regions of each gene (e.g., promoter regions and enhancer regions) and the 3'-terminal untranslated region of each gene. In this method, a DNA sample is first prepared from a biological sample. Examples of DNA samples include genomic DNA samples and cDNA samples prepared by reverse transcription from RNA.
[0200] The method for extracting genomic DNA or RNA from a biological sample is not particularly limited, and a known method can be appropriately selected and used. For example, methods for extracting genomic DNA include the SDS phenol method (a method in which tissue stored in a solution containing urea or ethanol is denatured with a protease (proteinase K), a surfactant (SDS), and phenol to denature the proteins in the tissue, and then DNA is precipitated and extracted from the tissue with ethanol), and DNA extraction methods using Clean Columns (registered trademark, manufactured by NexTec), AquaPure (registered trademark, manufactured by Bio-Rad), ZR Plant / Seed DNA Kit (manufactured by Zymo Research), AquaGenomicSolution (registered trademark, manufactured by Mo Bi Tec), prepGEM (registered trademark, manufactured by ZyGEM), and BuccalQuick (registered trademark, manufactured by TrimGen).
[0201] Furthermore, there are no particular limitations on the method for extracting RNA from a biological sample and the method for preparing cDNA from the extracted RNA, and any known method can be appropriately selected and used. Examples include an extraction method using phenol and a chaotropic salt (more specifically, an extraction method using a commercially available kit such as Trizol (Invitrogen) or Isogen (Wako Pure Chemical Industries)), and methods using other commercially available kits (RNAPrep Total RNA Extraction Kit (Beckman Coulter), RNeasy Mini (QIAGEN), RNA Extraction Kit (Pharmacia Biotech), etc.). Furthermore, the reverse transcriptase used to prepare cDNA from the extracted RNA is not particularly limited, and examples thereof include reverse transcriptases derived from retroviruses such as RAV (Rous associated virus) and AMV (Avian myeloblastosis virus), and reverse transcriptases derived from mouse retroviruses such as MMLV (Moloney murine leukemia virus).
[0202] In this embodiment, DNA containing the RB1 gene region is then isolated, and the nucleotide sequence of the isolated DNA is determined. The DNA can be isolated, for example, by PCR using genomic DNA or RNA as a template, using a pair of oligonucleotide primers designed to flank all or part of the RB1 gene region. The nucleotide sequence of the isolated DNA can be determined by methods known to those skilled in the art, such as the Maxam-Gilbert method or the Sanger method, and a next-generation sequencer or the like capable of rapid and comprehensive analysis of gene nucleotide sequences can also be used.
[0203] By comparing the determined DNA or cDNA base sequence with a control (for example, if the biological sample is derived from a cancer patient, with the DNA or cDNA base sequence derived from non-cancerous tissue of the same patient or with a publicly known database), it is possible to determine whether or not there is a mutation in the RB1 gene region in the cancer cells of the biological sample.
[0204] Mutations in the RB1 gene region can be detected by various methods that allow detection of mutations, in addition to direct determination of the base sequence of DNA or cDNA.
[0205] For example, mutation detection in the present invention can also be performed by the following method. First, a DNA or cDNA sample is prepared from a biological sample. Next, an oligonucleotide probe is prepared, which has a base sequence complementary to a base sequence containing the mutation site in the RB1 gene region and is labeled with a reporter fluorescent dye and a quencher fluorescent dye. The oligonucleotide probe is then hybridized to the DNA or cDNA sample, and the base sequence containing the mutation site in the RB1 gene region is amplified using the DNA or cDNA sample hybridized with the oligonucleotide probe as a template. Fluorescence emitted by the reporter fluorescent dye due to degradation of the oligonucleotide probe accompanying the amplification is then detected, and the detected fluorescence is then compared with that of a control. Examples of such methods include the double-dye probe method, also known as the TaqMan® probe method.
[0206] In yet another method, a DNA or cDNA sample is prepared from a biological sample. Next, in a reaction system containing an intercalator that emits fluorescence when inserted between DNA double strands, the DNA or cDNA sample is used as a template to amplify a base sequence containing a mutation site in the RB1 gene region. The temperature of the reaction system is then changed, and fluctuations in the intensity of the fluorescence emitted by the intercalator are detected. The detected fluctuations in the intensity of the fluorescence associated with the temperature change are compared with a control. Examples of such methods include high-resolution melting (HRM) analysis.
[0207] In yet another method, a DNA or cDNA sample is first prepared from a biological sample. Then, DNA containing all or part of the RB1 gene region is amplified. The amplified DNA is then cleaved with a restriction enzyme. The DNA fragments are then separated according to size. The sizes of the detected DNA fragments are then compared with a control. Examples of such methods include a method utilizing restriction fragment length polymorphism (RFLP) and a PCR-RFLP method.
[0208] In yet another method, a DNA or cDNA sample is first prepared from a biological sample. Then, DNA containing all or part of the RB1 gene region is amplified. The amplified DNA is then dissociated into single-stranded DNA. The dissociated single-stranded DNA is then separated on a non-denaturing gel. The mobility of the separated single-stranded DNA on the gel is compared with that of a control. An example of such a method is PCR-SSCP (single-strand conformation polymorphism).
[0209] In yet another method, a DNA or cDNA sample is first prepared from a biological sample. DNA containing all or part of the RB1 gene region is then amplified. The amplified DNA is then separated on a gel containing increasing concentrations of DNA denaturing agent. The mobility of the separated DNA on the gel is then compared with that of a control. Such a method includes, for example, denaturant gradient gel electrophoresis (DGGE).
[0210] Yet another method uses DNA containing a mutation site in the RB1 gene region prepared from a biological sample and a substrate on which an oligonucleotide probe that hybridizes to the DNA is immobilized, such as a DNA array method.
[0211] In yet another method, a DNA or cDNA sample is first prepared from a biological sample. An "oligonucleotide primer having a base 3' of all or part of the bases in the RB1 gene region and a base sequence complementary to the base sequence 3' of that base" is also prepared. Next, a ddNTP primer extension reaction is carried out using the DNA as a template and the primer. The primer extension reaction product is then subjected to a mass spectrometer to measure the mass. The genotype is then determined from the results of the mass measurement. The determined genotype is then compared with a control. Examples of such methods include MALDI-TOF / MS.
[0212] In yet another method, a DNA or cDNA sample is first prepared from a biological sample. Next, an oligonucleotide probe is prepared consisting of 5'-"all or a portion of the RB1 gene region and a base sequence complementary to the 5'-side base sequence"-"all or a portion of the RB1 gene region, one base 3'-side base, and a base sequence that does not hybridize to the 3'-side base sequence"-3' (flap). Also, an "oligonucleotide probe having a base sequence complementary to all or a portion of the RB1 gene region and a base sequence complementary to the 3'-side base sequence" is prepared. Next, the two types of oligonucleotide probes are hybridized to the prepared DNA or cDNA sample. The hybridized DNA is then cleaved with a single-stranded DNA cleavage enzyme to release the flap. The single-stranded DNA cleavage enzyme is not particularly limited, and examples include cleavase. In this method, an oligonucleotide probe having a sequence complementary to the flap and labeled with a reporter fluorescent compound and a quencher fluorescent compound is then hybridized to the flap. The intensity of the emitted fluorescence is then measured. The measured fluorescence intensity is then compared with a control. Such a method includes, for example, the Invader method.
[0213] In yet another method, a DNA or cDNA sample is first prepared from a biological sample. Next, DNA containing all or part of the RB1 gene region is amplified. The amplified DNA is then dissociated into single strands, and only one strand of the dissociated single-stranded DNA is separated. Next, an extension reaction is carried out base by base, starting from the vicinity of all or part of the base in the RB1 gene region. The pyrophosphate produced during this reaction is enzymatically induced to emit light, and the intensity of the emitted light is measured. The measured fluorescence intensity is then compared with that of a control. Examples of such methods include pyrosequencing.
[0214] In yet another method, a DNA or cDNA sample is first prepared from a biological sample. Then, DNA containing all or part of the RB1 gene region is amplified. Next, an "oligonucleotide primer having a base one base 3' of all or part of the RB1 gene region and a base sequence complementary to the base sequence 3' of that base" is prepared. Next, a single-base extension reaction is carried out using the prepared primer and the amplified DNA as a template in the presence of fluorescently labeled nucleotides. The degree of polarization of the fluorescence is then measured. The measured degree of polarization of the fluorescence is then compared with a control. Examples of such methods include the AcycloPrime method.
[0215] In yet another method, a DNA or cDNA sample is first prepared from a biological sample. Then, DNA containing all or part of the RB1 gene region is amplified. Next, an "oligonucleotide primer having a base one base 3' of all or part of the RB1 gene region and a base sequence complementary to the base sequence 3' of that base" is prepared. Next, a single-base extension reaction is carried out using the prepared primer and the amplified DNA as a template in the presence of a fluorescently labeled nucleotide. Next, the base type used in the single-base extension reaction is determined. The determined base type is then compared with a control. An example of such a method is the SNuPE method.
[0216] If the mutation involves an amino acid change in the RB1 protein, the sample prepared from the biological sample may be a protein. In such cases, the mutation can be detected by a method using a molecule (e.g., an antibody) that specifically binds to the site where the amino acid change occurs due to the mutation, peptide mass fingerprinting (PMF), protein sequencer (Edman degradation), or the like.
[0217] As used herein, "decreased expression of the RB1 gene or protein" means that, when the RB1 gene or protein of a subject is analyzed, the expression level of the RB1 gene or protein is lower than that of a control (e.g., expression level in a healthy subject or in non-cancerous tissue of the same patient). In a specific embodiment, the decreased expression level of the RB1 gene or protein is detected in a biological sample (e.g., cancer cells) derived from a cancer patient.
[0218] The method for detecting decreased expression of the RB1 gene is not particularly limited, and examples include a method in which the expression level of RB1 is detected at the transcription level or translation level and compared with the control. In a method for detecting the expression level of the RB1 gene at the transcription level, RNA or cDNA is first prepared from a biological sample. The method for extracting RNA from a biological sample and the method for preparing cDNA from the extracted RNA are not particularly limited, and known methods can be appropriately selected and used. Examples include extraction methods using phenol and chaotropic salts (more specifically, extraction methods using commercially available kits such as Trizol (Invitrogen) and Isogen (Wako Pure Chemical Industries)), and methods using other commercially available kits (RNAPrep Total RNA Extraction Kit (Beckman Coulter), RNeasy Mini (QIAGEN), RNA Extraction Kit (Pharmacia Biotech), etc.). Furthermore, the reverse transcriptase used to prepare cDNA from the extracted RNA is not particularly limited, and examples thereof include reverse transcriptases derived from retroviruses such as RAV (Rous associated virus) and AMV (Avian myeloblastosis virus), and reverse transcriptases derived from mouse retroviruses such as MMLV (Moloney murine leukemia virus).
[0219] The oligonucleotide primers or oligonucleotide probes are then used in an amplification reaction or hybridization reaction, respectively, to detect the amplified product or hybrid product. Examples of such methods include RT-PCR, Northern blotting, dot blotting, DNA arrays, in situ hybridization, RNase protection assays, and mRNA-seq. Those skilled in the art can routinely design oligonucleotide primers or oligonucleotide probes suitable for each method based on the nucleotide sequence of RB1 cDNA.
[0220] It is known in the art that promoter hypermethylation is one of the factors that contribute to decreased gene expression. Therefore, in detecting whether or not RB1 function is inhibited, it is conceivable to use methylation of the RB1 gene promoter as an indicator. Promoter methylation can be detected by known methods, such as a method in which a change in the base sequence after bisulfite treatment, which has the activity of converting methylated cytosine to uracil, is directly detected by base sequencing, or a method in which a restriction endonuclease that can recognize (cleave) the base sequence before bisulfite treatment but cannot recognize (cleave) the base sequence after bisulfite treatment.
[0221] The method for detecting decreased expression of RB1 protein is not particularly limited, and can be confirmed and determined, for example, by IHC (immunohistochemical staining) using an antibody specific to RB1 protein. In antibody-based protein detection methods, a protein sample is first prepared from a biological sample. Then, RB1 protein is detected by an antigen-antibody reaction using an antibody specific to RB1 protein. When the antibody specific to RB1 protein is labeled, RB1 protein can be detected directly. However, when the antibody is unlabeled, RB1 protein can be detected indirectly by further reacting it with a labeled molecule that recognizes the antibody (e.g., a secondary antibody or protein A), utilizing the label of the molecule. Examples of such methods include immunohistochemistry (immunostaining), Western blotting, ELISA, flow cytometry, imaging cytometry, radioimmunoassay, immunoprecipitation, and analysis using an antibody array. This method also has the advantage of simultaneously obtaining additional information, such as the morphology and distribution of cancer cells in tissue, through immunohistochemistry.
[0222] There are no particular limitations on the type or origin of the antibody used, but a monoclonal antibody is preferred. As long as it can detect the RB1 protein with sufficient specificity, an oligoclonal antibody (a mixture of several to several dozen types of antibodies) or a polyclonal antibody can also be used. Fab, Fab', F(ab')2 , Fv, scFv, sc(Fv) 2 Functional fragments of antibodies and multimers thereof (for example, dimers, trimers, tetramers, polymers) such as dsFv, diabodies, etc. can also be used. The anti-RB1 protein antibody may be a commercially available product.
[0223] RB1 protein can also be detected using mass spectrometry (MS). Analysis using a mass spectrometer coupled to liquid chromatography (LC / MS) is particularly advantageous due to its sensitivity. Detection by mass spectrometry can be performed, for example, by labeling the protein in the protein sample, fractionating the labeled protein, subjecting the fractionated protein to mass spectrometry, and identifying the RB1 protein from the mass spectrometry values. Isotopic labeling reagents known in the art can be used as the label, and suitable labeling reagents are commercially available. Fractionation can also be performed by methods known in the art, for example, using a commercially available ion exchange column.
[0224] As used herein, amplification of the copy number of the CCNE1 gene can be determined in a diagnostic or prognostic assay by assessing the copy number of the CCNE1 gene using a biological sample derived from a cancer patient (e.g., by next-generation sequencing, digital PCR, array CGH, or FISH).
[0225] As used herein, a "patient" may be a mouse, rat, guinea pig, monkey, dog, sheep, horse, or human. In the present invention, a "cancer patient" may refer not only to a person currently suffering from cancer, but also to a person suspected of suffering from cancer. In a specific embodiment, the subject to be treated or prevented is a cancer patient in whom an increase in the CCNE1 gene expression has not been detected compared to a control. Furthermore, in a specific embodiment, the subject to be treated or prevented is not a mouse transplanted with OVCAR3. The pharmaceutical composition can be suitably used in humans.
[0226] As used herein, the term "biological sample derived from a cancer patient" is not particularly limited as long as it is a biological sample capable of detecting the presence or absence of an RB1 gene mutation or reduced expression of the RB1 gene or protein, but is preferably a sample such as a cancer biopsy specimen, blood, urine, body cavity fluid, or tumor cell-derived circulating tumor DNA (ctDNA). Protein extracts or nucleic acid extracts (e.g., mRNA extracts, cDNA preparations or cRNA preparations prepared from mRNA extracts) obtained from the specimens may also be used. As used herein, "biological sample" includes samples derived from cancer patients and samples derived from cancer cell cultures.
[0227] The RB1 gene mutation may include a mutation that results in the insertion, deletion, or addition of at least one amino acid residue relative to the wild-type RB1 protein, or a mutation that results in the substitution of an existing amino acid residue. The RB1 gene mutation may also be a nonsense mutation, a frameshift mutation, a splice site mutation, a heterozygous deletion, or a homozygous deletion. Preferably, the RB1 gene mutation is a mutation that reduces the function of RB1. "Mutations that reduce the function of RB1" can be confirmed, for example, via the Internet at: https: / / www.oncokb.org / gene / RB1 [searched February 20, 2023].
[0228] A typical DNA (cDNA) nucleotide sequence of a human wild-type RB1 gene is shown in SEQ ID NO: 1 (NCBI Reference No.: NM_000321.3), and a typical amino acid sequence of a human wild-type RB1 protein is shown in SEQ ID NO: 2 (NCBI Reference No.: NP_000312.2). In the case of a human RB1 gene, an RB1 gene mutation refers to a nucleotide sequence that is different from the genomic sequence of human RB1 described at positions 48,303,751 to 48,481,890 in NCBI Reference No. NC_13.11, a nucleotide sequence that is different from the nucleotide sequence of human RB1 described at positions 4921 to 5161 in NCBI Reference No. NG_9009.1, or a mutation that results in an amino acid sequence that is different from the amino acid sequence of the human RB1 protein described as SEQ ID NO: 2, and may be a mutation that results in at least one of the following (1) to (5): Even in RB1 without mutation, individual differences in the sequence may occur due to polymorphism, etc. (1) The codon corresponding to the serine residue (S) at position 82 in the amino acid sequence of SEQ ID NO: 2 is replaced with a stop codon, (2) The codon corresponding to the arginine residue (R) at position 467 in the amino acid sequence of SEQ ID NO: 2 is replaced with a stop codon, (3) At least one base is inserted or deleted in the codon corresponding to the amino acid residue at position 182 in the amino acid sequence of SEQ ID NO: 2, forming a new reading frame starting with an isoleucine residue (I), and the third reading frame therefrom is a stop codon, (4) The glutamic acid residue (E) at position 837 in the amino acid sequence of SEQ ID NO: 2 is replaced with a lysine residue (K), and a portion of the RB1 gene is homozygously deleted, or (5) The glycine residue (G) at position 449 in the amino acid sequence of SEQ ID NO: 2 is replaced with a glutamic acid residue (E), and a portion of the RB1 gene is homozygously deleted.
[0229] As used herein, decreased expression of the RB1 gene or protein includes decreased gene expression due to methylation of the RB1 gene or via microRNA.
[0230] The pharmaceutical composition of the present invention can be used to treat or prevent cancer, and is particularly suitable for treating or preventing cancer in cancer patients who have been detected as positive for RB1 gene mutation or in whom reduced expression of the RB1 gene or protein has been detected, or in cancer patients who have been detected as positive for RB1 gene mutation or in whom reduced expression of the RB1 gene or protein has occurred. The pharmaceutical composition of the present invention can be used alone or in combination with a chemotherapeutic agent.
[0231] In a particular embodiment, the cancer is lung cancer. The pharmaceutical composition of the present invention is more suitable for the treatment or prevention of cancer, particularly for the treatment or prevention of lung cancer.
[0232] In one embodiment, the compounds represented by formulas (1) to (3) of the present invention, or salts thereof, or solvates thereof can be used as MYT1 inhibitors.
[0233] A pharmaceutical composition comprising, as an active ingredient, a compound represented by any one of Formulas (1) to (3) of the present invention, or a salt thereof, or a solvate thereof (first ingredient) (hereinafter also referred to as "pharmaceutical composition of the present invention") may be used in combination with a chemotherapeutic agent (second ingredient). In one embodiment, the pharmaceutical composition of the present invention is administered simultaneously with or separately from the chemotherapeutic agent. In another embodiment, the pharmaceutical composition of the present invention is administered as a combination drug with the chemotherapeutic agent.
[0234] A chemotherapeutic agent is a substance that has anti-cancer activity (also called anti-tumor activity). A chemotherapeutic agent can be, for example, an antimetabolite.
[0235] An antimetabolite is a substance that has a chemical structure similar to that of a metabolite (e.g., folic acid) and antagonizes or inhibits the metabolic mechanism of an organism. Examples of an antimetabolite include antifolates.
[0236] Antifolates are substances that inhibit DNA biosynthesis by suppressing or inhibiting the activity of enzymes that reduce folic acid to active folic acid, which is essential for nucleic acid synthesis. Examples of antifolates include methotrexate and pemetrexed. A more preferred antifolate is pemetrexed.
[0237] In this embodiment, a preferred combination of a MYT1 inhibitor and a chemotherapeutic agent is one in which the MYT1 inhibitor is a compound represented by any of formulas (1) to (3) of the present invention, a salt thereof, or a solvate thereof, and the chemotherapeutic agent is pemetrexed.
[0238] The dosage of the compounds represented by formulas (1) to (3) of the present invention, or salts thereof, or solvates thereof, is preferably 0.001 to 50 mg per kg of body weight of the subject per day (0.001 to 50 mg / kg / day), more preferably 0.001 to 20 mg / kg / day, and even more preferably 0.002 to 10 mg / kg / day. When the dosage of the compounds represented by formulas (1) to (3) of the present invention, or salts thereof, or solvates thereof, falls within these ranges, the therapeutic or preventive effect on cancer is further enhanced. The frequency of administration of the compounds represented by formulas (1) to (3) of the present invention, or salts thereof, or solvates thereof, can be, for example, once or more per week, twice per week, once per day, or twice per day.
[0239] The dosage of the chemotherapeutic agent is preferably 0.005 to 300 mg per kg of body weight of the subject per day (0.005 to 300 mg / kg / day), more preferably 0.01 to 250 mg / kg / day, and even more preferably 0.02 to 200 mg / kg / day. When the dosage of the chemotherapeutic agent is within these ranges, the cancer treatment or prevention effect is further enhanced. The frequency of administration of the chemotherapeutic agent can be, for example, once or more per week, twice per week, once per day, or twice per day.
[0240] The dosage of the compound represented by formulas (1) to (3) of the present invention or a salt thereof, or a solvate thereof (first component) and the chemotherapeutic agent (second component) is, per kg of body weight of the subject to be administered, preferably 0.0001 to 50 mg / kg / day for the first component and 0.005 to 300 mg / kg / day for the second component, more preferably 0.001 to 20 mg / kg / day for the first component and 0.01 to 250 mg / kg / day for the second component, and even more preferably 0.002 to 10 mg / kg / day for the first component and 0.02 to 200 mg / kg / day for the second component. When the dosages of the first component and the second component are within these ranges, the therapeutic or preventive effect on cancer is further enhanced.
[0241] In the present invention, administration methods include oral, rectal, parenteral (intravenous, intramuscular, subcutaneous, transdermal), intracisternal, intravaginal, intraperitoneal, intravesical, or topical (injection, infusion, powder, ointment, gel, or cream) administration, and inhalation (buccal or nasal spray). Dosage forms include, for example, tablets, capsules, granules, powders, pills, aqueous and non-aqueous oral solutions and suspensions, and parenteral solutions packaged in containers adapted for individual dosages. Dosage forms can also be adapted for various administration methods, including controlled-release formulations such as subcutaneous implants.
[0242] The first component can be administered by, for example, any of the administration methods described above, and the second component can be administered by, for example, the same or different administration method as the administration method of the first component. The interval between administrations of the first and second components can be, for example, 0 to 14 days, 0 to 10 days, or 0 to 7 days. The administration interval can be determined using, for example, AUC, Cmax, Tmax, elimination half-life, or the subject's health status as indicators. For example, the first component can be administered orally (tablets, capsules, etc.), and the second component can be administered by infusion. For example, both the first component and the second component can be administered orally (tablets, capsules, etc.). For example, the first component can be administered by infusion, and the second component can be administered orally (tablets, capsules, etc.). For example, both the first component and the second component can be administered by infusion. In such cases, the first component and the second component can be administered at any interval, such as three times a day, twice a day, once a day, once a week, or once every two weeks. More specifically, both the first component and the second component may be administered once a day, and in this case, they may be administered before, between, or after meals. Before, between, or after meals may refer to breakfast, lunch, dinner, a late-night snack, or a snack. If the administration interval between the first component and the second component is within 24 hours, both components can be administered once a day. If necessary, the first component and the second component may be administered twice a day and once a day, once a day and once a day, once a day and twice a day, once a day and once every two days, once a day and once every three days, once a day and once every seven days, three times a day and once every seven days, or twice a day and once every seven days. If necessary, the administration interval of the second component alone and / or the administration interval of the first component alone can be increased or decreased. The administration of the second component may be initiated on the same day as the administration of the first component, or the administration of the first component and the administration of the second component may be initiated on different days. The administration period is 7 days per course, and the total number of courses may be one or more courses, or may be two or more courses. Furthermore, each course may be administered consecutively, or a drug holiday may be provided. A drug holiday may also be provided midway between courses.If necessary, during the course of treatment, only the first component can be continuously administered and the second component can be discontinued, or only the first component can be discontinued and the second component can be continuously administered. The first and second components can also be contained in the same tablet, capsule, etc.
[0243] The pharmaceutical composition according to this embodiment can be administered in combination with, for example, a pharmaceutical composition containing a MYT1 inhibitor described below as "Second embodiment for the treatment or prevention of cancer" (combined administration).
[0244] One aspect of this embodiment is a MYT1 inhibitor for use in combination with a chemotherapeutic agent in the treatment or prevention of cancer in a patient who has been detected as positive for an RB1 gene mutation or in whom reduced expression of the RB1 gene or protein has been detected. One aspect of this embodiment is a MYT1 inhibitor for use in combination with a chemotherapeutic agent in the treatment or prevention of cancer in a patient who has been detected as positive for an RB1 gene mutation or in whom reduced expression of the RB1 gene or protein has occurred.
[0245] Another aspect of this embodiment is the use of a MYT1 inhibitor for the manufacture of a medicament to be administered in combination with a chemotherapeutic agent for the treatment or prevention of cancer in a patient in whom RB1 gene mutation or reduced expression of the RB1 gene or protein has been detected. Another aspect of this embodiment is the use of a MYT1 inhibitor for the manufacture of a medicament to be administered in combination with a chemotherapeutic agent for the treatment or prevention of cancer in a patient in whom RB1 gene mutation or reduced expression of the RB1 gene or protein has occurred.
[0246] [Second embodiment relating to the treatment or prevention of cancer] A second embodiment relating to the treatment or prevention of cancer of the present invention is a pharmaceutical composition comprising a chemotherapeutic agent as an active ingredient, in combination with a MYT1 inhibitor, for treating or preventing cancer in patients who have been detected to be positive for an RB1 gene mutation or to have decreased expression of the RB1 gene or protein.
[0247] For each term in this specification (e.g., MYT1 inhibitor, chemotherapeutic agent, RB1 gene mutation, administration method, type of cancer, etc.), reference can be made to the definition in "First embodiment of cancer treatment or prevention." Herein, cancer in a patient in which RB1 gene mutation or reduced expression of RB1 gene or protein has been detected may be cancer in a patient in which RB1 gene mutation is positive or reduced expression of RB1 gene or protein has occurred. The pharmaceutical composition according to this embodiment can be administered in combination with, for example, a pharmaceutical composition containing a MYT1 inhibitor described in "First embodiment of cancer treatment or prevention" (combined administration).
[0248] In certain embodiments, the pharmaceutical composition comprises a chemotherapeutic agent (second component) as an active ingredient. The pharmaceutical composition comprising a chemotherapeutic agent as an active ingredient is used in combination with a MYT1 inhibitor (first component). In some embodiments, the pharmaceutical composition comprising a chemotherapeutic agent is administered simultaneously with or separately from the MYT1 inhibitor. In another embodiment, the pharmaceutical composition comprising a chemotherapeutic agent is administered as a combination drug with the MYT1 inhibitor.
[0249] In this embodiment, a preferred combination of a MYT1 inhibitor and a chemotherapeutic agent is one in which the MYT1 inhibitor is a compound represented by any of formulas (1) to (3) of the present invention, a salt thereof, or a solvate thereof, and the chemotherapeutic agent is pemetrexed.
[0250] The dosages of the MYT1 inhibitor (first component) and the chemotherapeutic agent (second component) are preferably 0.0001 to 50 mg / kg / day of the first component and 0.005 to 300 mg / kg / day of the second component per kg of body weight of the subject, more preferably 0.001 to 20 mg / kg / day of the first component and 0.01 to 250 mg / kg / day of the second component, and even more preferably 0.002 to 10 mg / kg / day of the first component and 0.02 to 200 mg / kg / day of the second component. When the dosages of the first component and the second component are within these ranges, the therapeutic or preventive effect on cancer is further enhanced.
[0251] One aspect of this embodiment is also a chemotherapeutic agent for use in combination with a MYT1 inhibitor in the treatment or prevention of cancer in patients who have been detected as positive for RB1 gene mutation or in whom reduced expression of the RB1 gene or protein has been detected.
[0252] Another aspect of this embodiment is the use of a chemotherapeutic agent for the manufacture of a medicament for the treatment or prevention of cancer in a patient detected to be positive for an RB1 gene mutation or in which reduced expression of the RB1 gene or protein has been detected, in combination with a MYT1 inhibitor.
[0253] [Third Embodiment Relating to Cancer Treatment or Prevention] A third embodiment of the present invention relating to cancer treatment or prevention is a method for treating or preventing cancer in a patient in whom a positive RB1 gene mutation or reduced expression of the RB1 gene or protein has been detected, the method comprising administering a combination of a chemotherapeutic agent and a MYT1 inhibitor to the cancer patient. One aspect of this embodiment is a method for treating or preventing cancer, the method comprising detecting, or having a third party detect, a positive RB1 gene mutation or reduced expression of the RB1 gene or protein in a biological sample derived from the cancer patient, and administering a combination of a chemotherapeutic agent and a MYT1 inhibitor to the cancer patient.
[0254] The dosages of the MYT1 inhibitor (first component) and the chemotherapeutic agent (second component) are preferably 0.0001 to 50 mg / kg / day of the first component and 0.005 to 300 mg / kg / day of the second component per kg of body weight of the subject, more preferably 0.001 to 20 mg / kg / day of the first component and 0.01 to 250 mg / kg / day of the second component, and even more preferably 0.002 to 10 mg / kg / day of the first component and 0.02 to 200 mg / kg / day of the second component. When the dosages of the first component and the second component are within these ranges, the therapeutic or preventive effect on cancer is further enhanced.
[0255] When administering a chemotherapeutic agent and a MYT1 inhibitor in combination, both the MYT1 inhibitor and the chemotherapeutic agent may be administered simultaneously, or may be administered separately at a fixed interval. The administration routes of the MYT1 inhibitor and the chemotherapeutic agent may be the same or different. They may also be administered in the form of a combination drug containing the MYT1 inhibitor and the chemotherapeutic agent. That is, the pharmaceutical composition may contain both the MYT1 inhibitor and the chemotherapeutic agent.
[0256] [Fourth Embodiment Relating to Cancer Treatment or Prevention] A fourth embodiment of the present invention relating to cancer treatment or prevention is a method for suppressing cancer cell proliferation in a subject in which a positive RB1 gene mutation or reduced expression of the RB1 gene or protein has been detected, the method comprising contacting the cancer cells with a MYT1 inhibitor and a chemotherapeutic agent. One aspect of this embodiment is a method for suppressing cancer cell proliferation, the method comprising detecting, or having a third party detect, a positive RB1 gene mutation or reduced expression of the RB1 gene or protein in a biological sample from the cancer patient, and contacting the cancer cells with a MYT1 inhibitor and a chemotherapeutic agent.
[0257] The method according to this embodiment encompasses in vivo, in vitro, and ex vivo methods. For example, a subject in which a positive RB1 gene mutation or a decreased expression of the RB1 gene or protein has been detected may be any animal in which a positive RB1 gene mutation or a decreased expression of the RB1 gene or protein has been detected, and the animal species may be a mouse, rat, guinea pig, monkey, dog, sheep, horse, or human. In the in vivo method, cancer cell proliferation can be suppressed by administering a MYT1 inhibitor and a chemotherapeutic agent to the subject. In the in vitro method, cancer cell proliferation can be suppressed by adding a MYT1 inhibitor and a chemotherapeutic agent to a system containing cancer cells collected from the subject. In the ex vivo method, cancer cell proliferation can be suppressed by collecting an organ containing cancer cells from the subject (e.g., the lung in the case of lung cancer) and administering a MYT1 inhibitor and a chemotherapeutic agent to the organ. The dosage of the first component (MYT1 inhibitor) and the second component (chemotherapeutic agent) can be appropriately determined depending on the amount of cancer cells and the types of MYT1 inhibitor and chemotherapeutic agent used.
[0258] [Fifth Embodiment Relating to Cancer Treatment or Prevention] A fifth embodiment of the present invention relating to cancer treatment or prevention is a method for improving responsiveness to cancer treatment with a chemotherapeutic agent, the method comprising administering a MYT1 inhibitor to the cancer patient together with the chemotherapeutic agent, wherein the cancer is cancer in a patient in which a positive RB1 gene mutation or a reduced expression of the RB1 gene or protein has been detected. One aspect of this embodiment is a method for improving responsiveness to cancer treatment with a chemotherapeutic agent, the method comprising detecting, or having a third party detect, a positive RB1 gene mutation or a reduced expression of the RB1 gene or protein in a biological sample derived from the cancer patient, and administering a MYT1 inhibitor to the cancer patient together with the chemotherapeutic agent.
[0259] The method according to this embodiment includes administering a chemotherapeutic agent to a patient in whom a positive RB1 gene mutation or reduced expression of the RB1 gene or protein has been detected in combination with a MYT1 inhibitor, thereby improving the efficacy of cancer treatment with the chemotherapeutic agent.
[0260] When administering a MYT1 inhibitor together with a chemotherapeutic agent to a cancer patient, both the MYT1 inhibitor and the chemotherapeutic agent may be administered simultaneously, or may be administered separately at a fixed interval. The administration routes of the MYT1 inhibitor and the chemotherapeutic agent may be the same or different. The MYT1 inhibitor and the chemotherapeutic agent may also be administered in the form of a combination drug containing the MYT1 inhibitor and the chemotherapeutic agent. Even for patients for whom existing chemotherapeutic agents are insufficiently effective, sufficient therapeutic efficacy can be achieved by combining the MYT1 inhibitor with the MYT1 inhibitor.
[0261] The dosages of the MYT1 inhibitor (first component) and the chemotherapeutic agent (second component) are preferably 0.0001 to 50 mg / kg / day of the first component and 0.005 to 300 mg / kg / day of the second component per kg of body weight of the subject, more preferably 0.001 to 20 mg / kg / day of the first component and 0.01 to 250 mg / kg / day of the second component, and even more preferably 0.002 to 10 mg / kg / day of the first component and 0.02 to 200 mg / kg / day of the second component. When the dosages of the first component and the second component are within these ranges, the therapeutic or preventive effect on cancer is further enhanced.
[0262] [Sixth embodiment relating to cancer treatment or prevention] A sixth embodiment relating to cancer treatment or prevention of the present invention is a method for predicting responsiveness to cancer treatment with a combination of a MYT1 inhibitor and a chemotherapeutic agent, the method comprising: detecting, or having a third party detect, the presence or absence of an RB1 gene mutation or the presence or absence of reduced expression of the RB1 gene or protein in cancer cells derived from a cancer patient; and determining that the cancer patient will be responsive to cancer treatment with a combination of the MYT1 inhibitor and a chemotherapeutic agent if the RB1 gene mutation is positive or if the expression of the RB1 gene or protein is reduced.
[0263] In the method according to this embodiment, the presence or absence of an RB1 gene mutation or the presence or absence of reduced expression of the RB1 gene or protein is detected in cancer cells collected from a cancer patient to be treated, or a third party is made to detect this, and if the RB1 gene mutation is positive or the expression of the RB1 gene or protein is reduced, the cancer patient is determined to be responsive (effective) to treatment involving administration of a combination of a MYT1 inhibitor and a chemotherapeutic agent.
[0264] According to the method of this embodiment, even in a patient for whom the therapeutic efficacy of existing chemotherapeutic agents is insufficient, if the patient is a patient who is RB1 gene mutation-positive or has reduced expression of the RB1 gene or protein, it can be determined that the therapeutic efficacy is achieved by administering the chemotherapeutic agent in combination with a MYT1 inhibitor. This makes it possible to suggest effective chemotherapy in advance to cancer patients who have not achieved sufficient therapeutic effects with existing chemotherapeutic agents alone.
[0265] Detection of RB1 gene mutations or reduced expression of the RB1 gene or protein in cancer cells can be carried out by methods well known to those skilled in the art, such as direct sequencing, PCR, TaqMan genotyping, and next-generation sequencing.
[0266] One aspect of this embodiment is a method for selecting a cancer patient for whom administration of a combination of a MYT1 inhibitor and a chemotherapeutic agent is more effective. This method includes detecting or having a third party detect the presence or absence of an RB1 gene mutation or reduced expression of the RB1 gene or protein in cancer cells derived from a cancer patient, and identifying the cancer patient as a cancer patient for whom administration of a combination of a MYT1 inhibitor and a chemotherapeutic agent is more effective based on the presence of the mutation.
[0267] Another aspect of this embodiment is a method for diagnosing that administration of a combination of a MYT1 inhibitor and a chemotherapeutic agent is more effective for cancer treatment in a specific cancer patient than administration of the chemotherapeutic agent alone. This method includes detecting or having a third party detect the presence or absence of an RB1 gene mutation or reduced expression of the RB1 gene or protein in cancer cells derived from the cancer patient, and identifying the cancer patient as a cancer patient for whom administration of a combination of a MYT1 inhibitor and a chemotherapeutic agent would be more effective based on the presence of the mutation.
[0268] [Seventh embodiment relating to cancer treatment or prevention] A seventh embodiment relating to cancer treatment or prevention of the present invention is a method for screening for compounds effective in treating or preventing cancer in patients in whom a positive RB1 gene mutation or reduced expression of the RB1 gene or protein has been detected, the method comprising measuring the MYT1 inhibitory activity of candidate compounds and selecting candidate compounds having MYT1 inhibitory activity as compounds effective in treating cancer.
[0269] The method according to this embodiment includes measuring the MYT1 inhibitory activity of a candidate compound, and selecting the candidate compound as a compound effective in treating cancer if the candidate compound has MYT1 inhibitory activity.
[0270] In the present invention, a MYT1 inhibitor refers to a substance capable of directly or indirectly neutralizing, blocking, inhibiting, reducing, or interfering with the activity of MYT1. Examples of the activity of the MYT1 protein include threonine kinase activity or tyrosine kinase activity. The inhibition of MYT1 threonine kinase activity or tyrosine kinase activity by a compound can be confirmed, for example, by treating a purified MYT1 protein preparation with a test compound, adding ATP, and measuring the degree of ATP hydrolysis. The degree of ATP hydrolysis can be evaluated using Kinase-Glo (Promega) or ADP-Glo (Promega) (Non-Patent Document 8). When the threonine kinase activity or tyrosine kinase activity of MYT1 is inhibited by the test compound in comparison with a control (e.g., the degree of ATP hydrolysis by MYT1 not treated with the test compound), attenuation of the ATP hydrolysis is confirmed.
[0271] The inhibition of the threonine kinase activity of the MYT1 protein by a compound can be confirmed, for example, by treating a purified MYT1 protein preparation with a test compound, adding CDK1, a substrate of MYT1, and using the degree of phosphorylation of the Thr14 site of CDK1 as an indicator. The degree of phosphorylation of this site can be evaluated by Western blotting using an antibody (manufactured by Abcam) that specifically recognizes phosphorylation of the Thr14 site of CDK1, ELISA using an antibody that specifically recognizes CDK1 and an antibody that specifically recognizes phosphorylation of the Thr14 site of CDK1, or AlphaLISA (manufactured by PerkinElmer) using an antibody that specifically recognizes CDK1 and an antibody that specifically recognizes phosphorylation of the Thr14 site of CDK1. When the threonine kinase activity of MYT1 is inhibited by the test compound in comparison with a control (e.g., the degree of phosphorylation of the Thr14 site of CDK1 by MYT1 not treated with the test compound), attenuation of the phosphorylation is confirmed.
[0272] Furthermore, whether a compound inhibits the threonine kinase activity of MYT1 can be confirmed, for example, by measuring the degree of phosphorylation of the Thr14 site of CDK1, a substrate protein for the threonine kinase activity of MYT1, in a lysate of cells treated with the test compound. The degree of phosphorylation of this site can be evaluated by Western blotting using an antibody (manufactured by Abcam) that specifically recognizes phosphorylation of the Thr14 site of CDK1, ELISA using an antibody that specifically recognizes CDK1 and an antibody that specifically recognizes phosphorylation of the Thr14 site of CDK1, or AlphaLISA (manufactured by PerkinElmer) using an antibody that specifically recognizes CDK1 and an antibody that specifically recognizes phosphorylation of the Thr14 site of CDK1 (Non-Patent Document 8). When the test compound inhibits the threonine kinase activity of MYT1 in comparison with a control (e.g., the degree of phosphorylation of the Thr14 site of CDK1 in a lysate of cells not treated with the test compound), attenuation of the phosphorylation is confirmed.
[0273] Furthermore, inhibition of MYT1 expression by a compound can be confirmed, for example, by detecting decreased MYT1 expression in cells treated with the test compound. A typical method for detecting decreased MYT1 expression is to detect the expression level of MYT1 at the transcriptional or translational level and confirm that the expression level is lower than a control (e.g., the expression level in cells not treated with the test compound).
[0274] In a method for detecting the expression level of MYT1 at the transcription level, RNA or cDNA is first prepared from cells treated with a test compound. The method for extracting RNA from the cells is not particularly limited, and any known method can be appropriately selected and used. Examples include extraction methods using phenol and chaotropic salts (more specifically, extraction methods using commercially available kits such as Trizol (Invitrogen) and Isogen (Wako Pure Chemical Industries)), and methods using other commercially available kits (RNAPrep Total RNA Extraction Kit (Beckman Coulter), RNeasy Mini (QIAGEN), RNA Extraction Kit (Pharmacia Biotech), etc.). Furthermore, the reverse transcriptase used to prepare cDNA from the extracted RNA is not particularly limited, and examples thereof include reverse transcriptases derived from retroviruses such as RAV (Rous associated virus) and AMV (Avian myeloblastosis virus), and reverse transcriptases derived from mouse retroviruses such as MMLV (Moloney murine leukemia virus).
[0275] The oligonucleotide primers or oligonucleotide probes are then used in an amplification reaction or hybridization reaction, respectively, to detect the amplified product or hybrid product. Examples of such methods include RT-PCR, Northern blotting, dot blotting, DNA arrays, in situ hybridization, RNase protection assays, and mRNA-seq. Those skilled in the art can routinely design oligonucleotide primers or oligonucleotide probes suitable for each method based on the nucleotide sequence of the MYT1 cDNA.
[0276] In a method for detecting the expression level of MYT1 at the translational level, a protein sample is first prepared from cells treated with a test compound. An antigen-antibody reaction is then carried out using an antibody specific to the MYT1 protein to detect the MYT1 protein. In such a protein detection method using an antibody, for example, an antibody specific to the MYT1 protein is added to the protein sample to carry out an antigen-antibody reaction, and binding of the antibody to the MYT1 protein is detected. When the antibody specific to the MYT1 protein is labeled, the MYT1 protein can be detected directly. However, when the antibody is unlabeled, the MYT1 protein can be detected indirectly by further reacting it with a labeled molecule that recognizes the antibody (e.g., a secondary antibody or protein A), utilizing the label of the molecule. Examples of such methods include immunohistochemistry (immunostaining), Western blotting, ELISA, flow cytometry, imaging cytometry, radioimmunoassay, immunoprecipitation, and analysis using an antibody array.
[0277] There are no particular limitations on the type or origin of the antibody used, but a monoclonal antibody is preferred. Oligoclonal antibodies (a mixture of several to several dozen types of antibodies) or polyclonal antibodies can also be used, as long as they are capable of detecting the MYT1 protein with sufficient specificity. Functional fragments of antibodies and multimers thereof (e.g., dimers, trimers, tetramers, polymers), such as Fab, Fab', F(ab')2, Fv, scFv, sc(Fv)2, dsFv, and diabodies, can also be used. Such anti-MYT1 protein antibodies may be commercially available.
[0278] MYT1 protein can also be detected using mass spectrometry (MS). Analysis using a mass spectrometer coupled to liquid chromatography (LC / MS) is particularly advantageous due to its sensitivity. Detection by mass spectrometry can be performed, for example, by labeling the protein in the protein sample, fractionating the labeled protein, subjecting the fractionated protein to mass spectrometry, and identifying the MYT1 protein from the mass spectrometry values. Isotopic labeling reagents known in the art can be used as the label, and suitable labeling reagents are commercially available. Fractionation can also be performed by methods known in the art, for example, using a commercially available ion exchange column.
[0279] As used herein, "having MYT1 inhibitory activity" means reducing MYT1 activity in vitro, in a cell culture system, or in an animal, and is, for example, measured as an inhibitory activity of MYT1, IC 50 is preferably 10 μM or less, 5 μM or less, or 1 μM or less. More preferably, the MYT1 inhibitory activity (IC 50 ) is 100 nM or less, 10 nM or less, 3 nM or less, 100 pM or less, or 10 pM or less. 50 Particularly preferred are compounds having a MYT1 inhibitory activity (IC 50 ) is less than 20 nM, or 1 nM to 20 nM. 50 A compound with a smaller RB1 gene mutation rate can be selected as being more effective in treating or preventing cancer in patients who have been detected as having a positive RB1 gene mutation or a decrease in expression of the RB1 gene or protein.
[0280] The compound selected by the method of this embodiment has enhanced therapeutic efficacy when used in combination with a chemotherapeutic agent in the treatment of cancer in patients who have been detected to be positive for RB1 gene mutation or have had reduced expression of the RB1 gene or protein.
[0281] The present disclosure will be described in more detail below based on examples, but the present disclosure is not limited to the following examples.
[0282] NMR analysis was performed using a BRUKER AVANCE III HD400 (400 MHz) NMR data are given in ppm (parts per million) (δ) and referenced to the deuterium lock signal from the sample solvent.
[0283] Mass spectral data were obtained using a Shimadzu single quadrupole mass spectrometer (LCMS-2020) equipped with an ultra-high performance liquid chromatograph (Nexera UC) or a Waters single quadrupole mass spectrometer (SQD or SQD2) equipped with an Acquity ultra-high performance liquid chromatograph (UPLC or UPLC I-Class).
[0284] The analysis by high performance liquid chromatography was carried out under any of the analytical conditions A to W shown in Tables 1 and 2 below. In Tables 1 and 2 below, "TFA" means trifluoroacetic acid, "FA" means formic acid, "AA" means ammonium acetate, and "AC" means ammonium hydrogen carbonate.
[0285]
[0286]
[0287] The microwave reaction was carried out using an Initiator manufactured by Biotage. Snap-cap reaction vials were used for the microwave reaction. The operation of the instrument was carried out according to the manual that came with the instrument.
[0288] The photoredox catalytic reaction was carried out using a Penn PhD M2 Integrated Photoreactor (ACS Cent. Sci. 2017, vol. 3, issue 6, pp. 647-653 (Non-Patent Document 20)). The instrument was operated according to the manual provided with the instrument.
[0289] Commercially available reagents were used without further purification. All non-aqueous reactions were carried out using commercially available anhydrous solvents. Concentration under reduced pressure and solvent removal were carried out using a rotary evaporator.
[0290] As used herein, "room temperature" means a temperature of about 20°C to about 25°C.
[0291] Compound a-14-bromo-7-chloro-2-(oxan-2-yl)indazole 3,4-Dihydro-2H-pyran (32.68 g, 388 mmol) and pyridinium p-toluenesulfonate (9.77 g, 38.9 mmol) were added to a DCM solution (900 mL) of 4-bromo-7-chloro-1H-indazole (44.97 g, 194 mmol) in a reaction vessel, and the mixture was stirred at room temperature for 6 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction mixture, and the mixture was extracted twice with DCM. The organic layer was dried over anhydrous sodium sulfate, and the drying agent was removed by filtration. The mixture was then concentrated under reduced pressure. The resulting residue was suspended in a mixture of hexane / ethyl acetate (3 / 1), and the solid was collected by filtration. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography. The residue was combined with the previously obtained solid to give the title compound (55.17 g, yield 90%) as a yellow solid. LCMS: m / z 315 [M+H] + HPLC retention time: 4.97 minutes (Analysis conditions J)
[0292] Compound a-2 (2,4,6-trichlorophenyl) 7-chloro-2-(oxan-2-yl)indazole-4-carboxylate Triethylamine (15.5 g, 153.18 mmol) was added to a toluene solution (340 mL) of 4-bromo-7-chloro-2-(oxan-2-yl)indazole (compound a-1, 24.16 g, 76.55 mmol) in a reaction vessel, and the reaction vessel was degassed under reduced pressure and purged with nitrogen. Xantphos Pd G4 (3.69 g, 3.83 mmol) was added to the mixture, and the reaction vessel was further degassed under reduced pressure and purged with nitrogen. The reaction mixture was heated to 65°C, and then a toluene solution (54 mL) of 2,4,6-trichlorophenyl formate (19.85 g, 88 mmol) that had been degassed under reduced pressure and purged with nitrogen was added dropwise over 3 hours. The reaction mixture was stirred at 65°C under a nitrogen atmosphere for an additional 20 minutes, then cooled to room temperature, and filtered. The filtrate was concentrated under reduced pressure to give the title compound as a crude product (46.69 g). LCMS: m / z 459 [M+H] + HPLC retention time: 4.86 minutes (Analysis conditions K)
[0293] Compound a-37-chloro-2-(oxan-2-yl)indazole-4-carboxylic acid A 2M aqueous sodium hydroxide solution (230 mL, 460 mmol) was added to a THF suspension (470 mL) of the crude product (46.69 g) of (2,4,6-trichlorophenyl)7-chloro-2-(oxan-2-yl)indazole-4-carboxylate (compound a-2) in a reaction vessel, and the mixture was stirred at 60°C for 16 hours. The reaction mixture was cooled to room temperature, and ethyl acetate, water, and aqueous phosphoric acid solution were added to adjust the pH to 4, followed by extraction twice with ethyl acetate. The organic layer was washed with water (500 mL) and then extracted four times with saturated aqueous sodium bicarbonate solution (400 mL) and 5% aqueous sodium bicarbonate solution (400 mL). The resulting aqueous layers were combined, cooled to 5°C, and aqueous phosphoric acid solution was added to adjust the pH to 4. The mixture was extracted four times with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, the drying agent was removed by filtration, and the organic layer was combined with that of another lot synthesized in the same manner and concentrated under reduced pressure to give the title compound (38.76 g) as a pale yellow solid. LCMS: m / z 281 [M+H] + HPLC retention time: 2.79 minutes (Analysis conditions K)
[0294] Compound a-47-chloro-N-methoxy-N-methyl-2-(oxan-2-yl)indazole-4-carboxamide Triethylamine (55.89 g, 552 mmol), N,O-dimethylhydroxylamine hydrochloride (26.94 g, 276 mmol), and HATU (68.25 g, 180 mmol) were added to a THF solution (388 mL) of 7-chloro-2-(oxan-2-yl)indazole-4-carboxylic acid (compound a-3, 38.76 g, 138 mmol) in a reaction vessel, and the mixture was stirred at room temperature for 15 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium bicarbonate solution, dried over anhydrous sodium sulfate, and the desiccant was removed by filtration. The mixture was then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane / ethyl acetate) to give the title compound (31.74 g, 71% yield) as a colorless solid. LCMS: m / z 324 [M+H] + HPLC retention time: 0.66 minutes (Analysis conditions A)
[0295] Compound a-5 4-bromo-5-fluoro-2-iodoaniline N-iodosuccinimide (19.18 g, 85.248 mmol) was added to a solution of 4-bromo-3-fluoroaniline (15.43 g, 81.2 mmol) in acetic acid (200 mL) in a reaction vessel, and the mixture was stirred at room temperature under a nitrogen atmosphere for 1 hour. The reaction mixture was cooled to 0°C, and the solid was collected by filtration and washed with water. The resulting solid was dissolved in DCM and washed with saturated aqueous sodium carbonate. The organic layer was dried over anhydrous sodium sulfate, and the drying agent was removed by filtration, followed by concentration under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane / ethyl acetate) to give the title compound (22.01 g, yield 86%) as a brown solid. LCMS: m / z 316 [M+H] + HPLC retention time: 4.55 minutes (Analysis conditions J)
[0296] Compound a-6(E)-N'-(4-bromo-5-fluoro-2-iodophenyl)-N,N-dimethylmethaneimidamide 4-Bromo-5-fluoro-2-iodoaniline (compound a-5, 28.58 g, 190.47 mmol) in a reaction vessel was dissolved in EtOH (180 mL), and N,N-dimethylformamide dimethyl acetal (43.12 g, 361.9 mmol) was added, followed by stirring at 80°C for 1.5 hours. The reaction mixture was cooled to room temperature and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane / DCM) to give the title compound (31.7 g, yield 95%) as a pale red solid. LCMS: m / z 371 [M+H] + HPLC retention time: 2.59 minutes (Analysis conditions J)
[0297] Compound a-7(E)-N'-[4-bromo-2-[7-chloro-2-(oxan-2-yl)indazole-4-carbonyl]-5-fluorophenyl]-N,N-dimethylmethaneimidamide A toluene solution (164 mL) of (E)-N'-(4-bromo-5-fluoro-2-iodophenyl)-N,N-dimethylmethaneimidamide (Compound a-6, 16.39 g, 44.18 mmol) in a reaction vessel was cooled to -40 °C, and a 1.3 M solution of isopropylmagnesium chloride lithium chloride complex in THF (34 mL, 44.2 mmol) was added dropwise thereto, followed by stirring for 1 hour. A toluene solution (110 mL) of 7-chloro-N-methoxy-N-methyl-2-(oxan-2-yl)indazole-4-carboxamide (Compound a-4, 11.14 g, 34 mmol) was added dropwise to the reaction mixture over 30 minutes, followed by stirring at 0 °C for 1 hour. A saturated aqueous solution of sodium bicarbonate was added to the reaction mixture, and the mixture was extracted three times with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, the drying agent was removed by filtration, and the mixture was concentrated under reduced pressure to give the title compound as a crude product (22.38 g). LCMS: m / z 507 [M+H] + HPLC retention time: 3.65 minutes (Analysis conditions J)
[0298] Compound a-8 (2-amino-5-bromo-4-fluorophenyl)-[7-chloro-2-(oxan-2-yl)indazol-4-yl]methanone The crude product of (E)-N'-[4-bromo-2-[7-chloro-2-(oxan-2-yl)indazole-4-carbonyl]-5-fluorophenyl]-N,N-dimethylmethanimidamide (Compound a-7, 22.38 g) in a reaction vessel was dissolved in DMSO (220 mL), and 5 M aqueous sodium hydroxide solution (20.4 mL) was added, followed by stirring at room temperature for 30 minutes. Saturated aqueous ammonium chloride solution (300 mL) and water (1 L) were added to the reaction mixture. The solid was collected by filtration and washed with water. The obtained solid was purified three times by silica gel column chromatography to give the title compound (7.41 g, yield 48%) as a yellow solid. LCMS: m / z 452 [M+H] + HPLC retention time: 5.42 minutes (Analysis conditions J)
[0299] Compound a-9: N-[4-bromo-2-[7-chloro-2-(oxan-2-yl)indazole-4-carbonyl]-5-fluorophenyl]-2-chloroacetamide A DMA solution (120 mL) of (2-amino-5-bromo-4-fluorophenyl)-[7-chloro-2-(oxan-2-yl)indazol-4-yl]methanone (compound a-8, 7.41 g, 16.37 mmol) in a reaction vessel was cooled to 0° C., and chloroacetyl chloride (1.96 mL, 24.64 mmol) was added, followed by stirring at room temperature for 1 hour to obtain a DMA solution of the title compound. LCMS: m / z 528 [M+H] + HPLC retention time: 5.57 minutes (Analysis conditions J)
[0300] Compound a-10 6-bromo-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-3-pyridin-1-ium-1-yl-1H-quinolin-2-one; chloride Pyridine (74 mL) was added to a DMA solution of N-[4-bromo-2-[7-chloro-2-(oxan-2-yl)indazole-4-carbonyl]-5-fluorophenyl]-2-chloroacetamide (Compound a-9) in a reaction vessel, and the mixture was stirred at 60° C. for 4 hours. The reaction mixture was cooled to room temperature to give a DMA / pyridine solution of the title compound. LCMS: m / z 553 [M] +HPLC retention time: 3.44 minutes (Analysis conditions J)
[0301] Compound a-11 3-amino-6-bromo-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-1H-quinolin-2-one Hydrazine monohydrate (8.2 g, 163.8 mmol) was added to a DMA / pyridine solution of 6-bromo-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-3-pyridin-1-ium-1-yl-1H-quinolin-2-one; chloride (compound a-10), and the mixture was stirred at 60° C. for 4 hours and then at room temperature for a further 13 hours. Water was added to the reaction mixture, and the resulting solid was collected by filtration and washed with water. The resulting solid was purified by silica gel column chromatography (hexane / ethyl acetate) to give the title compound (7.3 g, yield 91%) as a colorless solid. LCMS: m / z 491 [M+H] + HPLC retention time: 4.65 minutes (Analysis conditions J)
[0302] Compound a-12 3-amino-6-bromo-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-1-[(4-methoxyphenyl)methyl]quinolin-2-one 3-Amino-6-bromo-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-1H-quinolin-2-one (Compound a-11, 7.3 g, 14.84 mmol) and potassium carbonate (5.13 g, 37.12 mmol) in a reaction vessel were suspended in NMP (73 mL), and p-methoxybenzyl chloride (2.83 mL, 20.78 mmol) was added, followed by stirring at 70°C for 2 hours. The reaction mixture was cooled to room temperature, and water was added. The solid was collected by filtration and washed with water and hexane. The resulting solid was purified by silica gel column chromatography to give the title compound (4.79 g, yield 53%) as a pale yellow solid. LCMS: m / z 611 [M+H] + HPLC retention time: 5.76 minutes (Analysis conditions J)
[0303] Compound a-13 3-amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-6-hydroxy-1-[(4-methoxyphenyl)methyl]quinolin-2-one 3-Amino-6-bromo-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-1-[(4-methoxyphenyl)methyl]quinolin-2-one (Compound a-12, 500 mg, 0.817 mmol) and tBuBrettPhos Pd G3 (69.8 mg, 0.0817 mmol) were added to a reaction vessel, and the reaction vessel was degassed under reduced pressure and replaced with argon. DMA (8 mL) and 8 M potassium hydroxide (245.1 μL, 1.961 mmol) were added, and the reaction vessel was degassed under reduced pressure and replaced with argon, followed by stirring at room temperature for 21 hours. Potassium dihydrogen phosphate (445 mg) and water were added, and the resulting solid was collected by filtration. The filtrate was extracted with ethyl acetate, and the organic layer was dried over anhydrous sodium sulfate. The desiccant was removed by filtration, and the mixture was concentrated under reduced pressure. The residue was combined with the solid obtained earlier and purified by silica gel column chromatography to give the title compound (308 mg, yield 68.7%) as a pale brown solid. LCMS: m / z 549 [M+H] + HPLC retention time: 4.49 minutes (Analysis conditions J)
[0304] Compound a-14: 3-amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-1-[(4-methoxyphenyl)methyl]-6-propan-2-yloxyquinolin-2-one 3-amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-6-hydroxy-1-[(4-methoxyphenyl)methyl]quinolin-2-one (Compound a-13, 210 mg, 0.383 mmol) and potassium carbonate (265 mg, 1.917 mmol) in a reaction vessel were suspended in DMF (4.4 mL), and 2-iodopropane (190.2 μL, 1.913 mmol) was added and stirred at room temperature for 18 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated aqueous sodium bicarbonate, then dried over anhydrous sodium sulfate. The desiccant was removed by filtration, and the mixture was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane / ethyl acetate) to give the title compound (201 mg, yield 89%) as a yellow solid. LCMS: m / z 591 [M+H] + HPLC retention time: 5.60 minutes (Analysis conditions J)
[0305] Compound A1 3-amino-4-(7-chloro-1H-indazol-4-yl)-7-fluoro-6-propan-2-yloxy-1H-quinolin-2-one TFA / water (3 / 1, 3 mL) was added to 3-amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-1-[(4-methoxyphenyl)methyl]-6-propan-2-yloxyquinolin-2-one (Compound a-14, 201 mg, 0.34 mmol) in a reaction vessel, and the mixture was stirred at 100°C for 4 hours. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. MeOH was added to the residue, and the mixture was further concentrated. MeOH (4 mL) and 12 M hydrochloric acid (100 μL) were added to the residue, and the mixture was stirred at room temperature for 20 hours. After concentrating the reaction mixture, the resulting residue was dissolved in MeOH, and triethylamine was added. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane / ethyl acetate) to give the title compound (48.3 mg, yield 37%) as a pale yellow solid. LCMS: m / z 387 [M+H] + HPLC retention time: 0.67 minutes (Analysis conditions A)
[0306] Compound a-15: 3-amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-6-(3,3-difluoropropoxy)-7-fluoro-1-[(4-methoxyphenyl)methyl]quinolin-2-one To 3-amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-6-hydroxy-1-[(4-methoxyphenyl)methyl]quinolin-2-one (Compound a-13, 231 mg, 0.421 mmol) and 3,3-difluoropropan-1-ol (123 mg, 1.28 mmol) in a reaction vessel, 0.5 M cyanomethylenetrimethylphosphorane THF solution (2.53 mL, 1.265 mmol) was added, and the reaction vessel was degassed under reduced pressure and purged with argon, followed by stirring at 80°C for 2.5 hours. The reaction mixture was cooled to room temperature, water (231 μL) was added, and the mixture was stirred at 80°C for 15 hours. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. THF was added to the resulting residue, and the mixture was further concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give the title compound (233 mg, yield 88%) as a pale yellow solid. LCMS: m / z 627 [M+H] + HPLC retention time: 5.40 minutes (Analysis conditions J)
[0307] Compound A2 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-(3,3-difluoropropoxy)-7-fluoro-1H-quinolin-2-one The title compound was synthesized from 3-amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-6-(3,3-difluoropropoxy)-7-fluoro-1-[(4-methoxyphenyl)methyl]quinolin-2-one (Compound a-15) under the same conditions as in the production example for Compound A1. LCMS: m / z 423 [M+H] + HPLC retention time: 0.65 minutes (Analysis conditions A)
[0308] Compound a-22 3-amino-6-bromo-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-1-(2-trimethylsilylethoxymethyl)quinolin-2-one A THF solution (25 mL) of 3-amino-6-bromo-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-1H-quinolin-2-one (Compound a-11, 1.732 g, 3.522 mmol) in a reaction vessel was cooled to 0 °C, and 60% sodium hydride / mineral oil (564 mg, 14.08 mmol) was added and stirred for 30 minutes. 2-(Chloromethoxy)ethyltrimethylsilane (1.86 mL, 10.6 mmol) was added to the reaction mixture, and the mixture was stirred for an additional 30 minutes. A saturated aqueous solution of sodium bicarbonate was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, the desiccant was removed by filtration, and the mixture was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane / ethyl acetate) to give the title compound (1.87 g, 85% yield) as a pale yellow solid. LCMS: m / z 621 [M+H] + HPLC retention time: 6.33 minutes (Analysis conditions J)
[0309] Compound a-23 3-amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-6-hydroxy-1-(2-trimethylsilylethoxymethyl)quinolin-2-one The title compound was synthesized from 3-amino-6-bromo-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-1-(2-trimethylsilylethoxymethyl)quinolin-2-one (Compound a-22) under the same conditions as in the production example for Compound a-13. LCMS: m / z 559 [M+H] + HPLC retention time: 5.35 minutes (Analysis conditions J)
[0310] Compound a-24: 3-amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-6-cyclobutyloxy-7-fluoro-1-(2-trimethylsilylethoxymethyl)quinolin-2-one The title compound was synthesized from 3-amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-6-hydroxy-1-(2-trimethylsilylethoxymethyl)quinolin-2-one (Compound a-23) under the same conditions as in the preparation example for Compound a-14. However, bromocyclobutane was used instead of 2-iodopropane used in the preparation example for Compound a-14. In addition, the reaction mixture was heated to 70°C. LCMS: m / z 613 [M+H] + HPLC retention time: 5.00 minutes (Analysis conditions K)
[0311] Compound A7 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-cyclobutyloxy-7-fluoro-1H-quinolin-2-one Anisole (125 mg, 1.15 mmol) and TFA (0.8 mL) were added to a DCM solution (0.8 mL) of 3-amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-6-cyclobutyloxy-7-fluoro-1-(2-trimethylsilylethoxymethyl)quinolin-2-one (Compound a-24, 70.8 mg, 0.115 mmol) in a reaction vessel, and the mixture was stirred at room temperature for 3.5 hours. The reaction mixture was concentrated under reduced pressure, MeOH was added, and the mixture was further concentrated under reduced pressure. The resulting residue was purified by reverse-phase column chromatography (0.1% TFA aqueous solution / 0.1% TFA acetonitrile solution). Fractions containing the title compound were combined and neutralized with saturated sodium bicarbonate. The mixture was concentrated under reduced pressure, and the resulting solid was collected by filtration and washed with water to give the title compound (10.7 mg, 23% yield) as a yellow solid. LCMS: m / z 399 [M+H] + HPLC retention time: 0.69 minutes (Analysis conditions A)
[0312] Compound A72: 3-amino-4-(7-chloro-1H-indazol-4-yl)-7-fluoro-6-[(1-fluorocyclopropyl)methoxy]-1H-quinolin-2-one The title compound was synthesized from 3-amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-6-hydroxy-1-(2-trimethylsilylethoxymethyl)quinolin-2-one (Compound a-23) under the same conditions as in the preparation examples for Compound a-15 and Compound A7. However, (1-fluorocyclopropyl)methanol was used in place of 3,3-difluoropropan-1-ol used in the preparation example for Compound a-15. LCMS: m / z 417 [M+H] + HPLC retention time: 0.65 minutes (Analysis conditions A)
[0313] Compound a-16: 6-bromo-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-2-[(4-methoxyphenyl)methoxy]quinolin-3-amine 3-Amino-6-bromo-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-1H-quinolin-2-one (Compound a-11, 1.496 g, 3.042 mmol) and silver carbonate (1.26 g, 4.57 mmol) were suspended in 1,2-dichloroethane (37 mL), and then p-methoxybenzyl chloride (705 μL, 5.18 mmol) was added and stirred at 95° C. for 16 hours. The reaction mixture was cooled to room temperature, filtered through Celite, and washed with ethyl acetate. The resulting filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane / ethyl acetate) to give the title compound (765 mg, yield 41%).
[0314] Compound a-17: 3-amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-2-[(4-methoxyphenyl)methoxy]quinolin-6-ol The title compound was synthesized from 6-bromo-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-2-[(4-methoxyphenyl)methoxy]quinolin-3-amine (Compound a-16) under the same conditions as in the production example for Compound a-13. LCMS: m / z 549 [M+H] + HPLC retention time: 4.39 minutes (Analysis conditions L)
[0315] Compound A3 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-(cyclopropylmethoxy)-7-fluoro-1H-quinolin-2-one The title compound was synthesized from 3-amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-2-[(4-methoxyphenyl)methoxy]quinolin-6-ol (Compound a-17) under the same conditions as in the preparation example for Compounds a-14 and A7. However, (iodomethyl)cyclopropane was used in place of 2-iodopropane used in the preparation example for Compound a-14. LCMS: m / z 399 [M+H] + HPLC retention time: 0.67 minutes (Analysis conditions A)
[0316] Compound a-102 (1s,3s)-3-fluorocyclobutyl trifluoromethanesulfonate A DCM solution (2 mL) of (1s,3s)-3-fluorocyclobutan-1-ol (200 mg, 2.22 mmol) in a reaction vessel was cooled to 0°C, and pyridine (197 µL, 2.44 mmol) and trifluoromethanesulfonic anhydride (413 µL, 2.44 mmol) were added, followed by stirring at room temperature for 1 hour. The reaction mixture was purified by silica gel column chromatography (DCM) to obtain the title compound (540 mg). 1 H-NMR (d 6 -DMSO) δ: 5.41-5.16 (1H, m), 5.28-5.16 (1H, m), 2.69-2.57 (4H, m)
[0317] Compound a-103 (1s,3s)-3-cyanocyclobutyl trifluoromethanesulfonate The title compound was synthesized using the corresponding alcohol under the same conditions as in the preparation example for compound a-102. 1 H-NMR (d 6 -DMSO) δ: 5.22-5.12 (1H, m), 3.61-3.39 (1H, m), 2.79-2.55 (4H, m).
[0318] Compound A4 3-amino-4-(7-chloro-1H-indazol-4-yl)-7-fluoro-6-((1r,3r)-3-fluorocyclobutyl)oxy-1H-quinolin-2-one The title compound was synthesized from 3-amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-2-[(4-methoxyphenyl)methoxy]quinolin-6-ol (Compound a-17) under the same conditions as in the preparation example for Compounds a-14 and A7. However, (1s,3s)-3-fluorocyclobutyl trifluoromethanesulfonate Compound (a-102) was used in place of 2-iodopropane used in the preparation example for Compound a-14. LCMS: m / z 417 [M+H] + HPLC retention time: 0.65 minutes (Analysis conditions A)
[0319] Compound A5 (1r,3r)-3-[[3-amino-4-(7-chloro-1H-indazol-4-yl)-7-fluoro-2-oxo-1H-quinolin-6-yl]oxy]cyclobutane-1-carbonitrile The title compound was synthesized from 3-amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-2-[(4-methoxyphenyl)methoxy]quinolin-6-ol (Compound a-17) under the same conditions as in the preparation examples for Compounds a-14 and A7. However, (1s,3s)-3-cyanocyclobutyl trifluoromethanesulfonate (Compound a-103) was used in place of 2-iodopropane used in the preparation example for Compound a-14. LCMS: m / z 424 [M+H] + HPLC retention time: 0.60 minutes (Analysis conditions A)
[0320] Compound A6 3-amino-4-(7-chloro-1H-indazol-4-yl)-7-fluoro-6-(3-fluoropropoxy)-1H-quinolin-2-one The title compound was synthesized from 3-amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-fluoro-2-[(4-methoxyphenyl)methoxy]quinolin-6-ol (Compound a-17) under the same conditions as in the preparation examples for Compounds a-14 and A7. However, 1-fluoro-3-iodopropane was used instead of 2-iodopropane used in the preparation example for Compound a-14. LCMS: m / z 405 [M+H] + HPLC retention time: 0.64 minutes (Analysis conditions A)
[0321] Compound a-25 4-bromo-5-chloro-2-iodoaniline The title compound was synthesized from 4-bromo-3-chloroaniline under the same conditions as in the preparation example for compound a-5. LCMS: m / z 332 [M+H] + HPLC retention time: 4.42 minutes (Analysis conditions N)
[0322] Compound a-26 (E)-N'-(4-bromo-5-chloro-2-iodophenyl)-N,N-dimethylmethanimidamide The title compound was synthesized from 4-bromo-5-chloro-2-iodoaniline (compound a-25) under the same conditions as in the preparation example of compound a-6. LCMS: m / z 387 [M+H] + HPLC retention time: 2.60 minutes (Analysis conditions N)
[0323] Compound a-27(E)-N'-[4-bromo-5-chloro-2-[7-chloro-2-(oxan-2-yl)indazole-4-carbonyl]phenyl]-N,N-dimethylmethaneimidamide The title compound was synthesized from (E)-N'-(4-bromo-5-chloro-2-iodophenyl)-N,N-dimethylmethanimidamide (Compound a-26) under the same conditions as in the production example for Compound a-7. LCMS: m / z 523 [M+H] + HPLC retention time: 3.88 minutes (Analysis conditions J)
[0324] Compound a-28 (2-amino-5-bromo-4-chlorophenyl)-[7-chloro-2-(oxan-2-yl)indazol-4-yl]methanone The title compound was synthesized from (E)-N'-[4-bromo-5-chloro-2-[7-chloro-2-(oxan-2-yl)indazole-4-carbonyl]phenyl]-N,N-dimethylmethanimidamide (Compound a-27) under the same conditions as in the production example for Compound a-8. LCMS: m / z 468 [M+H] + HPLC retention time: 5.66 minutes (Analysis conditions J)
[0325] Compound a-31 3-amino-6-bromo-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-1H-quinolin-2-one The title compound was synthesized from (2-amino-5-bromo-4-chlorophenyl)-[7-chloro-2-(oxan-2-yl)indazol-4-yl]methanone (Compound a-28) under the same conditions as in the production examples for Compounds a-9, a-10, and a-11. LCMS: m / z 507 [M+H] + HPLC retention time: 4.96 minutes (Analysis conditions J)
[0326] Compound a-32 3-amino-6-bromo-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-1-[(4-methoxyphenyl)methyl]quinolin-2-one The title compound was synthesized from 3-amino-6-bromo-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-1H-quinolin-2-one (compound a-31) under the same conditions as in the production example for compound a-12. LCMS: m / z 627 [M+H] + HPLC retention time: 4.14 minutes (analysis condition O)
[0327] Compound a-33 3-amino-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-6-hydroxy-1-[(4-methoxyphenyl)methyl]quinolin-2-one The title compound was synthesized from 3-amino-6-bromo-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-1-[(4-methoxyphenyl)methyl]quinolin-2-one (Compound a-32) under the same conditions as in the production example for Compound a-13. LCMS: m / z 565 [M+H] + HPLC retention time: 3.09 minutes (analysis condition O)
[0328] Compound a-34: 3-amino-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-1-[(4-methoxyphenyl)methyl]-6-propan-2-yloxyquinolin-2-one The title compound was synthesized from 3-amino-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-6-hydroxy-1-[(4-methoxyphenyl)methyl]quinolin-2-one (Compound a-33) under the same conditions as in the production example for Compound a-14. LCMS: m / z 607 [M+H] + HPLC retention time: 3.98 minutes (Analysis conditions O)
[0329] Compound A8 3-amino-7-chloro-4-(7-chloro-1H-indazol-4-yl)-6-propan-2-yloxy-1H-quinolin-2-one The title compound was synthesized from 3-amino-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-1-[(4-methoxyphenyl)methyl]-6-propan-2-yloxyquinolin-2-one (Compound a-34) under the same conditions as in the production example for Compound A1. LCMS: m / z 403 [M+H] + HPLC retention time: 0.72 minutes (Analysis conditions A)
[0330] Compound a-35: 3-amino-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-6-(3,3-difluoropropoxy)-1-[(4-methoxyphenyl)methyl]quinolin-2-one The title compound was synthesized from 3-amino-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-6-hydroxy-1-[(4-methoxyphenyl)methyl]quinolin-2-one (Compound a-33) under the same conditions as in the preparation example for Compound a-15. However, cyanomethylenetributylphosphorane and THF were used instead of the 0.5 M cyanomethylenetrimethylphosphorane THF solution used in the preparation example for Compound a-15. LCMS: m / z 643 [M+H] + HPLC retention time: 3.68 minutes (Analysis conditions O)
[0331] Compound A9: 3-amino-7-chloro-4-(7-chloro-1H-indazol-4-yl)-6-(3,3-difluoropropoxy)-1H-quinolin-2-one The title compound was synthesized from 3-amino-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-6-(3,3-difluoropropoxy)-1-[(4-methoxyphenyl)methyl]quinolin-2-one (Compound a-35) under the same conditions as in the production example for Compound A1. LCMS: m / z 439 [M+H] + HPLC retention time: 0.69 minutes (Analysis conditions A)
[0332] Compound a-36 6-bromo-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-2-[(4-methoxyphenyl)methoxy]quinolin-3-amine The title compound was synthesized from 3-amino-6-bromo-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-1H-quinolin-2-one (Compound a-31) under the same conditions as in the production example for Compound a-16. LCMS: m / z 627 [M+H] + HPLC retention time: 5.04 minutes (Analysis conditions O)
[0333] Compound a-37: 3-amino-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-2-[(4-methoxyphenyl)methoxy]quinolin-6-ol The title compound was synthesized from 6-bromo-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-2-[(4-methoxyphenyl)methoxy]quinolin-3-amine (Compound a-36) under the same conditions as in the production example for Compound a-13. LCMS: m / z 565 [M+H] + HPLC retention time: 2.98 minutes (Analysis conditions O)
[0334] Compound A10 3-amino-7-chloro-4-(7-chloro-1H-indazol-4-yl)-6-cyclobutyloxy-1H-quinolin-2-one The title compound was synthesized from 3-amino-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-2-[(4-methoxyphenyl)methoxy]quinolin-6-ol (Compound a-37) under the same conditions as in the preparation examples for Compounds a-15 and A7. However, cyanomethylenetributylphosphorane, THF, and cyclobutanol were used in place of the 0.5 M cyanomethylenetrimethylphosphorane THF solution and 3,3-difluoropropan-1-ol used in the preparation example for Compound a-15. LCMS: m / z 415 [M+H] + HPLC retention time: 0.74 minutes (Analysis conditions A)
[0335] Compound A11 3-amino-7-chloro-4-(7-chloro-1H-indazol-4-yl)-6-((1r,3r)-3-fluorocyclobutyl)oxy-1H-quinolin-2-one The title compound was synthesized from 3-amino-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-2-[(4-methoxyphenyl)methoxy]quinolin-6-ol (Compound a-37) under the same conditions as in the preparation example for Compounds a-14 and A7. However, (1s,3s)-3-fluorocyclobutyl trifluoromethanesulfonate Compound (a-102) was used in place of 2-iodopropane used in the preparation example for Compound a-14. LCMS: m / z 433 [M+H] + HPLC retention time: 0.70 minutes (Analysis conditions A)
[0336] Compound A12 (1r,3r)-3-[[3-amino-7-chloro-4-(7-chloro-1H-indazol-4-yl)-2-oxo-1H-quinolin-6-yl]oxy]cyclobutane-1-carbonitrile The title compound was synthesized from 3-amino-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-2-[(4-methoxyphenyl)methoxy]quinolin-6-ol (Compound a-37) under the same conditions as in the preparation example for Compounds a-14 and A7. However, (1s,3s)-3-cyanocyclobutyl trifluoromethanesulfonate (Compound a-103) was used in place of 2-iodopropane used in the preparation example for Compound a-14. LCMS: m / z 440 [M+H] + HPLC retention time: 0.64 minutes (Analysis conditions A)
[0337] Compound A13 3-amino-7-chloro-4-(7-chloro-1H-indazol-4-yl)-6-(cyclopropylmethoxy)-1H-quinolin-2-one The title compound was synthesized from 3-amino-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-2-[(4-methoxyphenyl)methoxy]quinolin-6-ol (Compound a-37) under the same conditions as in the preparation examples for Compounds a-14 and A7. However, (iodomethyl)cyclopropane was used in place of 2-iodopropane used in the preparation example for Compound a-14. LCMS: m / z 415 [M+H] + HPLC retention time: 0.72 minutes (Analysis conditions A)
[0338] Compound A14 3-amino-7-chloro-4-(7-chloro-1H-indazol-4-yl)-6-(3-fluoropropoxy)-1H-quinolin-2-one The title compound was synthesized from 3-amino-7-chloro-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-2-[(4-methoxyphenyl)methoxy]quinolin-6-ol (Compound a-37) under the same conditions as in the preparation example for Compounds a-14 and A7. However, 1-fluoro-3-iodopropane was used instead of 2-iodopropane used in the preparation example for Compound a-14. LCMS: m / z 421 [M+H] + HPLC retention time: 0.68 minutes (Analysis conditions A)
[0339] Compound a-43 5-bromo-3-iodo-6-methylpyridin-2-amine The title compound was synthesized from 6-amino-3-bromo-2-methylpyridine under the same conditions as in the preparation example of compound a-5. LCMS: m / z 313 [M+H] + HPLC retention time: 2.55 minutes (Analysis conditions N)
[0340] Compound a-44(E)-N'-(5-bromo-3-iodo-6-methylpyridin-2-yl)-N,N-dimethylmethanimidamide The title compound was synthesized from 5-bromo-3-iodo-6-methylpyridin-2-amine (compound a-43) under the same conditions as in the production example for compound a-6. LCMS: m / z 368 [M+H] + HPLC retention time: 2.37 minutes (Analysis conditions N)
[0341] Compound a-45(E)-N'-[5-bromo-3-[7-chloro-2-(oxan-2-yl)indazole-4-carbonyl]-6-methylpyridin-2-yl]-N,N-dimethylmethaneimidamide The title compound was synthesized from (E)-N'-(5-bromo-3-iodo-6-methylpyridin-2-yl)-N,N-dimethylmethanimidamide (Compound a-44) under the same conditions as in the production example for Compound a-7. LCMS: m / z 504 [M+H] + HPLC retention time: 3.69 minutes (Analysis conditions J)
[0342] Compound a-46 (2-amino-5-bromo-6-methylpyridin-3-yl)-[7-chloro-2-(oxan-2-yl)indazol-4-yl]methanone The title compound was synthesized from (E)-N'-[5-bromo-3-[7-chloro-2-(oxan-2-yl)indazole-4-carbonyl]-6-methylpyridin-2-yl]-N,N-dimethylmethanimidamide (Compound a-45) under the same conditions as in the production example for Compound a-8. LCMS: m / z 449 [M+H] + HPLC retention time: 4.53 minutes (Analysis conditions J)
[0343] Compound a-49: 3-amino-6-bromo-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-methyl-1H-1,8-naphthyridin-2-one The title compound was synthesized from (2-amino-5-bromo-6-methylpyridin-3-yl)-[7-chloro-2-(oxan-2-yl)indazol-4-yl]methanone (compound a-46) under the same conditions as in the production examples for compounds a-9, a-10, and a-11. LCMS: m / z 488 [M+H] + HPLC retention time: 4.61 minutes (Analysis conditions J)
[0344] Compound a-50: 3-amino-6-bromo-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-methyl-1-(2-trimethylsilylethoxymethyl)-1,8-naphthyridin-2-one The title compound was synthesized from 3-amino-6-bromo-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-methyl-1H-1,8-naphthyridin-2-one (Compound a-49) under the same conditions as in the preparation example for Compound a-22. However, potassium carbonate and DMA were used instead of 60% sodium hydride / mineral oil and THF used in the preparation example for Compound a-22. In addition, the reaction mixture was heated to 70°C. LCMS: m / z 618 [M+H] + HPLC retention time: 6.51 minutes (Analysis conditions J)
[0345] Compound a-51: 3-amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-6-hydroxy-7-methyl-1-(2-trimethylsilylethoxymethyl)-1,8-naphthyridin-2-one The title compound was synthesized from 3-amino-6-bromo-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-7-methyl-1-(2-trimethylsilylethoxymethyl)-1,8-naphthyridin-2-one (Compound a-50) under the same conditions as in the production example for Compound a-13. LCMS: m / z 556 [M+H] + HPLC retention time: 5.44 minutes (Analysis conditions J)
[0346] Compound A15: 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-((1r,3r)-3-fluorocyclobutyl)oxy-7-methyl-1H-1,8-naphthyridin-2-one The title compound was synthesized from 3-amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-6-hydroxy-7-methyl-1-(2-trimethylsilylethoxymethyl)-1,8-naphthyridin-2-one (Compound a-51) under the same conditions as in the preparation example for Compounds a-14 and A7. However, (1s,3s)-3-fluorocyclobutyl trifluoromethanesulfonate (Compound a-102) was used in place of 2-iodopropane used in the preparation example for Compound a-14. LCMS: m / z 414 [M+H] + HPLC retention time: 0.65 minutes (Analysis conditions A)
[0347] Compound A16 (1r,3r)-3-[[6-amino-5-(7-chloro-1H-indazol-4-yl)-2-methyl-7-oxo-8H-1,8-naphthyridin-3-yl]oxy]cyclobutane-1-carbonitrile The title compound was synthesized from 3-amino-4-[7-chloro-2-(oxan-2-yl)indazol-4-yl]-6-hydroxy-7-methyl-1-(2-trimethylsilylethoxymethyl)-1,8-naphthyridin-2-one (Compound a-51) under the s...
Claims
1. Formula (1): [In the formula, R 4 is an optionally substituted C 6 -C 10 Aryl (R 4A ), optionally substituted 4- to 10-membered heterocyclyl, and optionally substituted 5- to 10-membered heteroaryl (R 4HA R 5 and R 6 are taken together with the atom to which they are attached to form an optionally substituted D ring; D ring is a 3- to 10-membered monocyclic alicyclic ring, a benzene ring, a 3- to 12-membered monocyclic heterocycle, and a 5- to 6-membered monocyclic aromatic heterocycle (D HA any two adjacent substituents on ring D may be taken together with the atoms to which they are attached to form an optionally substituted ring E.] or a salt thereof, or a solvate thereof.
2. The D ring is a benzene ring or a 5- to 6-membered monocyclic aromatic heterocycle (D HA 2. The compound according to claim 1 , or a salt thereof, or a solvate thereof.
3. The D ring is unsubstituted or contains one or more R D and one or more R D Each independently represents halogen, cyano, hydroxy, C 1 -C 6 Alkylthio, C 1 -C 6 Acylamino, Mono C 1 -C 6 Alkylamino, C 1 -C 6 Alkylsulfonylamino, C 3 -C 8 Cycloalkylsulfonylamino, C 1 -C 6 Alkoxy, HaloC 1 -C 6 Alkoxy, Hydroxy C 1 -C 6 Alkoxy, C 1 -C 6 Alkoxy C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkoxy, 4- to 10-membered heterocyclyl C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkoxy, 4-10 membered heterocyclyloxy, C 1 -C 6 Acyl, Mono C 3 -C 8 Cycloalkylaminocarbonyl, 4- to 8-membered cyclic aminocarbonyl, diC 1 -C 6 Alkylphosphoryl, C 1 -C 6 Alkyl, haloC 1 -C 6 Alkyl, Hydroxy C 1 -C 6 Alkyl, DiC 1 -C 6 Alkylaminocarbonyl C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, Hydroxy C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, Hydroxy C 2 -C 6 Alkynyl, C 3 -C 8 Cycloalkyl, 4-10 membered heterocyclyl, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, 1 -C 6 Alkylthio, C 1 -C 6 Alkoxy, C 1 -C 6 Alkoxy C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkoxy, 4- to 10-membered heterocyclyl C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkoxy, 4-10 membered heterocyclyloxy, C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkyl C 3 -C 8 Cycloalkyl, 4-10 membered heterocyclyl, C 6 -C 10 Aryl and 5- to 10-membered heteroaryl may further independently be selected from halogen, cyano, hydroxy, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, oxo, haloC 1 -C 6 Alkyl, and C 3 -C 8 The compound according to claim 1 or 2, or a salt thereof, or a solvate thereof, optionally substituted with one or more substituents selected from the group consisting of cycloalkyl.
4. The D ring is unsubstituted or contains one or more R D and one or more R D Each independently represents a halogen, C 1 -C 6 Alkoxy, HaloC 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkoxy, C 1 -C 6 Alkyl, haloC 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkyl, and C 3 -C 8 The compound according to any one of claims 1 to 3, or a salt thereof, or a solvate thereof, wherein the compound is selected from the group consisting of cycloalkyl.
5. The compound according to any one of claims 1 to 4, or a salt thereof, or a solvate thereof, wherein any two adjacent substituents on ring D are taken together with the atoms to which they are attached to form ring E which may be substituted.
6. The D and E rings have the following formula: (wherein * represents R in formula (1) 5 is the carbon atom to which R is bonded, and ** is the R 6 and each represent a carbon atom to which the ring is bonded. In the formula, the D ring is represented as "D ring" and the E ring is represented as "E ring". The compound according to any one of claims 1 to 5, or a salt thereof, or a solvate thereof, which forms a bicyclic ring represented by the formula:
7. Formula (2): [In the formula, R 4 is an optionally substituted C 6 -C 10 Aryl (R 4A ), optionally substituted 4- to 10-membered heterocyclyl, and optionally substituted 5- to 10-membered heteroaryl (R 4HA X is selected from the group consisting of 5 is CR x5 or N; X 6 is CR x6 or N; X 10a is CR x10a or N; R x5、 R x6 , R 6a and R x10a are each independently hydrogen, deuterium, halogen, cyano, nitro, hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 Cycloalkyl, 4-10 membered heterocyclyl, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 Cycloalkyl, 4-10 membered heterocyclyl, C 6 -C 10 Aryl and 5- to 10-membered heteroaryl may be further substituted or R x5 and R x6 , R x6 and R 6a , or R 6a and R x10a and R may be taken together with the atom to which they are attached to form an optionally substituted E ring.
8. X 5 is CH, and X 6 is CR x6 And X 10a is CR x10a The compound according to claim 7, or a salt thereof, or a solvate thereof.
9. R 6a is hydrogen, halogen, cyano, haloC 1 -C 6 Alkoxy, and C 1 -C 6 The compound according to claim 7 or 8, or a salt thereof, or a solvate thereof, wherein the compound is selected from the group consisting of alkyl.
10. R x10a is hydrogen, halogen, cyano, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, and C 3 -C 8 The compound according to any one of claims 7 to 9, or a salt thereof, or a solvate thereof, wherein the compound is selected from the group consisting of cycloalkyl.
11. The E ring has the formula: (wherein * represents R in formula (2) 6a is the carbon atom to which R is bonded, and ** is the carbon atom to which R is bonded in formula (2). x10a and each represent a carbon atom to which each of the carbon atoms is bonded. In the formula, the E ring is represented as "E ring". The compound according to any one of claims 7 to 10, or a salt thereof, or a solvate thereof, 12. The E ring is unsubstituted or contains one or more R E and one or more R E Each independently represents a halogen, C 1 -C 6 Alkoxy, boryl, and C 1 -C 6 The compound according to any one of claims 1 to 11, or a salt thereof, or a solvate thereof, wherein the compound is selected from the group consisting of alkyl.
13. Formula (3): [In the formula, R 4 is an optionally substituted C 6 -C 10 Aryl (R 4A ), optionally substituted 4- to 10-membered heterocyclyl, and optionally substituted 5- to 10-membered heteroaryl (R 4HA X is selected from the group consisting of 5 is CR x5 or N; X 6 is CR x6 or N; X 7 is CR x7 or N; X 8 is CR x8 or N; X 9 is CR x9 or N; X 10 is CR x10 or N; R x5、 R x6 , R x7 , R x8 , R x9 and R x10 are each independently hydrogen, deuterium, halogen, cyano, nitro, hydroxy, thio, amino, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 Cycloalkyl, 4-10 membered heterocyclyl, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, carbonyl, carboxy, sulfonyl, phosphoryl, boryl, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 8 Cycloalkyl, 4-10 membered heterocyclyl, C 6 -C 10 The compound according to claim 1 or 7, wherein the aryl and the 5- to 10-membered heteroaryl are optionally further substituted.
14. X 5 is CH, and X 6 is CR x6 And X 7 is CR x7 or N; X 8 is CR x8 or N; X 9 is CR x9 or N; X 10 is CR x10 or N, or a salt thereof, or a solvate thereof, according to claim 13.
15. X 7 is N and X 8 is CR x8 And X 9 is CR x9 And X 10 is CR x10 or X 7 is CR x7 And X 8 is N and X 9 is CR x9 And X 10 is CR x10 or X 7 is CR x7 And X 8 is CR x8 And X 9 is N and X 10 is CR x10 or X 7 is CR x7 And X 8 is CR x8 And X 9 is CR x9 And X 10 is N or X 7 is N and X 8 is CR x8 And X 9 is CR x9 And X 10 is N or X 7 is CR x7 And X 8 is N and X 9 is CR x9 And X 10 is N or X 7 is N and X 8 is N and X 9 is CR x9 And X 10 is CR x10 The compound according to claim 13 or 14, or a salt thereof, or a solvate thereof.
16. R x6 is hydrogen, halogen, hydroxy, C 1 -C 6 Alkylthio, C 1 -C 6 Acylamino, Mono C 1 -C 6 Alkylamino, C 1 -C 6 Alkylsulfonylamino, C 3 -C 8 Cycloalkylsulfonylamino, C 1 -C 6 Alkoxy, HaloC 1 -C 6 Alkoxy, Hydroxy C 1 -C 6 Alkoxy, C 1 -C 6 Alkoxy C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkoxy, 4- to 10-membered heterocyclyl C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkoxy, 4-10 membered heterocyclyloxy, C 1 -C 6 Acyl, Mono C 3 -C 8 Cycloalkylaminocarbonyl, 4- to 8-membered cyclic aminocarbonyl, diC 1 -C 6 Alkylphosphoryl, C 1 -C 6 Alkyl, haloC 1 -C 6 Alkyl, Hydroxy C 1 -C 6 Alkyl, DiC 1 -C 6 Alkylaminocarbonyl C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, Hydroxy C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, Hydroxy C 2 -C 6 Alkynyl, C 3 -C 8 Cycloalkyl, 4-10 membered heterocyclyl, C 6 -C 10 aryl, and 5- to 10-membered heteroaryl, 1 -C 6 Alkylthio, C 1 -C 6 Alkoxy, C 1 -C 6 Alkoxy C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkoxy, 4- to 10-membered heterocyclyl C 1 -C 6 Alkoxy, C 3 -C 8 Cycloalkoxy, 4-10 membered heterocyclyloxy, C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl C 1 -C 6 Alkyl, C 3 -C 8 Cycloalkyl, 4-10 membered heterocyclyl, C 6 -C 10 Aryl and 5- to 10-membered heteroaryl may further independently be selected from halogen, cyano, hydroxy, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, oxo, haloC 1 -C 6 Alkyl, and C 3 -C 8 The compound according to any one of claims 7 to 15, or a salt thereof, or a solvate thereof, which is optionally substituted with one or more substituents selected from the group consisting of cycloalkyl.
17. R x6 is selected from the group consisting of hydrogen, methoxy, ethoxy, propoxy, propan-2-yloxy, 3-methylbutoxy, [(2S)-butan-2-yl]oxy, [(2R)-butan-2-yl]oxy, methyl, ethyl, propyl, propan-2-yl, 2-methylpropyl, butan-2-yl, 3-methylbutyl, pentan-3-yl, cyclopropyl, cyclobutyl, cyclopentyl, 1-methylcyclopropyl, 3,3-dimethylcyclobutyl, and spiro[2.3]hexan-5-yl, or a salt thereof, or a solvate thereof according to any one of claims 7 to 16.
18. R x7 is hydrogen, halogen, C 1 -C 6 Alkoxy or C 1 -C 6 The compound according to any one of claims 13 to 17, or a salt thereof, or a solvate thereof, wherein R is alkyl.
19. R x8 is hydrogen, halogen, C 1 -C 6 Alkoxy or C 1 -C 6 The compound according to any one of claims 13 to 18, or a salt thereof, or a solvate thereof, wherein R is alkyl.
20. R x9 is hydrogen, halogen, C 1 -C 6 Alkoxy, C 1 -C 6 The compound according to any one of claims 13 to 19, wherein the compound is selected from the group consisting of alkyl and boryl, or a salt thereof, or a solvate thereof.
21. R x10 is hydrogen, halogen, C 1 -C 6 Alkoxy or C 1 -C 6 The compound according to any one of claims 13 to 20, or a salt thereof, or a solvate thereof, wherein R is alkyl.
22. R 4 is an optionally substituted 5- to 10-membered heteroaryl (R 4HA 22. The compound according to claim 1, or a salt thereof, or a solvate thereof, 23. 5-10 membered heteroaryl (R 4HA 23. The compound according to claim 22, wherein R is selected from the group consisting of pyrimidyl, benzimidazolyl, indolyl, indazolyl, and pyrazolopyridyl, or a salt thereof, or a solvate thereof.
24. 5-10 membered heteroaryl (R 4HA ) is unsubstituted or has one or more R a and one or more R a are each independently a halogen, a cyano, a hydroxyl, an amino, 1 -C 6 Alkyl, haloC 1 -C 6 Alkyl, Hydroxy C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, HaloC 1 -C 6 24. The compound according to claim 22 or 23, wherein the compound is selected from the group consisting of alkoxy, and alkylsulfonylamino, or a salt thereof, or a solvate thereof.
25. 5-10 membered heteroaryl (R 4HA 25. The compound according to any one of claims 22 to 24, wherein R is 1H-indazol-4-yl or 1H-indazol-4-yl substituted with one or more halogens, or a salt thereof, or a solvate thereof.
26. A compound selected from the following compounds, or a salt thereof, or a solvate thereof: 3-amino-7-chloro-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-benzo[h]quinolin-2-one, 3-amino-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-benzo[h]quinolin-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methyl-1H-benzo[h]quinolin-2-one, 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-cyclopropyl-1H-benzo[h]quinolin-2-one, 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-methyl-1H-benzo[h]quinolin-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-propan-2-yl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-propan-2-yloxy-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-cyclopropyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-cyclobutyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-ethyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(5-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-6-cyclopropyl-4-(5-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one, (S)-3-amino-6-cyclopropyl-4-(5-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-6-cyclopropyl-4-(6,7-difluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-ethyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-chloro-6-fluoro-1H-indazol-4-yl)-6-ethoxy-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-chloro-6-fluoro-1H-indazol-4-yl)-6-propan-2-yloxy-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-chloro-6-fluoro-1H-indazol-4-yl)-6-cyclopropyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-chloro-6-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-propoxy-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-ethoxy-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-6-propan-2-yloxy-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-chloro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-chloro-6-fluoro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthrolin-2-one, 3-amino-6-ethoxy-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one, 3-amino-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-6-ethyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one, 3-amino-6-cyclobutyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methoxy-1H-1,10-phenanthrolin-2-one, 3-amino-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,10-phenanthrolin-2-one, 3-amino-4-(7-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,10-phenanthrolin-2-one, 3-amino-6-ethyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,10-phenanthrolin-2-one, 3-amino-9-fluoro-4-(7-fluoro-1H-indazol-4-yl)-6-methoxy-1H-1,7-phenanthrolin-2-one, 3-amino-9-fluoro-4-(7-fluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-9-fluoro-6-methoxy-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-9-fluoro-6-methyl-1H-1,7-phenanthrolin-2-one, 8-amino-7-(7-fluoro-1H-indazol-4-yl)-5-methoxy-10H-pyrido[2,3-f]quinoxalin-9-one, 8-amino-7-(7-fluoro-1H-indazol-4-yl)-5-propan-2-yloxy-10H-pyrido[2,3-f]quinoxalin-9-one, 8-amino-7-(7-fluoro-1H-indazol-4-yl)-5-methyl-10H-pyrido[2,3-f]quinoxalin-9-one, 8-Amino-5-cyclopropyl-7-(7-fluoro-1H-indazol-4-yl)-10H-pyrido [2,3-f]quinoxalin-9-one, 8-amino-7-(7-fluoro-1H-indazol-4-yl)-5-methyl-10H-pyrido[3,2-h]quinazolin-9-one, 8-amino-5-cyclopropyl-7-(7-fluoro-1H-indazol-4-yl)-10H-pyrido[3,2-h]quinazolin-9-one, 3-amino-6-cyclopropyl-4-(7-fluoro-1H-indazol-4-yl)-1H-1,8-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-5,6-dimethyl-1H-1,7-phenanthrolin-2-one, 3-amino-6-cyclopropyl-4-(6,7-difluoro-1H-indazol-4-yl)-5-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-5-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-5-fluoro-6-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-6-cyclopropyl-4-(6,7-difluoro-1H-indazol-4-yl)-5-fluoro-1H-1,7-phenanthrolin-2-one, 3-amino-4-(6,7-difluoro-1H-indazol-4-yl)-5-fluoro-1H-1,7-phenanthrolin-2-one, 3-amino-4-(5,7-difluoro-1H-indazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one, 3-amino-6-methyl-4-(1H-pyrazolo[4,3-c]pyridin-4-yl)-1H-1,7-phenanthrolin-2-one, 3-amino-4-(1H-benzotriazol-4-yl)-6-methyl-1H-1,7-phenanthrolin-2-one, and 3-amino-6-(tert-butyl)-4-(7-fluoro-1H-indazol-4-yl)-1H-1,7-phenanthrolin-2-one.
27. A pharmaceutical composition comprising the compound or a salt thereof, or a solvate thereof according to any one of claims 1 to 26 as an active ingredient.
28. A pharmaceutical composition for treating or preventing cancer in a cancer patient in which a positive RB1 gene mutation or reduced expression of the RB1 gene or protein has been detected in combination with a chemotherapeutic agent, comprising as an active ingredient a MYT1 inhibitor, wherein the MYT1 inhibitor is a compound according to any one of claims 1 to 26, or a salt thereof, or a solvate of either.
